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Sydänpysähdys aiheuttaa nopeasti hapenpuutevaurion etenkin aivoissa 
ja sydänlihaksessa. Onnistuneen elvytyksen jälkeisestä verenkierron 
palautumisesta huolimatta aivojen ja sydämen hapenpuutevaurio jatkuu 
(reperfuusiovaurio), jota voidaan jonkin verran rajoittaa lämpötilan-
hallinnalla pitämällä potilaan lämpötila 33 – 36 ºC välillä ja estämällä 
kuumeen aiheuttama vaurion paheneminen. 
Jalokaasu ksenon on anestesiakaasu, jonka on aiemmin osoitettu eri 
eläinmalleissa vähentävän hapenpuutteen aiheuttamaa vauriota aivoissa 
ja sydänlihaksessa yksin ja jäähdytyshoitoon yhdistettynä.
Tässä tutkimuksessa verrattiin ksenonin ja jäähdytyshoidon (33 ºC) 
yhdistelmää pelkän jäähdytyshoidon vaikutukseen 110:llä kam-
miovärinästä elvytetyllä sydänpysähdyspotilaalla. Yhdistelmähoito 
vähensi sekä aivojen valkean aineen vauriota että sydänlihasvauriota 
enemmän kuin jäähdytyshoito yksin.
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ABSTRACT 
Cardiac arrest leads often to death or permanent neurological damage, despite prompt 
advanced life support and resuscitation. Ischaemia-reperfusion injury persists, although 
circulation and cardiac function has been restored. The most vulnerable organs for 
hypoxemia and reperfusion injury are the brain and heart. The only proven intervention 
against ongoing ischaemia-reperfusion injury is targeted temperature management to 
core temperature of 33–36 °C for 24 hours after cardiac arrest. Still, at least on average 
third of the succesfully from ventricular fibrillation-generated cardiac arrest 
resuscitated patients die, particularly to hypoxic-ischaemic brain injury. 
The noble gas xenon is an anaesthetic gas, which has been demonstrated in 
preclinical animal models to attenuate posthypoxic brain and myocardial injury. Xenon 
has many properties of ”an ideal anaesthetic”, but being so scarce and laborous to 
extract makes it expensive.  
In this clinical trial, the standard-of-care after out-of-hospital cardiac arrest, 
targeted temperature management to 33 °C for 24 hours, was compared to hypothermia 
supplemented with inhaled xenon for 24 hours. Both study groups consisted of 55 
cardiac arrest victims and the postarrest care was identical in both groups and in 
accordance with current international guidelines. 
Cerebral hypoxic-ischaemic injury was assessed with brain diffusion tensor 
magnetic resonance imaging after rewarming. Fractional anistrophy (FA) value 
corresponds to the microintegrity of brain white matter tracts and is diminished after 
injury. Cardiac troponin-T is a marker of cardiomyocyte injury, which was serially 
assessed during 72 hours following resuscitation. 
The main findings of this study were, that combining inhaled xenon and 
therapeutic hypothermia in cardiac arrest patients was safe and feasible. The 
combination of xenon and hypothermia significantly attenuated brain white matter 
injury illustrated with higher FA-values. After adjustements for age, sex, study site, 
primary coronary percutaneous intevention (PCI) and noradrenaline dose, Troponin-T 
values were lower at 72 hours post OHCA in the xenon group corresponding to an 
mitigating effect in myocardial injury. These results translate to significant neuro- and 
cardioprotection against ongoing ischaemia-reperfusion injury by xenon inhalation 
combined with hypothermia. 
The overall mortality in this study was 30,9 %. The study was underpowered to 
demonstrate differences in outcome or functional neurological recovery. 
KEY WORDS: Xenon, cardiac arrest, ventricular fibrillation, cardiopulmonary 
resuscitation, mild therapeutic hypothermia, targeted temperature management, 
neuroprotection, cardioprotection 
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TIIVISTELMÄ 
Sydänpysähdys johtaa viiveettä aloitetusta elvytyksestä huolimatta usein potilaan 
kuolemaan tai vakavaan neurologiseen vammautumiseen. Hapenpuutteen ja 
reperfuusion aiheuttama kudosvaurio jatkuu, vaikka verenkierto ja sydämen toiminta 
onnistutaan elvytystoimin palauttamaan. Erityisen alttiita hapenpuutteelle ja 
reperfuusiovauriolle ovat aivot ja sydän. Ainoa tehokkaaksi todettu reperfuusiovaurion 
hoito on potilaan jäähdyttäminen 33–36 °C lämpötilaan vuorokaudeksi elvytyksen 
jälkeen. Hoidosta huolimatta noin kolmannes onnistuneesti kammiovärinästä 
elvytetyistä potilaista kuolee, tavallisimmin hapenpuuteaivovaurion seurauksiin. 
Jalokaasu ksenon on anestesiakaasu, jonka on tämän lisäksi lukuisissä 
prekliinisissä eläintutkimuksissa todettu vähentävän hermo- ja sydänlihaskudoksen 
vauriota hapenpuutteen jälkeen. Ksenon-anestesialla on monia ihanteellisen anestesian 
piirteitä, mutta sen käytettävyyttä rajoittaa kaasun harvinaisuus ja työläs 
puhdistamisprosessi, minkä takia ksenon on kallista. 
Tässä tutkimuksessa verrattiin vakiintunutta sydänpysähdyspotilaan jatkohoitoa 
teho-osastolla – vuorokauden jäähdytyshoitoa – jäähdytyshoitoon ja samanaikaiseen 
ksenon-kaasun hengittämiseen yhteensä 110:llä onnistuneesti kammiovärinästä 
elvytetyillä potilailla. Näiden kahden tutkimusryhmän potilaita (55 potilasta 
kummassakin ryhmässä) hoidettiin muuten samankaltaisesti noudattaen viimeisimpiä 
kansainvälisiä suosituksia sydänpysähdyksestä elvytettyjen jatkohoidossa. 
Keskushermoston hapenpuutevauriota arvioitiin potilaan normaaliin lämpötilaan 
lämmittämisen jälkeen aivojen magneettitutkimuksen diffuusiotensorikuvauksen frakti-
oidun anisotrofia (FA) -arvon perusteella, jonka pieneneminen viittaa aivojen valkean aineen 
vaurioon ja mikrointegraation hajoamiseen. Sydänpysähdyksen jälkeistä sydänvauriota 
arvioitiin sydänlihassoluvaurion merkkiaineen troponiini-T:n muutosten perusteella. 
Tutkimuksen perusteella ksenonin ja jäähdytyshoidon yhdistelmä oli turvallista ja 
hengitys ja verenkierto olivat hoidon aikana vakaita myös juuri elvytetyillä sydän-
pysähdyspotilailla, joilla valtaosalla oli merkittävä sepelvaltimotauti. Ksenon-
yhdistelmähoito vähensi merkitsevästi aivojen valkean aineen vauriota magneettikuva-
uksen FA-arvoja verrattaessa. Myös sydänlihaksen vauriomerkkiaineen, troponiini-T:n 
arvot vähenivät elvytystä seuranneen 72 tunnin kuluessa merkitsevästi, sopien 
pienempään sydänlihasvaurioon yhdistelmähoitoa saaneessa tutkimusryhmässä. Nämä 
tulokset viittaavat ksenonin merkittävään neuro- ja kardioprotektiiviseen vaikutukseen 
käynnissä olevan hapenpuute-reperfuusiovaurion rajoittamisessa.  
Tutkimuspotilaiden kuolleisuus oli 30,9 %. Hoitoryhmien koko oli liian pieni 
merkitsevän eron havainnointiin henkiinjäämisessä tai toiminnallisessa neurologisessa 
selviytymisessä.  
AVAINSANAT: ksenon, sydänpysähdys, kammiovärinä, sydämen ja verenkierron 
elvytys, jäähdytyshoito, neuroprotektio, kardioprotektio 
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Abbreviations 
ADC  Apparent Diffusion Coefficient  
AED Automated External Defibrillator 
aEEG Amplitude Integrated Electroencephalography 
AKI Acute Kidney Injury 
ALS Advanced Life Support 
AMI Acute Myocardial infarction 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (receptor) 
ATA Atmosphere Absolute 
ATP Adenosine Triphosphatase 
BLS Basic Life Support 
CABG Coronary Artery Bypass Grafting 
CAD Coronary Artery Disease 
CKD Chronic Kidney Disease 
CK-MB Creatinine Kinase -MBmass 
CaM K II  Ca2+-calmodulin dependent protein kinase II 
CmH2O Centimetres of Water 
CPB Cardiopulmonary Bypass 
CPC Cerebral Performance Category 
CPP Cerebral Perfusion Pressure 
CPR Cardiopulmonary Resuscitation 
CT Computed Tomography (-scanning) 
DTI  Diffusion Tensor Imaging 
DWI  Diffusion Weighted Imaging 
EEG Electroencephalography  
ECG Electrocardiogram 
EMS Emergency Medical Service(s) 
FiO2 Fraction of Inhaled Oxygen 
FLAIR Fluid-Attenuated Inversion Recovery 
GABA γ-Amino-Butyric Acid 
GLS Global peak systolic Longitudinal Strain 
GM (brain) Grey Matter 
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GOS Glasgow Outcome Scale 
GWR (Brain) Grey matter to White matter ratio 
HACA Hypothermia After Cardiac Arrest (trial) 
HIF-1ɑ Hypoxia Inducible Factor 
HRV Heart Rate Variability 
HSP27 Heat shock protein 27 
ICP Intracranial Pressure 
ICU Intensive Care Unit 
IHCA In-hospital Cardiac Arrest 
IRI Ischaemia Reperfusion Injury 
i.v. Intravenous  
KATP Adenosine Triphosphate-sensitive Potassium channel 
LDH Lactate Dehydrogenase 
LV Left Ventricular 
LVEF Left Ventricular Ejection Fraction 
MAC Minimal Alveolar Concentration 
MAP Mean Arterial Pressure 
MAPK Mitogen Activated Protein Kinase 
MAPKAPK-2 MAPK-activated Protein Kinase-2 
MBF Myocardial Blood Flow 
MIF Macrophage migration Inhibitory Factor  
MmHg Millimetres of Mercury 
MRI  Magnetic Resonance Imaging 
mRS Modified Rankin Scale 
MTH Mild Therapeutical Hypothermia 
mPTP Mitochondrial Permeability Transition Pore 
NDS Neurologic Deficit Score 
NFL (serum) Neurofilament Light Chain  
NMDA N-methyl-D-aspartate 
NO Nitric Oxide 
N2O Nitrous oxide 
NSE Neuron-Specific Enolase 
NSTEMI non- ST Elevation Myocardial Infarct 
OHCA Out-of-hospital Cardiac Arrest 
OPCAB Off-pump Coronary Artery Bypass 
PCI Percutaneuous Coronary Intervention 
PEA Pulseless Electrical Activity 
PKC nonselective Protein Kinase C 
PKC-ε epsilon isoform of PKC 
POCD Postoperative Cognitive Dysfunction 
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PONV Postoperative Nausea and Vomiting 
PPM Parts per Million 
RASS Richmond Agitation Sedation Scale 
RIFLE Risk, Injury, Failure, Loss of kidney function, and End-stage 
kidney disease 
RISK Reperfusion Injury Salvage Kinase 
ROC Receiver Operating Characteristic curve 
ROS Reactive Oxygen Species 
ROSC Restoration of Spontaneous Circulation 
PRCS Post Resuscitation Cardiogenic Shock 
SAFE Survivor Activating Factor Enhancement 
SCD Sudden cardiac death 
SDF-1α Stromal cell-Derived Factor-1α 
SSEP Short-latency Somatosensory Evoked Potential  
STE ST Segment Elevation 
STEMI ST Elevation Myocardial Infarct 
TBSS Tract Based Spatial Statistics 
TIVA Total Intravenous Anaesthesia 
TNF-α Tumor Necrosis Factor α 
TnT Troponin T 
TREK-1 Two pore-domain potassium channel 
TTM Targeted Temperature Management 
VBM Voxel Based Morphometry 
VF  Ventricular Fibrillation 
VT (pulseless) Ventricular Tachycardia 
WLST Withdrawal of Life-Sustaining Therapy 
WM (brain) White Matter 
Xe Xenon  
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1 Introduction 
Cardiac arrest remains the most frequent unresolved cause of premature death in 
developed countries claiming annually over 3.7 million lives worldwide 
(Kudenchuk 2015). Out-of-hospital cardiac arrest (OHCA) is afflicting annually 
275,000–500,000 persons in Europe and 420,000–500,000 in the United States 
(Sans 1997, Rea 2004, Atwood 2005, Daya 2015, Girotra 2015, Kudenchuk 2015, 
Mozaffarian 2015, Gräsner 2016), of whom emergency medical service (EMS)-
assessed advanced life support is applied in 60 % of cases (Churg 2004). In an 
European one-month progressive registry in 27 countries any cardiopulmonary 
resuscitation (CPR) by a bystander or by the EMS was started in 66 % of cases 
(Gräsner 2016). The outcome of all-rhythm OHCA victims even with attempted 
resuscitation is currently still dismal; the survival 30 days post arrest is extremely 
low, below 10 % (Nichol 2008, Ragosta 2018) or even as low as 3.2 % (Perkins 
2018). In a significant proportion of patients, sudden cardiac death (SCD) 
manifests with several different causes, often untreatable, without warning or a 
triggering mechanism (Fishman 2010).  
The outcome after sudden cardiac arrest is a reflection of the critical 
interventions taken during resuscitation; delay to bystander or first responder EMS 
CPR provision, prompt defibrillation, high-performance chest compressions, 
assisted ventilation and early advanced cardiac life support (Cummins 1991, 
Sanders 2008, Daya 2015, Kudenchuk 2015). At best, in industrialised countries, 
60% of patients, in whom witnessed cardiac arrest presents as ventricular 
fibrillation (VF) and receive bystander CPR, are “successfully” resuscitated and 
admitted to intensive care unit (ICU) (Nolan 2007). However, only 50 % of these 
(30 %) survive to hospital discharge (Kudenchuk 2015). Importantly, there is a 
large variation in survival after OHCA between European countries and currently, 
in Nordic countries, mortality after OHCA presenting with a shockable rhythm, i.e. 
VF or pulseless ventricular tachycardia (VT), is on average round 30–35 % (Holzer 
2005, Sunde 2007, Bro-Jeppesen 2009, Vaahersalo 2013, Strömsöe 2015, 
Kirkegaard 2017). 
Furthermore, if the initial rhythm is nonshockable, i.e. asystole or pulseless 
electrical activity (PEA), only 20–30% of these patients regain spontaneous 
Olli Arola 
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circulation. Disappointingly, after eventually successful resuscitation, only 2 to 
5 % of asystole/PEA-resuscitated patients survive to hospital discharge (Cobb 
2002, Kudenchuk 2015). Presenting rhythm of PEA is associated with less 
likelihood of witnessed cardiac arrest, less bystander CPR and longer first 
responder response times (Wolbinski 2016). 
Taken the accumulation of remarkable insight into the importance of treatment 
of ischaemic heart disease, major advances in resuscitative techniques, increasing 
availability of defibrillators, automated external defibrillators (AED), early 
defibrillation programs, actions promoting out-of-hospital EMS and improvements 
in understanding the mechanisms of cardiac arrest in recent decades (Lopshire 
2006, Daya 2015, Hasselqvist-Ax 2015), translation of this knowledge into novel 
strategies to affect overall outcome remain still currently unsatisfying poor 
(Kudenchuk 2015). Despite recent improved short-term survival from OHCA to 
hospital admission, the overall hospital survival rate with favourable 
neurocognitive outcomes has essentially remained practically unchanged during 
recent decades (Peberdy 2005, Bardy 2011, Mark 2014). Furthermore, fundamental 
understanding of the precipitating factors leading to VF/VT is incomplete, although 
VF is commonly associated with an acute coronary cause (Jaeger 2018).  
Cardiac arrest with standstill of circulation causes global widespread 
ischaemia, whereas the vital organs heart and brain are most susceptible to 
ischaemic injury (Eastwood 2014). Ischaemia affects the brain particularly in 
distinct regions of tissue (hippocampus, neocortex, cerebellum and cerebral white 
matter), which are exquisitely sensitive to lack of oxygen, occasionally referred 
with selective vulnerability hypothesis (Schmidt-Kastner 1991, Pantoni 1996, Madl 
2004, Matute 2012). Often, the consequence is death or severe permanent 
neurologic impairment (Angelos 2001, Neumar 2008). The cause of death in 
patients who achieved sustained restoration of spontaneous circulation (ROSC) but 
do not survive to hospital discharge is often withdrawal of intensive care based on 
preponderance of poor expectations of neurological recovery. However, death can 
occur also after recurrent cardiac arrest without ROSC, refractory haemodynamic 
shock, respiratory failure or multi-organ failure (Witten 2019). Furthermore, there 
is evidence, that the interventions applied after restoration of circulation may 
significantly modify the chances of survival (Nolan 2010). 
Subsequent post cardiac arrest care targets are consequences of global 
ischaemia: posthypoxemic cerebral injury, ubiquitous myocardial dysfunction, the 
systemic ischaemia-reperfusion response and the persisting precipitating pathology 
(Neumar 2008, Girotra 2015). Coronary reperfusion with percutaneous coronary 
intervention (PCI) in ST-segment elevation myocardial infarcts (STEMI) improves 
survival in limited observational studies (Vyas 2015, Jaeger 2018). However, the 
reperfusion response potentially emphasizes both cardiac and cerebral injury, often 
Introduction 
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resulting in permanently incapacitating neurologic deficit and delayed death (Wolff 
2009).  
Since two major prospective randomized controlled studies published in 2002 
illustrated the advantages of mild therapeutic hypothermia (MTH) in comatose 
survivors of OHCA in both survival and functional neurological outcome, this 
treatment became the current standard-of-care in post-resuscitation management 
(Bernard 2002, Holzer 2002). Induced mild hypothermia or targeted temperature 
management (Nielsen 2013) is to date the only in clinical trials proven therapy to 
improve outcome and it is recommended by international guidelines as the routine 
intervention for selected comatose adult survivors of witnessed OHCA (Neumar 
2008, Field 2010). Although the survival rate has increased and mortality rates 
have declined and an improving trend in outcomes after admission to intensive care 
units (ICU) following cardiac arrest has been documented (Strömsöe 2015), the 
overall survival prospects following OHCA are still very low (Daya 2015). 
Complete cerebral recovery after all-rhythm OHCA is currently still a rare event 
(Madl 2004). 
The worldwide magnitude of sudden cardiac arrest, however, is such that every 
intervention affecting improvement in survival translates into thousands of lives 
saved (Sanders 2008). Therefore, the future holds great promise, if novel 
therapeutic approaches can provide any improvement in individual survival and 
neurological recovery. 
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2 Review of the literature 
2.1 Cardiac arrest 
Sudden cardiac death (SCD) is defined usually as an abrupt and unexpected death 
without an obvious noncardiac cause with or without pre-existing cardiac disease 
and without warning of a recognized triggering mechanism. Besides witnessed 
SCD, unwitnessed SCD is defined as a death within 24 hours of last being 
observed in a person with normal health (Zipes 2006, Fishman 2010). Cardiac 
arrest is the leading cause of death in industrialized countries and many authorities 
describe SCD originating from ventricular tachycardia (VT) degenerating to 
ventricular fibrillation (VF) and subsequent dissolution to fatal asystole or 
pulseless electrical activity (PEA) (Huikuri 2001, Lopshire 2006, Skjeflo 2018). 
Historically, about 70% of OHCA victims were in VF at the arrival of EMS 
personnel, but these data originated from selected patient populations observed by 
EMS crew (Myerburg 1980). Previously, more patients were declared already dead 
on EMS arrival without indication for attempted resuscitation (Cobb 2002).  
However, a major decline in the incidence of out-of-hospital VF has been 
observed past decades with a concomitant decline in coronary artery disease 
mortality, mainly originating from a marked reduction of in-hospital mortality 
(Kuisma 2001, Cobb 2002, Weisfeldt 2011, Karam 2019). Simultaneously, 
symptoms of acute myocardial infarction have lately resulted in attenuated delay in 
seeking care. Even though, prehospital sudden cardiac arrest, representing the very 
first sign of coronary artery disease, is still currently a feared complication of ST-
elevation myocardial infarction (Karam 2019). The decline of VF incidence has 
been more pronounced in patients with unwitnessed collapse and patients 
collapsing at home, which apparently reflect lengthened delay, which allows VF to 
dissolve into asystole within minutes, probably more rapidly in patients with 
advanced and compromised myocardial disease (Bardy 2011, Weisfeldt 2011, 
Hulleman 2015). However, conversion of VF to asystole can happen also relatively 
slowly, as 20 minutes after collapse, 25 % of patients are still in VF (Holmberg 
2000). Recent studies suggest the incidence of VF or pulseless VT as the initial 
rhythm in OHCA or in-hospital cardiac arrests (IHCA) to be only 16–22 % of cases 
(Gräsner 2016, Andersen 2017, Jabre 2018). The current annual incidence of out-
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of-hospital potentially lethal VF-generated SCD in Finland has stabilized to 11,6 
(95 % CI, 9,7–13,5) per 100,000 inhabitants (Väyrynen 2011). Some investigators 
have connected the decline of VF to increase of usage of β–blockers (Youngquist 
2008).  
Currently, of all resuscitations, a non-shockable rhythm is present 
approximately in 40–70 % of patients (asystole) whereas pulseless electrical 
activity (PEA) incidence is 19–46 % (Myerburg 2013, Andersen 2017, Jabre 2018). 
In the Finnish 6-month observational study of 1042 OHCA patients from 2010 
(FINNRESUSCI), a shockable rhythm (VF or pulseless VT) was present in 31.4 % 
of cases (Hiltunen 2012). However, despite that the incidence of VF/VT is 
decreasing, the incidence of cardiac arrest with any initial rhythm is not decreasing 
(Herlitz 2001, Mozaffarian 2015). The true occurrence of initial VF at the time of 
SCD is not known, as downtime, response time and baseline characteristics 
between populations all affect first observed rhythm (Engdahl 2002). The evolution 
of pre-hospital care is likely to translate to increased hospital admissions of 
arrested and severely unstable patients (Olasveengen 2015).  
PEA, which was earlier referred as electromechanical dissociation, is a 
complex presentation with multiple hypoxic/anoxic possible causes progressed to a 
stage where cardiac compensation is no longer possible (Parish 2003). Asystole is 
often considered a sign of a dying or a dead heart rather than an arrhythmia in adult 
patients. Despite presumed non-cardiac aetiology, there is still a chance of 
recovery, although usually bleak (Engdahl 2002). SCD with asystole or PEA 
results often from non-arrhythmic non-cardiac causes, such as drug overdose, 
asphyxia, exsanguination, primary respiratory failure, myocardial rupture or aortic 
aneurysm rupture, all of which portend a poor prognosis (McGinniss 2015, 
Katritsis 2016).  
VF or pulseless VT in OHCA is generated by a complex interaction of a 
receptive anatomical or electrophysiological substrate, such as acute coronary 
occlusion, previous myocardial infarction scar or left ventricular hypertrophy. 
After a transient initiating event of functional myocardial contraction alteration 
caused by ischaemia, hypoxia, electrolyte imbalance, acidosis, drug toxicity or 
haemodynamic failure interacts with the substrate, arrhythmia with a circulatory 
collapse may ensue (Zipes 1998, Huikuri 2001).  
Coronary artery disease is the most common cause of VF-generated SCD in 
developed countries, afflicting for 75 – 80 % of cases (Deo 2012). In autopsy after 
SCD, occlusive coronary artery disease and coronary atheromas are consistently 
identified as the most important responsible underlying cause (Chugh 2004). 
Previous myocardial infarction is apparent in 40–80 % cases (Soo 2001). 
Additionally, concurrent hypertension-generated left ventricular hypertrophy, 
which is independent of the severity of coronary disiease, is present in 75 % cases 
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(Perper 1975). STEMI originating from left main or left anterior descending 
coronary artery occlusion dominate in the patients presenting with sudden cardiac 
arrest (Demirel 2015).  
Apart from evident ischaemia or acute coronary occlusion, myocardial scarring 
from a previous infarct, infiltrative or inflammatory myocardial disease may yield 
an explanation to ventricular tachyarrhythmias (Soo 2001). However, 6 to 14 % 
SCD cases generated by ventricular tachyarrhytmias occur in persons without 
structural heart disease (Zipes 1998, Haïssaguerre 2008). Rhythmic vulnerability 
involves often genetic channelopathies (e.g. long/short QT syndrome, Brugada 
syndrome) and other conditions that predispose to SCD, such as catecholaminergic 
polymorphic VT, arrhytmogenic right ventricular cardiomyopathy, hypertrophic 
cardiomyopathy, early repolarization syndrome etc., which account for only a 
small proportion of OHCA (Huikuri 2001, Mozaffarian 2015, Katritsis 2016). The 
commonest causes for non-ischaemic SCD are cardiomyopathy related to 
alcoholism or obesity and fibrotic cardiomyopathy (Hookana 2011). In an analysis 
of 206 idiopathic VF case subjects, electrocardiographic early repolarization was 6 
times more frequent than in 412 matched control subjects without heart disease 
(Haïssaguerre 2008).  
The ultimate goal of VF- or VT- generated cardiac arrest resuscitation is to 
rapidly restore organized electrical and contractile function and to prevent hypoxic-
ischaemic brain injury (Angelos 2001, Nolan 2018).  
Contemporary cardiopulmonary resuscitation (CPR) was first described in 
1960, when 14 patients were salvaged from cardiac arrest by the application of 
closed chest cardiac massage (Kouwenhoven 1960). The absent perfusion during 
arrest, if no CPR is provided, is termed no-flow perfusion. This is a major issue, as 
only 20 % to 50 % of the OHCA victims receive bystander-initiated CPR – 
depending on the place were the collapse occurred (Loppshire 2006, Weisfeldt 
2011, Mozaffarian 2015).  
As advanced life support (ALS) by EMS providers is at the best only 
commenced several minutes after OHCA, initiation of basic life support (BLS) by 
first responder lay bystanders is the cornerstone to ensure a timely perfusion of the 
brain and optimize outcomes beyond return of spontaneous circulation (ROSC) 
(Field 2010). Bystander – initiated CPR increases 30-day survival more than twice 
as high in comparison with no CPR before EMS arrival (Hasselqvist-Ax 2015). 
Bystander CPR and defibrillation is additionally associated with lower risk of 
cerebral injury and death from any cause during 1-year follow-up (Kragholm 
2017). 
Defibrillation is the primary and only effective ALS intervention in pulseless 
ventricular tachyarrhytmias, but it is extremely time-sensitive as successful 
treatment of VF becomes increasingly more difficult when the VF exceeds 4 
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minutes (Valenzuela 1993, Angelos 2001, Nolan 2005). The success rate for 
defibrillation declines by approximately 10% per minute of VF (Eisenberg 1990). 
Good quality CPR consists of meticulous attention to the details of chest 
compression rate, depth, full chest recoil and minimised CPR interruptions 
(Kudenchuk 2015). High-performance CPR is obviously of paramount importance, 
although the cardiac function, cardiac output and systemic oxygen delivery 
achieved during adequate CPR only vaguely resembles that of a spontaneous 
cardiac output and is therefore termed low-flow perfusion (Neumar 2008, Schindler 
2015). CPR –maintained circulation and perfusion is associated with a 
compensatory increment in general oxygen extraction, with the aftermath of 
oxygen debt (the difference between adumbrated oxygen consumption and actual 
consumption multiplied by time duration) and significantly decreased central 
venous oxygen saturation (Rivers 1992). Finally, the quality of bystander-initiated 
CPR strongly depends on experience and expertise (Rea 2010a, Koster 2015), 
demonstrated with a significant increase in OHCA survivors in comparison of 
trained responders vs. layperson bystanders (Park 2017).  
Additionally, despite extended use of automated external defibrillators, public 
education campaigns to increase awareness and encouragement to bystander-
initiated CPR, CPR is provided in less than half of victims of witnessed OHCA 
(Blom 2014, Mozaffarian 2015). Therefore interventions such as chest-
compression-only CPR (Bobrow 2010, Svensson 2010, Rea 2010b, Nichol 2015), 
emergency dispatchers providing instructions to laypersons for performing CPR 
(Nelson 2019) and large-scale targeted public CPR training have been launched 
(Bobrow 2010, Olasveengen 2017). 
Successful cardiac arrest resuscitation has been traditionally considered as 
merely achieving restoration of spontaneous circulation (ROSC). The ultimate goal 
of resuscitation is, however, a return to a prior quality of life and functional state of 
health (Field 2010). The interval to ROSC, proportion of the duration no-flow and 
low-flow phase and CPR quality all affect outcome after reperfusion (Angelos 
2001). Fundementally, former comorbidity strongly decreases 30-day survival after 
eventually successful resuscitation (Hirlekar 2018). 
2.1.1 Ischaemia-reperfusion injury 
Unfortunately, ROSC does not indicate an end of cellular injury or cellular death 
(Püttgen 2007, Hoesch 2008, Varon 2012) and it merely heralds the start of 
reperfusion injury (Eastwood 2014). After restoration of perfusion, the patient is 
only technically alive (Nolan 2008). Organ injury following restored blood flow to 
the ischaemic tissues after cardiac arrest has three distinct mechanisms.  
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Firstly, at the early stage during circulation standstill and absent tissue 
perfusion, delivery of oxygen and removal of metabolic substrates is abruptly 
halted, despite still ongoing consumption of oxygen, ATP and glucose (McGinniss 
2015). The brain is especially vulnerable to ischaemia, even though it constitutes 
less than 2 % of total body weight. However, brain devours 15–20 % of the cardiac 
output and consumes 20 % of resting total body oxygen (Mink 1981, Eastwood 
2014). This results to that oxygen stores in the brain are depleted within 20 
seconds, and ATP- generating oxidative fosforylation and sufficient glucose level 
maintenance are terminated within 5 minutes of complete anoxia (Siesjö 1976, 
Hoesch 2008, Neumar 2011, Weng 2012). This perfusion failure concludes in 
pervasive whole-body no-reflow, which was originally attributed as the “inability 
to reperfuse a previously ischaemic region” (Krug 1966). During no-reflow 
reduced oxygen supply is offset by lower metabolic needs, resulting in 
unconsciousness within 10 seconds and transient global hyperaemia with delayed, 
prolonged and multifocal hypoperfusion (Mongardon 2011). Initially after cardiac 
arrest, victims may conserve abnormal brainstem mediated gasping type of 
breathing, often depicted “agonal breathing”, which is associated with, 
surprisingly, improved survival and outcome (Debaty 2017). However, 
contrastingly, preservation of “agonal breathing” may lead to significant delay in 
bystander initiation of cardiopulmonary resuscitation in witnessed arrests 
(Brinkrolf 2018). 
Secondly, in the intermediate phase – after ROSC, reperfusion of the ischaemic 
tissue initiates multiple independent chemical fatal pathways, including an 
ischaemic destructive cytotoxic cascade and oxidative stress from the 
consequences of reperfusion and re-oxygenation injury (Shao 2007). This triggers 
several reactions, namely intracellular voltage-dependent calcium influx and 
diminished calcium regulation, which is associated with insufficent provision of 
ATP and oxygen (Mongardon 2011). Further consequences are lipid peroxidation 
of cell membranes, intracellular acidosis and programmed cell death (apoptosis) 
(Weng 2012). Mitochondrial permeability transition pore (mPTP) opens, reactive 
oxygen species (ROS) are generated from damaged mitochondria and 
bioavailability of nitric oxide (NO) is altered.  
This leads to endothelial dysfunction, “endotheliitis”, associated with impaired 
glucose and oxygen metabolism (Callaway 2012, McGinniss 2015). Reperfusion 
can paradoxically cause cell death and subsequent irreversible organ injury, termed 
ischaemia reperfusion injury (IRI) (Xia 2016). IRI evolves toward systemic 
inflammation and triggers release of circulating proinflammatory mediators 
including cytokines (e.g. TNFα, IL-1ra, IL-6, IL-8, IL-10), leukocyte adhesion 
molecules, endotoxins, complement activation and coagulopathy with platelet 
dysfunction (Mongardon 2011). In effect, these reactions cause accumulation of 
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inflammatory cells in the injured tissue, endothelial dysfunction, fibrinolysis 
impairment and general thrombosis (Madathill 2016). This inflammatory cascade 
and features of exacerbation of the inflammatory balance are similar to sepsis and 
the post-arrest patient after severe global hypoxemia often presents with a “sepsis-
like syndrome”, which is associated with poor prognosis and death (Adrie 2002). 
However, the alteration of the inflammatory response after cardiac arrest is not the 
key component and necessary for the favourable effects of post arrest interventions, 
such as hypothermia. This corresponds, that circulating cytokines have no specific 
role in post arrest neurological injury, which was demonstrated in a rodent model 
of asphyxial cardiac arrest (Callaway 2008). 
In the brain, IRI involves abrupt release of excitatory amino acids and 
glutamate, activation of N-methyl-D-aspartate (NMDA) receptors, and subsequent 
mPTP opening results in depolarization of the membrane potential and brain matrix 
swelling causing rupture of the outer cell membrane and release of proteins (e.g. 
cytochrome C) to cytosol (Erecinska 1996, Hoesch 2008).  
Thirdly, in the late phase, a pro-imflammatory state causes secondary cell 
injury (McGinniss 2015). The integrity of blood-brain barrier is destroyed, which 
further contributes to exacerbation of cerebral edema (Weng 2012). The 
simultaneous glutamatergic storm by excessive stimulation by neurotransmitters in 
glutamate receptors (NMDA, AMPA) causes excitotoxicity, which leads to influx 
of sodium and chloride into brain cells, causing intracellular hyperosmolarity. The 
high osmolarity is followed by an influx of water into the cell, resulting in 
intracellular oedema and neuronal death (Gonzalez-Ibarra 2011). 
Acute respiratory and kidney dysfunction are common, appearing in 40 to 50 % 
of patients resuscitated from cardiac arrest. The digestive track IRI is often 
underestimated – it is associated with severe global hypoxemia facilitating bacteria 
translocation and major source of endotoxemia, which results in a state resembling 
lethal septic shock (Mongardon 2011). 
2.1.2 Post cardiac arrest syndrome 
Resumption of spontaneous circulation (ROSC) after prolonged global ischemia is 
an unnatural pathophysiological state involving multiple organs, generated by 
eventually successful CPR, which in the past was termed “postresuscitation 
disease” (Neumar 2008). Whole-body ischaemia causes global tissue and organ 
injury, which is exacerbated by the paradoxical injury after reperfusion. This 
precipitates a complex set of pathophysiological processes depicted lately as post-
cardiac arrest syndrome, which has four principal components: post-cardiac arrest 
brain injury, post-cardiac arrest cardiac dysfunction, systemic ischaemia/ 
reperfusion response and persisting precipitating pathology that caused or 
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contributed to the cardiac arrest itself (Neumar 2008, Nolan 2010). Treating the 
precipitating pathology is often superimposed in the expense of the former 
components (Neumar 2008). In effect, it should be acknowledged, that the patient’s 
outcome is defined by the cerebral injury rather than the myocardial damage 
(Ragosta 2018). Nevertheless, significant myocardial dysfunction is common after 
cardiac arrest but usually starts to recover by 2–3 days (Kern 1996). The severity of 
these disorders after ROSC varies and is strongly dependent of how rapidly 
resumption of perfusion was achieved (Neumar 2008).  
Post-cardiac arrest brain injury is the utmost cause for mortality following 
successful resuscitation. Among those fortunate few resuscitated patients surviving 
to ICU admission but subsequently deceasing in-hospital, brain injury is the 
primary driver of death in two thirds of surviving patients after OHCA. The brain 
is vulnerable and intolerant to even short periods of ischaemia and reperfusion 
response (Madl 2004). The cerebral injury mechanisms involve excitotoxicity, 
disrupted calcium homeostasis, free oxygen radical formation and activated 
apoptotic pathways. Cerebral oxygen delivery is compromised also by 
hypotension, hypoxemia, impaired cerebrovascular autoregulation and brain 
oedema, which peak 24 to 72 hours after arrest (Neumar 2008). Additional factors 
impacting brain injury after cardiac arrest are hyperglycaemia, seizures and 
pyrexia, which are common during the first 48 hours post arrest. Myoclonus and 
seizures can occur up to 40 % in comatose survivors of cardiac arrest and portend 
poor neurological outcome (Dragancea 2015). Seizures are likely to be caused by, 
as well exacerbate, post-cardiac arrest cerebral injury (Nielsen 2011a). Clinical 
manifestations of post-cardiac arrest brain injury involve unresolved 
unconsciousness, seizures and myoclonic status epilepticus. Residual 
unresponsiveness reflects injury in the arousal systems in the rostral brainstem and 
basal ganglia associated with cognition (Stevens 2014). The general consideration 
is, however, that survivors of cardiac arrest regaining consciousness have a good 
long-term neurological outcome. Intimidately, there are still substantial 
neurocognitive disturbances in almost half of the population surviving (Cronberg 
2009, Wachelder 2009).  
2.1.3 Factors affecting resuscitation outcome 
Several factors influence the outcome of OHCA victims from the very beginning of 
resuscitation. These include whether or not the arrest was witnessed and the 
promptness of resuscitation efforts, including defibrillation, were initiated (Engdahl 
2002, Schulman 2006). Those patients who receive CPR from a bystander or EMS 
provider, and those who are found in shockable rhythms (VF/VT) and who regain 
ROSC in the field before hospital admission are much more likely to survive than 
Review of the literature 
 23 
those who do not (Weng 2012). Other factors affecting survival are younger age, 
location of arrest outside home, and low adrenaline dose delivered during 
resuscitation (Weisfeldt 2011, Bougoin 2014). Interruptions of manual chest 
compressions for rescue breathing during CPR had been thought to affect blood 
flow and survival. However, in the comparison of groups with continuous or for 
rescue breathing interrupted chest compressions there were no differences in 
outcome (Nichol 2015). 
The duration of resuscitation before regaining ROSC relates directly to extent 
of brain injury and to a more pronounced reperfusion injury, more severe 
manifestations of low-flow phase and metabolic consequences (Püttgen 2007). 
Extended time to ROSC (> 25 min) is a predictive factor for poor outcome. Long 
interval to ROSC has been discouraged, however, to be utilized as a sole predictor 
of outcome, because other factors and circumstances surrounding CPR like the 
quality of CPR might be equally important (Nielsen 2009, Peberdy 2010).  
Those OHCA victims, who have had an abrupt period of cardiac arrest 
responding immediately to CPR may regain immediate normal cerebral function 
and do not require tracheal intubation and assisted ventilation (Nolan 2015). 
Spontaneous hypothermia on ICU admission has been identified as a predictor of 
unfavourable outcome and increased in-hospital mortality (den Hartog 2010). This 
associates with impaired thermoregulation, which is suggested to be an important 
physiologic determinant of post-resuscitation morbidity and OHCA prognosis 
(Benz-Woerner 2012). Curiously, on the contrary, those OHCA survivors, who are 
cooled sooner to target hypothermia temperature, have more favourable neurologic 
outcome (Wolff 2009). 
Adrenaline has been recommended as an integral component of ALS already 
for a half of century (Pearson 1963, Safar 1964), although there is contradictory 
evidence of its beneficence. Adrenaline improves myocardial blood flow through 
constriction of arterioles, which increase aortic diastolic pressure augmenting 
coronary blood flow. This may promote achieving of ROSC, but potentially offset 
by myocardial oxygen balance, global vasoconstriction, oxidative stress and tissue 
hypoperfusion (Krishnamoorthy 2013, Perkins 2014). In a recent randomized, 
double blind trial of 8014 all-rhythm OHCA patients in the United Kingdom, 
adrenaline during resuscitation was compared with placebo (saline) injections. The 
survival rate at 30 days post OHCA was significantly higher in the adrenaline 
group (3.2 %) vs. placebo (2.4 %) (Unadjusted odds ratio for survival, 1.39; 95 % 
confidence interval 1.06 to 1.82; p = 0.02), but among the survivors almost twice 
the number in the adrenaline group had severe neurologic impairment in 
comparison to the placebo group. This reflects the poor prognosis in cardiac arrest 
patients who do not response to initial CPR and defibrillation (Perkins 2018).  
Olli Arola 
 24 
During prolonged CPR, more cycles of adrenaline are required, which 
translates to acquired hyperglycaemia on hospital admission, which used to be 
considered an independent sign of poor outcome (Bellomo 2015). Antiarrhytmic 
drugs are utilized to treat VF and pulseless VT, in situations, where these rhythms 
persist after attempted shock deliveries (Soar 2018) However, none of the 
suggested and studied ALS drugs (adrenaline, lidocaine, vasopressin or 
amiodarone) has evidence that their use during resuscitation leads to improved 
short-termed survival, survival to discharge or improved neurological outcome 
(Olasveengen 2009, Olasveengen 2012, Nolan 2013, Ali 2018, Soar 2018). 
Moreover, in a placebo-controlled trial, neither amiodarone nor lidocaine resulted 
in a significantly higher rate of survival than the rate with placebo among patients 
with OHCA (Kudenchuk 2016). In the latest European Resuscitation Council 
guidelines for resuscitation, there is absent confidence to support any prophylactic 
antiarrhytmic agents immediately after resuscitation. A weak recommendation is 
given to use of amiodarone or lidocaine after five unsuccessful defibrillation 
attempts (Soar 2019). 
2.2 Post cardiac arrest organoprotection 
2.2.1 Mild therapeutic hypothermia (MTH) 
Because cardiac arrest is not a predictable emergency, organoprotective actions 
must act, when initiated after CPR or ROSC (Rittenberger 2013). Contemporarily, 
the only approved cardio- and neuroprotective strategy after cardiac arrest is mild 
therapeutic hypothermia (MTH). MTH involves intentional controlled lowering of 
a patient’s core temperature in an attempt to reduce ischaemia-mediated and 
reperfusion-mediated organ injury (Moore 2011, Girotra 2015). Lately, in 2011, 
five international critical care societies advocated the term MTH to be replaced 
with targeted temperature management (TTM) (Nunnally 2011). The beneficial 
effects of TTM include several mechanisms.  
Firstly, hypothermia reduces the metabolic rate for oxygen by 6–10 % for 
every 1 °C temperature reduction (Small 1999). During hypothermia oxygen 
demand decreases, and as oxygen supply is interrupted or limited, cooling brings it 
closer to actual oxygen delivery capacity while simultaneously decreased net ATP 
consumption maintains acceptable high-energy ATP stores (Erecinska 2003). This 
was formerly considered the sole mechanism of hypothermia-based neurological 
protection (Polderman 2008).  
Secondly, there are various other mechanisms explaining the protective effects 
of hypothermia: hypothermia diminishes oxygen and glucose consumption and 
counteracts the problems associated with reperfusion and re-oxygenation 
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(Polderman 2009). This contains protection of lipid membrane fluidity and 
inhibition of lipid peroxidation, which restores membrane integrity and prevents 
swelling of the post-anoxic tissue (Holzer 2005a). Nitric oxide and protein kinase 
C generation as well as calcium homeostasis is restored. On the other hand, 
proinflammatory signaling, cell destructing enzymatic processes and apoptotic 
pathways are inhibited. Hypothermia prevents additionally the progressive 
development of vascular permeability disorders and reduces postischaemic brain 
oedema. Moreover, therapeutic hypothermia provides cardio- and neuroprotection 
by increasing tissue tolerance to ischaemia and hinders the reperfusion injury -
generated development of inflammatory cascade and reactive oxygen species 
(ROS) production (Moore 2011). However, TTM plays a dual role, as it is likely to 
promote infection and it impairs both usual infectious criteria and host defences 
(Mongardon 2011). 
In regard of myocardial reperfusion injury, every 1 °C decrease in body 
temperature results in a 10 % reduction in myocardial infarct size, demonstrated in 
experimental studies in rabbits (Chien 1994). 
Practically, induced hypothermia is considered a relatively simple and 
inexpensive intervention to deploy, which does not require substantial increase of 
resources (Holzer 2005b). In a meta-analysis of eleven studies exploring the impact 
of hypothermia following cardiac arrest, the use of TTM after OHCA was 
associated with improved survival and neuroprotection. This was consistent also in 
patients with non-shockable rhythms, more indulgent downtimes, unwitnessed 
arrest and/or persistent shock (Schenone 2016). However, early initiation of TTM 
is indisputable, as each 1-hour delay in initiation of TTM resulted in 20 % increase 
of mortality in a meta-analysis of human OHCA studies (Mooney 2011). 
2.2.2 Historical considerations 
The history of intentional manipulation of body temperature for treatment of a 
disease or mitigation of its symptoms is ancient, as already e.g. Hippocratic school 
on Cos (500 BC) recommended induced local hypothermia with cold water, ice or 
snow to seriously injured parts of the body to reduce blood loss or to gouty 
swellings, sprains, fractures, haemorrhages, tetanus or febrile convulsions (Adams 
1929). However, due to the high risk of complications, the use of medical 
hypothermia was scarce during the following centuries and millennia. 
Use of hypothermia in modern clinical medicine is only 200 years old. Russian 
doctors described in 1803 a surmised approach to cardiac arrest resuscitation, 
which consisted of covering the patient with snow in desperate hope to gain return 
of spontaneous circulation (Varon 2008). Contemporarily, the chief surgeon to 
Napoleon Bonaparte’s Imperial Guard, baron Dominique-Jean Larrey, realized, 
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that the wounded infantrymen, who were adjacent to campfire, had greater 
morbidity and mortality than those, who were located remote from the warmth. 
Larrey utilized induced hypothermia also in (pre-anaesthesia era) amputations 
(Larrey 1817, Remba 2010). 
Early studies on hypothermia demonstrated, that cooling exhibits a “cold 
narcosis” in the central nervous system, equivalent to hibernation, which was 
entirely reversible (Britton 1930). First clinical reports on the anaesthetic properties 
of therapeutic hypothermia were presented in the Third International Cancer 
Congress in 1939, contemplating mainly intentional human refrigeration after 
traumatic and infectious brain lesions and anecdotally on cancer patients in an 
attempt to prevent cancer cells from further multiplying at reduced temperatures 
(Fay 1940, Fay 1959). However, atrocious inhumane hypothermia experiments in 
Nazi concentration camps declined the interest in further hypothermia research for 
decades (Wang 2006).  
Bigelow and McBirnie demonstrated in 1953, that therapeutic hypothermia 
reduced the myocardial and brain injury during cardiac surgery in a canine and 
monkey model (Bigelow 1953). In 1954, Rosomoff and Holaday showed, that in a 
canine model, the cerebral blood flow decreased 6,7 % per degree decline of 
temperature during induced hypothermia resulting in reduced brain volume and 
metabolic rate (Rosomoff 1954). The first clinical trial of therapeutic hypothermia 
in cardiac arrest patients was published in 1959. Of the 19 patients, who had 
cardiac arrest during surgery, 12 were cooled to 30–32 °C and hypothermia 
maintained for 24–72 hours. 7 of the 12 patients cooled survived without major 
neurological deficits compared to only 1 of 7 patients in the control group (Benson 
1959). These pioneering experimental studies demonstrated the effect of long-
lasting neuroprotection by cooling during and after severe hypoxemia. However, 
the main clinical issue was and is, how to affect hypoxemic injury after 
resuscitation from asphyxial or circulation standstill injuries, when the injury was 
in escalation (Gunn 2006). Resuscitative mild hypothermia after successful 
resuscitation from cardiac arrest was advocated by Peter Safar already in 1964 in 
his ABC of post cardiac arrest care (Safar 1964). 
Since the 1950’s, induced intraoperative moderate and deep hypothermia was 
utilized in specific surgical procedures (Dripps 1956). In 1958, extracorporeal 
cooling with a pump oxygenator was successfully used in open-heart surgery 
(Sealy 1958). This pioneering work of hypothermia for neuroprotection during 
cardiovascular and neurosurgical procedures was, however, again abandoned 
because of injurious systemic effects and significant side effects, including cardiac 
irritability, pneumonia and cumbersome management problems associated with 
deep hypothermia, which made hypothermia hazardous (De Guzman 1963). 
Hypothermia affects immune response and pneumonia and other infections were 
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incessant. Life-threatening arrhythmias were frequent in deep (below 28 °C) 
hypothermia (Varon 2012). Hypothermia-induced coagulopathy and electrolyte 
disorders were common, as well as hypothermia -induced electrolyte shifts and 
tubular dysfunction, leading to increased diuresis and subsequent loss of 
electrolytes (Wang 2006). 
In the 1980’s, Safar’s group rekindled therapeutic hypothermia research in a 
canine model of cardiac arrest (Brader 1985). Hypothermia after prolonged cardiac 
arrest was discovered to be beneficial illustrated both as recovered brain function 
and mitigated histological findings. Even mild hypothermia was demonstrated to 
confer dramatic neuro- and cardioprotection in numerous experimental models in 
different sized animals; rats, gerbils, rabbits and human-sized (60–80 kg) pigs (Dae 
2002). In the interim, small clinical trials in comatose patients following cardiac 
arrest demonstrated improved outcomes with hypothermia when compared to 
historical controls (Zeiner 2000). 
2.2.3 Targeted temperature management (TTM) 
In 2002, two prospective controlled randomized clinical trials were published in the 
same February issue of New England Journal of Medicine illustrating that 
intentional lowering of body temperature to 33 °C improved neurological outcome 
and salvaged lives in comatose survivors of OHCA. 
Holzer and colleagues in Europe and Bernard and co-workers in Australia 
conducted these trials. The European trial was organized in conjunction with nine 
centers in five European countries. A total of 275 patients with OHCA secondary 
to ventricular fibrillation were enrolled, 137 randomized to mild hypothermia 
(bladder temperature 32–34 °C) for 24 h and 138 patients randomized to 
normothermic controls, which at that time allowed also uncontrolled fever. The 
hypothermia group was cooled with an external cooling device (circulating cold air 
in a cooling tent) and if needed, with external ice packs, to maintain the target core 
temperature. The primary outcome was favourable neurological outcome within 6 
months, defined as either a Pittsburgh Cerebral Performance Category (CPC) 1 
(good recovery) or 2 (moderate cerebral disability). Secondary end points were 
mortality at 6 months and rate of adverse effects during the first 7 days following 
cardiac arrest. The hypothermia group had a favourable outcome in 55 % of 
patients and normothermia group in 39 % (p = 0.009) (Holzer 2002). 
The Australian therapeutic hypothermia trial was a quasi-randomized 
(assignment was based on the parity of the day of the month) study with four 
participating Melbourne emergency departments and without blinded outcomes or 
treatment. A total of 77 OHCA patients, all presenting an initial rhythm of 
ventricular fibrillation, were enrolled. 43 patients were assigned to hypothermia, 
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which was initiated in the ambulance and continued on hospital admission using 
cold packs on the head, neck, torso and limbs; the target pulmonary artery 
temperature was 33 °C, which was maintained for 12 h following hospital 
admission. To the normothermic group, 34 patients were assigned. A favourable 
neurological outcome was obtained nearly twice as often in the hypothermia group 
(49 % of patients) as opposed to the normothermia group (26 % of patients, 
p = 0.046) (Bernard 2002). 
The intensive care community then very rapidly adopted mild therapeutic 
hypothermia (MTH) therapy in cardiac arrest survivors. In the beginning of 2003, 
the International Liaison Committee on Resuscitation (ILCOR) published a special 
report recommending that all patients who achieved ROSC following a VF-
generated OHCA should be cooled as quickly as possible. Hypothermia was 
additionally considered beneficial in arrests from non-shockable (asystole, PEA) 
arrests (Nolan 2003). In Turku University Hospital, first OHCA patient was cooled 
in July 2003. In 2005, these recommendations were reviewed and re-endorsed by 
the American Heart Association (AHA class I recommendation) (ECC Committee, 
Subcommittees and Task Forces of the American Heart Association 2005) and 
European Resuscitation Council of the European Society of Cardiology (Nolan 
2005a).   
MTH gained widespread use and became the standard-of-care in unconscious 
survivors of OHCA. Nevertheless, using MTH in patients without shockable 
rhythms remained controversial, as the results from numerous trials remained 
contradictory (Testori 2011, Dumas 2011). None of the trials have, however, 
demonstrated any survival benefit with MTH in in-hospital cardiac arrests (IHCA). 
On the contrary, a recent large cohort study of 26183 IHCA patients, of whom only 
6 % were treated with MTH, indicated, that MTH was associated with lower in-
hospital survival and lower rates of favourable neurological survival (Chan 2016). 
The seminal 2002 trials were also criticized about some major limitations: low 
number of enrolled patients, quasi-randomization in the Australian trial, inclusion 
of highly select population of patients (based on inclusion/exclusion criteria, 92 % 
of patients were excluded) and the care personnel were not blinded to the treatment 
arm. Ultimately, in both studies, failure to treat hyperthermia in the control group, 
or control for it did not produce uniform control group. Furthermore, both trials 
reported the intention-to-treat population, which resulted in study patients, who did 
not get hypothermic, to be also included in the hypothermia group. The Australian 
trial used hospital discharge destination as a proxy for neurological outcome, 
depicting home as a good outcome and all other options (rehabilitation or long-
term care facility or death) as a poor outcome. This assumption of decision to home 
discharge corresponding solely functional neurological status did not consider any 
other sosio-economic and family factors influencing placement (Little 2014). In a 
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systematic review using GRADE (Grading of Recommendations Assessment, 
Development and Evaluation) methodology (Schünemann 2003) and trial 
sequential analysis it was demonstrated that the quality of evidence for 
hypothermia treatment in cardiac arrest patients to 33 °C was actually very low. In 
effect, it was ambiquous whether acknowledged treatment benefit was due to 
hypothermia or simply, to the prevention of fever (Nielsen 2011b).  
To confirm or refute the existing guidelines, a new trial was designed and 
launched, randomizing OHCA patients to two controlled temperatures, 33 and 
36 °C (Nielsen 2012). The Target Temperature Management after Out-of-hospital 
Cardiac Arrest trial (TTM-trial) included and randomized, in 32 study sites across 
Europe and Australia, 950 OHCA patients, which was more than twice the amount 
of patients from the previous trials combined. The principal differences in TTM 
trial in comparison to the 2002 trials were: firstly and most importantly, every 
single patient received controlled temperature management preventing fever in 
both study groups. Secondly, the overall care was contemporary; with attention to 
modern intensive care including improved pre-hospital care with high bystander 
CPR rate, and improved hospital care with adherence to modern post cardiac arrest 
care recommendations. As an example, 62–63 % of patients in both groups were 
subjected to an early (within 24h) coronary angiography with subsequent PCI if 
indicated (44 %). Additionally, in contrast to the former trials, the design, the 
statistical analysis plan and very importantly, the prognostication protocol for 
withdrawal of life-sustaining treatment were transparently published in advance 
(Nielsen 2012).  
The study found no difference in in-hospital mortality (50 % vs. 48 %, 
p = 0.51) or survival with favourable neurological outcome at 6 months (13 % vs. 
19 %, p= 0.02). These results reinforced the importance of controlled temperature 
at either of the two studied temperatures including active and simultaneous careful 
prevention of fever for 72 hours after OHCA without any reinforcement to 
dissuade hypothermia treatment per se (Nielsen 2013). 
The intensive care community again reacted absurdly speedily: after 
publication of TTM-trial in December 2013, the use of MTH dropped in a US 
retrospective registry cohort of 45935 OHCA patients from 52.5 % (2013) to 
46.0 % (2016). Concurrently, the overall risk-adjusted patient survival declined 
from 36.9 % to 34.3 %. This reflected a change in practice rather than a change in 
patient population (VF incidence declining, PEA/ASY increasing) (Bradley 2018). 
This alarming trend had also other explanations than allowing a more lenient 
temperature control after OHCA. In an Australian and New Zealand retrospective 
cohort study (from January 2005 to December 2016) with greater than 2 million 
post-OHCA ICU admissions, it was demonstrated, that after discharging MTH, 
also applying TTM was reduced, allowing post-OHCA patients to practically, have 
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hyperthermia, which was not seen in TTM-trial (Salter 2018). Hyperthermia is 
associated with increased mortality in OHCA patients (Zeiner 2001). This does not 
translate to that hyperthermia causes mortality, and conventional isolated fever 
treatment with e.g. scheduled administration of paracetamol has not been 
investigated in comparison with any cooling strategies (Bradley 2018). However, 
no modification in applying TTM was reported in an European survey (from May 
2014 to January 2015) of 264 ICUs in 11 countries (Deye 2016). The Ilcor 2015 
guidelines recommended TTM for adults with OHCA with initially shockable 
rhythm at constant temperature between 32 and 36 °C for at least 24 h (Donnino 
2016). 
2.2.4 Anaesthesia and adverse effects during targeted 
temperature management 
Adequate sedation will reduce oxygen consumption, which is further reduced with 
therapeutic hypothermia. Both analgetics (opioids) and hypnotics (e.g. propofol or 
midazolam) are required (Elmer 2017). Sedative agents, which cause 
vasodilatation, such as propofol, commonly generate the need for vasoactive 
supportive medication, mainly noradrenaline. In haemodynamically stable patients, 
propofol is effective for insuring adequate sedation, and its short half-life allows 
eventually meaningful serial neurologic examinations, when the sedation 
ultimately is terminated. In patients without significant bradycardia, 
dexmedetomidine, which directly reduces the shivering threshold via central α-2 
agonism, can alternatively be used (Callaway 2015). MTH affects cardiac 
conductance and induces electrocardiographic (ECG) changes, namely bradycardia 
and prolongation of PR- and QTc -intervals. The risk for serious arrhythmias is still 
low despite the significant ECG changes (Lebiedz 2012).  
Shivering is a common consequence of therapeutic hypothermia, particularly in 
the induction phase. It may increase the metabolic rate, oxygen consumption, work 
of breathing, heart rate and myocardial oxygen consumption, all unwanted factors 
exacerbating postischaemic injury. Shivering propagates acidosis and increases 
sympathetic discharge (Moore 2011, Nunnally 2011). Adequate sedation may 
enhance vasodilatation, which promotes heat loss and possibly suppresses the 
unfavourable effects of shivering and target temperature is achieved earlier (Sessler 
2009). If shivering occurs despite deep sedation, neuromuscular blocking agents 
(as an intravenous bolus or continuous infusion) could be used. Naturally, patients 
require airway protection and assisted mechanical ventilation. During 
neuromuscular blockade convulsive activity is obscured, which can delay the 
diagnosis of early posthypoxic myoclonus and appropriate anticonvulsive therapy 
(Moore 2011, Elmer 2017).  
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Shivering response can be reduced also with the use of skin counter-warming, 
i.e. warming of the non-cooled areas of skin (Badjatia 2009). Lastly and 
importantly, hypothermia decreases most enzyme-based reactions prolonging half-
life of drugs, such as sedatives and anaelgesic agents (e.g. bentzodiazepams, 
midazolam, fentanyl). At 34 °C, the clearance of sedative and paralytic agents is 
reduced by up to 30 % (Tortorici 2007). Additionally, some patients may have 
altered renal and hepatic function, which may affect drug clearance (Ben-Hamouda 
2014). This should be carefully considered in prognostication, which should not 
take place earlier than 72 hours after rewarming and discontinuation of sedation 
(Elmer 2017). 
Mild hypothermia increases peripheral systemic vascular resistance, which 
reduces cardiac output. Simultaneously, heart rate is reduced and contractility is 
increased, which is believed to be due to increased calcium concentration in 
cardiomyocytes (Nunnally 2011). However, the inotropic effect is observed only in 
bradycardia and not in higher heart rates. Bradycardia is an expected physiologic 
consequence, which is common during hypothermia. Unless associated with 
hypotension, a heart rate of 34 to 40 beats per minute is an acceptable goal at the 
target temperature (Polderman 2009). In two recent studies, bradycardia during 
hypothermia was independently associated with lower mortality and improved 
neurological outcome (Stær-Jensen 2015, Thomsen 2016). The effects of 
hypothermia on the myocardium and its contractility directly depend on the 
patient’s volume status and adequacy of sedation. 
During induction of hypothermia initial urine output (“cold diuresis”) increases 
following peripheral vessel constriction and increase in venous return, resulting in 
changes in renal perfusion and to a failure of reabsorbtion of sodium in distal 
tubules, translating to constrained water wasting (Varon 2010, Moore 2011). 
Coexisting hypovolemia will compound haemodynamic instability. Hypothermia-
induced tubular dysfunction and intracellular electrolyte shift potentially produces 
arrhythmia –generating electrolyte abnormalities, including hypophosphataemia, 
hypokalaemia, hypomagnesaemia and hypocalcaemia, in aggregate significant 
derangements in electrolyte and water homeostasis (Moore 2011, Nunnally 2011). 
However, vigorous repletion of hypokalaemia is discouraged, since serum 
potassium levels will predictably increase after rewarming (Elmer 2017).  
Slow rewarming not faster than 0,5 °C per hour in order to prevent temperature 
overshoot is recommended (Bernard 2003). Most patients may develop 
hyperthermia after rewarming, and continuing targeted temperature management to 
prevent fever after rewarming has been advocated (Varon 2012). 
As hypothermia can impair the immune system and suppresses the host’s pro-
inflammatory response, the risk for infections, particularly pneumonia is 
potentially increased. This is exacerbated by the concomitant use of invasive 
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catheters, cooling devices and assisted ventilation, which break natural barriers of 
intact skin and mucous membranes (Kuchena 2014). In the HACA study, 
pneumonia was more common in the cooled group, but this difference was not 
statistically significant (Holzer 2002). Neither has increased rate of pneumonia nor 
bacteremia during temperature management been demonstrated to impact mortality 
or neurological recovery (Kuchena 2014).  
Post cardiac arrest circumstances result in a prothrombotic state. A marked 
increase in thrombin-antithrombin complexes is prevailing, which originates from 
exposed tissue factor after endothelial damage and “endotheliitis” (Callaway 
2012). However, counteracting effects on platelet and clotting function by 
hypothermia include mild platelet dysfunction at 33–35 °C and reduction in platelet 
count. Clotting factors are affected at temperatures below 33 °C (Moore 2011). 
Bleeding related to therapeutic hypothermia has not been identified as a clinical 
problem (Lebiedz 2012). The bleeding risk is, however, multiplied, if coronary 
angiography with or without PCI was performed. This associates with the use of 
heparin and antithrombotic platelet inhibitors during and after invasive procedures 
(Nielsen 2009).  
Hypothermia decreases insulin levels secondary to catecholamine release. 
Peripheral insulin sensitivity is reduced and insulin secretion is altered, which 
results in hyperglycaemia also in non-diabetic patients. This is exacerbated by the 
release of stress hormones, which induce insulin resistance (“critical illness 
hyperglycaemia”) (Nunnally 2011). Additionally, deep sedation and hypothermia is 
linked with delayed gastric emptying and reduced gut function (Bernard 2003). 
Targeted temperature management at 36 °C is closer to normal temperatures 
and causes less shivering and other cooling-related adverse effects. Deep sedation 
and neuromuscular blocking agents are not required as frequently as in lower 
temperatures. In the TTM-trial, the number and severity of adverse events in the 
two intervention arms did not differ, although there was a tendency towards less 
events in the 36 °C – arm (p = 0.086) (Nielsen 2013).  
2.2.5 Percutaneous coronary intervention after cardiac 
arrest 
Randomized trials advocate early coronary angiography and immediate, complete 
and sustained revascularization with PCI in STEMI and also in NSTEMI patients 
(Javat 2017). However, specific evidence of PCI in cardiac arrest patients has been 
contradictory, since many of these patients have been excluded from randomized 
trials of early revascularization due to limitations of post-arrest electro-
cardiography-based diagnosis, unclear neurological recovery and high risk of 
mortality (Jobs 2017). Early coronary angiography in OHCA patients also with 
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NSTEMI is feasible, and associated with improved survival to hospital discharge, 
although the benefit is inconsistent (Hollenbeck 2014, Vyas 2015, Jobs 2017). It is 
likely, that early coronary angiography is selectively offered to patients with good 
prognosis for neurological recovery and omitted, if the outcome is prognosticated 
poor (Jaeger 2018). Post-arrest electrocardiogram (ECG) can be misleading: in a 
Norwegian study, 1 out of 7 postresuscitated survivors presenting with NSTEMI 
had surprisingly an acutely occluded coronary artery. Furthermore, 31 % of 
patients with VF/VT had an occluded coronary, but also in the patients with initial 
rhythm of PEA or asystole, 22 % had additionally an acute coronary occlusion 
(Stær-Jensen 2015). 
In a recent large French registry study, early invasive strategy was 
independently associated with improved survival in low-risk patients and coronary 
angiogram after OHCA was recommended in patients with presumed favourable 
neurological outcome according to risk score calculations. The authors 
acknowledged the risk of selection bias (Bougouin 2018). In another French 
registry and cohort analysis of 63394 OHCA patients, both the survival and 
favourable neurological recovery were significantly higher in the patients, who 
underwent an immediate coronary angiogram after resuscitation. However, the 
major determinant of favourable outcome was, whether coronary revascularition 
with PCI was performed (Jaeger 2018). The consensus statement by European 
Association for Percutaneous Cardiovascular Interventions/Stent for Life groups 
advocated an immediate coronary angiography and subsequent revascularization in 
comatose OHCA patients with STEMI. In the absence of non-coronary cause, and 
given the high incidence of acute coronary syndrome in patients with OHCA, the 
committee finds it appropriate to consider immediate coronary angiography also in 
NSTEMI arrests (Noc 2014).  
Recent study demonstrated, that an early coronary angiogram may be 
associated with improved short and long term survival in NSTEMI patients with 
initial shockable rhythm, whose CA was bystander –witnessed. These factors, 
however, are otherwise associated with improved outcome on their own (Elfwén 
2018). Unfavourable resuscitation circumstances, which suggest refraining from 
early coronary angiogram, include unwitnessed arrest, non-shockable rhythm, lack 
of bystander CPR, extended (> 30 min) time to ROSC, ongoing CPR, end stage 
renal disease and severe lactic acidosis (pH < 7,2; lactate > 7 mmol/l) (Rab 2015). 
In a recent meta-analysis on NSTEMI patients undergoing coronary angiogram 
following OHCA, one third of patients presented an acute lesion necessitating 
emergent PCI (Millin 2016). In a prospective registry trial, early coronary 
angiogram (within 24 hours) following OHCA improved survival (56,2 vs. 31 %) 
and functional outcome, but only early PCI was associated with significant survival 
benefit (Jentzer 2018).  
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Very recently, it was demonstrated in 522 OHCA patients without STEMI, that 
immediate or delayed (until neurological recovery) coronary angiography resulted 
in comparable, nonsignificantly different overall survival at 90 days (Lemkes 
2019). However, unstable and clinically significant acute coronary lesions were 
present in less than 20 % of the total study population and revascularizing coronary 
interventions were performed in less than 40 % of patients, which translates to that 
only minor part of the trial population was affected by the timing of coronary 
angiography. Intimidately, an early coronary angiography without absolute 
indication for performing it, can potentionally delay inception of targeted 
temperature management (Abella 2019, Lemkes 2019). Similarly, the potentially 
devastative neurologic injury leading to imminent premature death should be 
considered before executing excessive revascularization therapies (Ragosta 2018). 
2.2.6 Subsequent post cardiac arrest care 
2.2.6.1 Ventilation and tissue oxygenation 
Temperature management and early coronary angiography are not the only parts of 
post-resuscitation care following cardiac arrest and patients need additionally 
intensive monitoring and advanced critical care. Firstly, optimizing ventilation, 
adequate arterial oxyhemoglobin provision and reversal of tissue hypoxia is 
addressed (Neumar 2011). During resuscitation, the fraction of inhaled oxygen is 
recommended to be 100 % (Spindelboeck 2013). Under-arrest hypoxemia portends 
lower survival, which is associated with the urge of resumption of ATP synthesis 
through oxidative phosphorylation (Neumar 2011, Spindelboeck 2016). However, 
after ROSC, post arrest hyperoxemia should be avoided because it potentially 
exacerbates injurious mechanisms involved in the burst of reactive oxygen species 
(ROS) generation. Controlled ventilation-induced hyperventilation and ensuing 
hypocapnia associates with cerebral vasoconstriction and worse outcome (Buunk 
1996, Cokkinos 2009, Kilgannon 2010, Neumar 2011, Chu 2018, Skrifvars 2019). 
Metabolic lactic acidosis is common, and represents a biomarker of the CPR 
duration and reflects hypoperfusion originating from cardiogenic shock. Mild 
hypercapnia following resuscitation within the OHCA survivors may increase the 
likelihood of discharge from hospital (Eastwood 2014). Controlled re-oxygenation 
after ROSC with normoventilation and the lowest level of inspired oxygen 
concentration required to an arterial oxygen saturation target of 94–96 % results in 
better neurological outcome (Neumar 2011, Soar 2015). Cerebral autoregulation 
can be impaired after cardiac arrest, but the cerebrovascular reactivity to changes in 
arterial carbon dioxide (PaCO2) is usually preserved (Neumar 2008).  
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2.2.6.2 Haemodynamic impairment 
Secondly, after hospital admission, many cardiac arrest survivors develop systemic 
haemodynamic impairment, which is associated with global ischaemia-reperfusion 
injury leading to myocardial stunning (Laurent 2002). When compared to historical 
controls, a proactive therapeutical protocol with early goal-directed haemodynamic 
optimization improved survival in hypothermia treated OHCA victims (Gaieski 
2009). Circulatory support is required to maintain adequate cardiac output, organ 
perfusion and systemic oxygen delivery. The optimal mean arterial pressure (MAP) 
for post-arrest patients has not been defined by prospective clinical trials. 
Management guidelines reflect early goal directed therapy, which has been studied 
in randomized prospective clinical trials with patients with severe sepsis (Rivers 
2001). However, the optimal targets and strategies to achieve these targets 
potentially differ in PCAS, given the concomitant presence of post arrest cerebral 
injury, myocardial dysfunction and persistent precipitating arrest causes (Neumar 
2008).  
Cerebral perfusion pressure (CPP) is predominantly dependent of MAP, as 
elevated intracranial pressure (ICP) during the early post-cardiac arrest phase is 
uncommon (CPP = MAP – ICP). Good neurological outcomes have been reported 
from published studies in which the MAP target was as low as 65 to 75 mmHg 
(Sunde 2007). Inotropic (e.g. dobutamine) and vasoactive medication (e.g. 
noradrenaline) should be considered if haemodynamic goals, target blood pressure, 
cardiac output and systemic perfusion, are not achieved despite optimized preload.  
Post cardiac arrest global myocardial dysfunction is generally reversible and 
responsive to inotropes. No individual drug or combination of drugs has been 
demonstrated to be superior in the treatment of post-cardiac arrest cardiovascular 
dysfunction (Neumar 2008). In a retrospective study, 168 OHCA patients 
undergoing MTH were analyzed in respect of mean arterial pressure (MAP), 
vasoactive agent requirements and outcome. Higher MAP was associated with 
improved outcome, but requirement of vasoactive medication was associated with 
mortality and poor neurological outcomes (Beylin 2013). In a Finnish trial, the 
effect of low-normal and high-normal MAP was compared in respect of brain 
injury biochemical marker (neuron specific enolase (NSE)) release at 48 hours post 
arrest. Targeted MAP during post-resuscitation care was feasible, but it did not 
affect NSE concentrations or any secondary outcomes (Jakkula 2018a). The same 
study group assessed also the effect of different arterial carbon dioxide and oxygen 
concentrations in OHCA patients. The low-normal and high-normal concentrations 
of arterial carbon dioxide or oxygen concentrations did not affect NSE at 48 hours 
(Jakkula 2018b).  
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2.2.6.3 Metabolic impairment 
Thirdly, the post-cardiac arrest patient is likely to acquire metabolic abnormalities 
such as hyperglycaemia. Blood glucose concentrations need to be monitored 
frequently and hyperglycaemia treated with insulin infusion. Very tight glucose 
control is no longer advocated as the outcome benefit has not been re-established 
since the original trial in surgical ICU-patients (Van den Berghe 2001). In a 
randomized trial of 90 comatose survivors of ventricular fibrillation-generated 
OHCA, 2 glucose target groups were compared: a strict (4 to 6 mmol/l) glucose 
control group and a moderate (6 to 8 mmol/l) glucose control group. No difference 
in day 30 mortality was demonstrated. There were either no episodes of severe (< 
2.2 mmol/l) hypoglycaemia, which in previous trials has been connected to worse 
outcomes (Oksanen 2007). Current recommendation for glucose target after OHCA 
resuscitation is below 10 mmol/l with concomitant avoidance of hypoglycaemia 
(Nolan 2015). 
2.2.6.4 Seizures and status myoclonus 
Fourthly, post cardiac arrest brain injury frequently involves seizures, myoclonus 
or both in 5 to 15% of patients achieving ROSC and 10 to 40 % in those who 
remain comatose (Cokkinos 2009, Dragancea 2015). Post cardiac arrest seizures 
can present particularly refractory to traditional antiepileptic therapy. However, 
during hypothermia, routinely administered sedatives, such as propofol, are 
effective to control myoclonus (Wijdicks 2002). Furthermore, clinical seizures are 
potentially masked and suppressed by temperature management, sedation and in 
particular by neuromuscular blocking agents (Hovland 2006, Bouwes 2012, 
Rittenberger 2012). 
Prolonged, untreated seizures are detrimental in post anoxic brain injury as they 
inflict cerebral metabolic rate by up to 3-fold, which exacerbates the ongoing 
injury through excitotoxicity and enhanced metabolic stress (Ingvar 1986, 
Fujikawa 2005). Post arrest electroencephalography (EEG) is generally 
unequivocally pathologic reflecting varying extents of hypoxic ischaemic brain 
injury (Cloostermans 2012). It is ambiguous, whether electrographic status 
epilepticus is simply the electrographic expression of severe brain injury or a truly 
modifiable condition (Ko 2011). Epileptic activity without clinical signs and 
symptoms (nonconvulsive status epilepticus) is frequently described. Intimidately, 
no general agreement on the definition of electroencephalographic status 
epilepticus after cardiac arrest exists (Backman 2017). 
If electroencephalographic status epilepticus is surmised, current practice 
includes unstandardized, moderate treatment with anticonvulsant drugs. Although 
widely used, this does not apparently improve patients’ outcome. Currently, there 
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is inadequate evidence to recommend any prophylactic pharmacological strategies 
post arrest to prevent seizures (Ruijter 2014).  
Myoclonus and electrographic seizure activity, including status epilepticus, are 
associated with grave clinical prognosis; in prospective case series mortality has 
been 90–100 % (Hofmeijer 2014). However, it is still possible, that even 10 % of 
individual resuscitated patients with myoclonus may survive with good functional 
outcome (Seder 2015).  
Extended observation without premature prognostication is warranted 
especially after treatment of seizures with sedative agents, given the prolonged 
clearance of these drugs during hypothermia (Samaniego 2011). The optimum 
duration for anticonvulsive therapy after OHCA is unknown, but it should not be 
extended beyond 2 weeks, if the patient fails to awake (Rossetti 2016). 
2.2.6.5 Acute Kidney Injury 
Fifthly, acute kidney injury (AKI) following OHCA is common, ranging from 12 
to 40 % of patients. The most used and validated consensus definition and method 
of classifying AKI is the RIFLE (Risk, Injury, Failure, Loss of kidney function, 
and End-stage kidney disease) classification system (Bellomo 2004). Severe AKI 
(RIFLE class I/F) is usually associated with post-resuscitation cardiogenic shock 
(PRCS). Other acknowledged independent risk factors for AKI include higher 
cumulative dose of noradrenaline during the first 24 hours in ICU (reflecting 
PRCS), previous use of blockers of renin-angiotensin-aldosterone system and 
higher baseline creatinine levels (Chua 2012). AKI is commonly transient and 
hypothermia does not increase the need for renal replacement therapy (Knafelj 
2007). In another recent study, extension of hypothermia treatment at 33 °C to 48 
hours did not increase renal failure when compared to hypothermia for 24 hours 
(Kierkegaard 2017). Usually renal function returns to normal by 28 days (Zeiner 
2004).  
2.3 Xenon 
In 1898, British chemist Sir William Ramsay and his student Dr Morris Travers 
found unknown residue of evaporating components of liquid air and discovered 
xenon, a noble gas with the lowest concentration in air. The noble gases helium, 
neon, argon, krypton, xenon and radon stand at the far right in the periodic table 
and are colourless, tasteless and odourless monoatomic gases that are characterized 
by a fully occupied (complete octet, except helium) outer atomic shell of electrons, 
making them inert or at least less capable of interaction with other biological 
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compounds. At the first sight, this inertness might cause an assumption that these 
gases are unreactive and would not exert any biological activity (Preckel 2006).  
However, the research of physiological effects under hyperbaric conditions and 
deep-sea diving provided evidence on the biological effects of inert gases. In 1939, 
US Navy captain, medical doctor Albert Behnke Jr. published observations in 
deep-sea divers using various breathing mixtures, including xenon, in his studies of 
exploring the “stupefaction” and “mental fogginess” during deep dives. He 
anticipated, that gases other than nitrogen could also facilitate narcosis (Behnke 
1939). Nitrogen narcosis is common when diving below 30 meters seawater, 
corresponding to fourfold ambient pressure (4 ATA). In this environment and with 
breathing compressed air (21 % oxygen, 78 % nitrogen), the nitrogen partial 
pressure increases and can facilitate a narcosis. If the diver goes deeper, the 
increased nitrogen partial pressure may eventually cause loss of consciousness. To 
avoid nitrogen narcosis and make deeper dives possible, nitrogen was replaced 
with other gases in the breathing mixture (Behnke 1938). This led to the discovery 
that noble gases had a potential to produce anaesthesia, which was initially 
deduced, when Behnke and Yarbrough reported the development of progressive 
narcosis in divers exposed to xenon, argon or krypton in 20 % oxygen under 
hyperbaric conditions (Behnke 1939). Xenon was predicted to be anaesthetic at 
atmospheric pressures, based on its low relative solubility in fat compared to argon, 
krypton and nitrogen. Lawrence and co-workers corroborated the anaesthetic 
properties of Xenon in mice (Lawrence 1946). Eventually, Cullen and Gross 
reported in 1951 the first clinical xenon anaesthesias, performed on two voluntary 
patients undergoing orchiectomy or ligation of the fallopian tubes (Cullen 1951).  
Xenon was approved for anaesthesia in Russian Federation in the year 2002, 
authorized in Germany in 2005 and the approval for the usage of xenon as an 
anaesthetic agent was extended to all Western Europe in 2007. To date, however, 
marketing authorization for xenon use as an anaesthetic in North America by the 
US Food and Drug Administration is still in progress and not yet warranted (Maze 
2016).  
The assumption of xenon’s putative role in neuroprotection was associated with 
the discovery of xenon’s molecular sites of anaesthetic action. Xenon was 
identified as an inhibitor of N-methyl-d-aspartate (NMDA) subtype of glutamate 
receptor (Franks 1998). NMDA receptor plays a major role in controlling synaptic 
plasticity and memory function (Winkler 2016). However, overexcitation of 
NMDA receptor is involved in various conditions of neuronal injury, which 
prompted the idea and investigation of xenon’s use as a neuroprotective agent 
(Franks 1998). Overactivation of NMDA receptor appears to be crucial to the 
initiation of neuronal injury and cell death from various pathological conditions 
such as ischaemia and brain injury (Wilhelm 2002). In cultured hippocampal 
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neurons xenon inhibited NMDA-evoked currents by 60 % in a xenon concentration 
of 80 %, which is beyond sufficient to maintain anaesthesia. The inhibition was 
similar at micro-island cultures of glutamatergic hippocampal synapses, but in this 
study xenon had no effect on synaptic “non-NMDA” AMPA/kainate receptors 
(Franks 1998). However, recent evidence suggests, that all glutamatergic receptors, 
NMDA, AMPA and kainate are inhibited by xenon. NMDA and AMPA inhibition 
could both contribute to xenon’s putative neuroprotective effect (Hasaneder 2009). 
The pre-synaptic effects of xenon must be minimal, consistent with the observation 
that several voltage-gated ion channels in cardiac tissue are unaffected by clinically 
relevant concentrations of xenon (Stowe 2000). Unlike most general anaesthetics 
(e.g. isoflurane, sevoflurane, propofol, etomidate) xenon has little or no effect on 
inhibitory GABAA receptors. The specifity of xenon for the NMDA-mediated 
component together with the lack of effect at the inhibitory GABAergic synapses 
imply that xenon acts postsynaptically (de Sousa 2000, Dickinson 2010). 
In 2000, Preckel and co-workers provided first evidence that xenon exerts 
cardioprotective effects in a rabbit model of ischaemic myocardium (Preckel 
2000). These protective effects by xenon in ischaemic myocardium and eventually, 
demonstrated also in ischaemic brain injury represent a post-conditioning effect, 
which is targeted to the ischaemia-reperfusion injury with a goal to restrict an 
ongoing injury (Smit 2015).  
The evidence of synergistic organoprotection with simultaneous hypothermia 
and xenon inhalation was first confirmed in animal models of neonatal asphyxia 
and ischaemia (Ma 2005, Martin 2007, Hobbs 2008). This was corroborated in a 
randomized trial in a porcine model of cardiac arrest, which ostensively 
demonstrated the synergistic effects of these interventions as even a short exposure 
to xenon during induction of mild therapeutic hypothermia resulted in significant 
improvements in functional recovery and improved myocardial dysfunction (Fries 
2012).  
2.3.1 Chemical and physical characteristics 
Xenon is the only noble gas, which is anaesthetic at normobaric and normothermic 
conditions. It is stable, non-flammable, nontoxic, non-irritant, non-explosive and 
does not maintain combustion. Xenon has no metabolites, active or inactive, under 
biologic conditions (Goto 1998). In contrast to other NMDA antagonists, such as 
ketamine and nitrous oxide N2O, xenon does not produce psychotomimetic side 
effects (Ma 2002). The molecular weight of xenon is 131,2 Daltons, which makes 
it 3,2 times denser than air. The higher density makes the viscosity of xenon 
consequently 1,7 -fold greater than air. In effect, during xenon inhalation, airway 
resistance is expected to rise, especially if the airways are compromised. However, 
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it must be bourne in mind that the airway pressure measured at the circuit end of 
the tracheal tube in the breathing circuit may overestimate the airway pressure 
exerted within the bronchial tree (Schmidt 2009). Being chemically inert with fully 
occupied outer electron shell prevents covalent bonding and makes xenon molecule 
stable and non-reactive. However, in extreme nonbiologic conditions in laboratory 
environment, xenon can constitute for example oxides and halides. Interestingly, 
biological interactions can still occur through non-covalent van der Waals 
intermolecular forces. The monoatomic xenon molecule with a very large electron 
shell can be polarized and distorted by nearby molecules creating e.g. an induced 
dipole (Lynch 2000). This enables interaction with amphiphilic domains of 
surrounding molecules, such as human amino acids, enzymes, receptors and 
bilayered lipid membranes. This is the fundamental basis of xenon’s biological 
effects (Trudell 1998). Xenon’s ability to be polarized is greatest among other 
noble gases (Jawad 2009). 
Xenon is currently produced by the same method of fractional distilling and 
purification of liquefied air, described by Ramsay and Travers. The majority of the 
produced xenon is used in space aeronautics or industry using it in car headlights 
and light bulbs. In medicine, the majority of consumed xenon is used up in 
imaging, as the radioactive isotope Xe133. For anaesthesia, xenon is supplied in gas 
cylinders containing non-radioactive Xe131 (Arch 2011). 
2.3.2 Xenon anaesthesia 
Xenon anaesthesia is characterized by a very rapid onset and emergence (Nakata 
1997). The rapidity with which patients emerge from xenon anaesthesia is 
remarkable compared with even propofol (Maze 2016b). The blood/gas partition 
coefficient, which describes the solubility of inhaled anaesthetics in blood, of 
xenon is lowest of all known anaesthetics (0.115), which results in a very fast 
induction (Goto 1998). In comparison with other current inhalational anaesthetics, 
the blood/gas coefficient is consistently higher than xenon, e.g. sevoflurane (0,65), 
desflurane (0,42) and nitrous oxide N2O (0,47) (Steward 1973). Minimum Alveolar 
Concentration (MAC) is the median concentration required to produce anaesthetic 
effects – an inverse indicator of anaesthetic potency. The proposed original 
approximate of xenon MAC was 71 % (Cullen 1969). With contemporary 
techniques, xenon MAC is assumed to be 63 % (Nakata 2001). It should be 
acknowledged, that these MAC values were defined from studies in which 
halothane or sevoflurane was co-administered and xenon MAC was extrapolated 
by the lowering the MAC of the additional inhalation anaesthetic (Nakata 2001). 
Furthermore, it is argued that there is a wide variability of xenon MAC 
between sexes, being 51 % in women and 69 % in men. In elderly patients, the 
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MAC value is, however, significantly even lower (Goto 2002). The implications of 
this high MAC include the limitation of the inhaled oxygen concentration delivered 
to the patient, especially in closed circuit ventilators. In some conditions it is 
difficult to maintain sufficient anaesthetic concentration of xenon, if it is utilized as 
the sole and single anaesthetic. To avoid hypoxemic gas mixtures, safe end-tidal 
oxygen concentration requires to be maintained over 30 %. Particularly in 
compromised oxygenation situations, such as pulmonary congestion or other 
parenchymal pulmonary disease, increased FiO2 is required (Law 2016). 
Practically, xenon must be supplemented with other anaesthetic agents and 
techniques (Nakata 2009). When compared to other volatile anaesthetic regimens 
(N2O, fluorinated alkans, hydro-chloro-fluorocarbons, alkyl ethers etc.), which are 
greenhouse gases with atmospheric lifetimes measured in years and involved in the 
depletion of ozone layer, xenon is occupationally and environmentally attractive, as 
it is a normal constituent of the atmosphere and not a greenhouse gas. However, 
xenon purification from air consumes plenty of energy, as production of one liter of 
xenon requires 1000 000 times more energy than for one liter of N2O (Rossaint 
2003). 
2.3.2.1 Mechanism of action 
Hypnotic drugs take action by activating inhibitory and/or blocking excitatory 
pathways (Franks 1994). To produce anaesthesia, a sufficient anaesthetic 
concentration has to be achieved at the site of action: the effect-site compartment 
(Hanne 2001). The three acknowledged anaesthetic molecular and ionic channel 
targets are γ–aminobuturic acid type A (GABAA) receptor (etomidate, propopol, 
volatile agents), the glycine receptor (volatile agents) and the NMDA receptor 
(xenon, nitrous oxide, cyclopropane, ketamine) (Dickinson 2007). 
When inhaled in concentrations exceeding 40 %, xenon causes an immediate 
loss of consciousness. Inhaled xenon is dissolved into blood in the alveoli and 
rapidly crosses the blood-brain barrier, exerting its anaesthetic effect by inhibiting 
excitatory glutamatergic signaling (Franks 1998, Nagele 2005).  
Besides anaesthesia, xenon has been demonstrated to have anaelgesic 
properties, illustrated by diminished opioid expenditure during surgery (Lachmann 
1990, Boomsma 1990, Nakata 1999). Xenon’s antihyperaelgesic and anaelgesic 
potency may be related to NMDA antagonism, since other NMDA antagonists 
(ketamine, N2O) have similar effects. The anaelgesic effect may be mediated by 
inhibition of NMDA receptors and nociceptive responsiveness in the dorsal horn of 
the spinal cord.  
On the contrary to N2O anaelgesia, however, xenon anaelgesia is not 
antagonized by naloxone, suggesting that the anaelgesic effects are not mediated by 
Olli Arola 
 42 
opioid receptors (Yagi 1995). In a rodent model, xenon anaelgesia was not 
mediated via opioidergic or adrenergic receptor systems, which supports the 
assumption of a spinal mechanism of antinociception (Ohara 1997). Marx and co-
workers demonstrated in a porcine model, that xenon prevented, without additional 
anaelgesia, haemodynamic reactions caused by nociceptive surgical stimulation. 
Additionally, there was a substantially lower plasma adrenaline concentration 
during xenon anaesthesia, not only in concentrations of about one MAC, but also at 
subanaesthetic concentrations of half and one-third of this amount. Their 
conclusion was, that xenon provides anaelgesic effects even in concentrations 
below its MAC (Marx 1997, Marx 1998). 
2.3.2.2 Closed circuit ventilation 
All noble gases exist in various concentrations within the atmosphere (ranging 
from 934000 ppm (0.934 %) for abundant argon to 0.0875 ppm (0.000 008 75) for 
very scarce xenon. For an illustrative example, a room of 50 m3 contains 5 
milliliters of xenon (Marx 2000). The purification and production cost of noble 
gases increases in proportion to their relative atmospheric rarity, and the laborious 
and costly technique of sequential cryogenic fractional distillation makes the 
scarcest of them expensive. In modern anaesthesia ventilators, the average amount 
of fresh gas required is usually 1 liter per minute. To economize the expenditure of 
an expensive gas, fully closed low-flow circuit ventilators are used. To simplify, 
the very same anaesthetic gas molecules are scavenged from exhalation and 
recycled within the system, which in effect reduces the gas expenditure after 
induction to 150 to 200 milliliters per minute. The consumption of xenon for 
inhalation anaesthesia induction or wash-in was demonstrated to be approximately 
8 to 9 liters (Nakata 1997). The gas expenditure is highest during the first 15 
minutes of anaesthesia; thereafter uptake reduces to 0.6 liters per every 15 minutes 
(Luttropp 1994). The major portion of total xenon consumption is the gas that 
remains in the anaesthesia machine after disconnection. Therefore, recycling 
devices have been constructed, using filters and cooling traps to remove other 
gases from the mixture. Marx and others have reported, that 67 % of the xenon 
with a purity of 89 % can be recycled and retrieved with this method (Marx 1996). 
In our study, the average expenditure of xenon inhalation for 24 hours was 56,3 
liters, which corresponds within the average current price of 18 € per one liter of 
xenon to an average cost of 1013 € per single study patient xenon administration. 
The fully closed-system ventilator used in our study was PhysioFlex (Dräger, 
Lübeck, Germany), where the circuit volume is about four liters (Hanne 2001). The 
ventilator has four membrane chambers, whose volume is constantly monitored 
(Baum 2005). There are no unidirectional valves in the ventilator. The anaesthetic 
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gas circulates within “the system” (i.e. patient airways, soluble in patient 
circulation and ventilator) at a rate of 70 liters per minute, driven by a blower. The 
volume and concentrations of oxygen, exhaled carbon dioxide (absorbed by filters) 
and anaesthetic gas (xenon) are continuously monitored. The concentration of 
oxygen is preselected as a target. Xenon anaesthesia maintaining requires  
 
Figure 1.  PhysioFlex (Dräger, Lübeck, Germany), fully closed circuit ventilator, used in our 
study. Gas cylinder containing xenon on the right. Values of volume, pressure, carbon 
dioxide, oxygen and xenon concentration are constantly displayed 
a fraction of 50–70 % of inhaled xenon with FiO2 25–30 %. Oxygen is delivered to 
the system by an electronically controlled measurement system to reach the 
predetermined target with the sufficient compensatory flushes of oxygen. However, 
the tissue nitrogen ought to be lowered in advance in order to prevent exhaled 
nitrogen interference and accumulation in closed circuit ventilation. 
Denitrogenization is achieved with 100 % oxygen inhalation for 15 to 30 minutes 
before starting xenon administration (Dingley 2001). Importantly, the gas circuit 
ought to be as closed as possible; requiring distinguished non-leaking, non-silicon, 
rubber plastic tubes and connectors. 
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2.3.2.3 Adverse effects 
As opposed to other inhaled anaesthetic agents, xenon is devoid of substantial side 
effects. It is not associated with malignant hyperthermia (Baur 2000), coagulopathy 
(Sanders 2005) or reactions with absorbent (Hanne 2001). Xenon is not 
embryotoxic or teratogenic and does not cause allergic reactions (Natale 1998, 
Burov 1999). In comparison to other anaesthetic regimens, xenon anaesthesia 
produces the highest regional blood flow in the brain, liver, kidney and intestine 
(Hecker 2004). However, in a porcine model, xenon reduced portal venous flow 
and may compromise hepatic perfusion (Iber 2008).  
One of the adverse effects related to NMDA inhibition is postoperative nausea 
and vomiting (PONV). These are well-known adverse effects of other NMDA-
inhibitors, such as ketamine and N2O. Xenon has this property also. In a study with 
healthy volunteers, inhalation of 35 % xenon induced nausea in 10 % of subjects 
(Bedi 2002). In another study comparing xenon and isoflurane in patients 
undergoing elective surgery, the incidence of xenon-associated PONV was 26 % 
(Rossaint 2003). Premedication with 4 mg of dexamethasone was not effective 
preventing nausea (Fahlenkamp 2016). In a Turku University study on anaesthesia 
depth monitors, 8 of the 17 healthy volunteers (47.0 %) exposed to xenon had 
nausea during recovery, and despite antiemetic therapy 17.6 % also vomited (Laitio 
2008). In a recent meta-analysis of randomized controlled trials comparing xenon 
to inhaled agents or propofol anaesthesia, the incidence of PONV was higher for 
xenon anaesthesia (34.4 %) than volatile anaesthesia or TIVA (19.9 %), risk ratio 
1.72 (CI 1.1–2.69) (Law 2016).  
The laminar flow within the respiratory tract corresponds to that airway 
resistance depends primarily on viscosity, and if the flow is turbulent, the density 
of the gas is responsible of airway resistance increase (Hecker 2004). During xenon 
anaesthesia, the respiratory rate is decreased and tidal volume increased, which 
maintains constant minute volume. The airway pressure increase observed during 
xenon anaesthesia is attributed to its higher density and viscosity. Xenon does not 
affect airway diameter. Airway pressure increment during xenon anaesthesia is 
merely a characteristic than an adverse effect (Baumert 2002). In a retrospective 
study with patients mechanically ventilated with 33 % xenon/67 % oxygen and 
undergoing cerebral blood flow measurements by means of stable xenon-enhanced 
computerized tomography (CT) scanning, xenon increased the mean airway 
pressure from 31.6 cmH2O to 42.7 cmH2O. The airway pressure reversed 
immediately when xenon exposure was terminated (Rueckoldt 1999). 
Diffusion hypoxia or “Fink effect” can theoretically occur also during 
emergence of xenon anesthesia. Simply, when xenon administration is 
discontinued, quantities of this gas cross from the blood into the alveolus (based on 
the concentration gradient). Accidentally, the oxygen and carbon dioxide 
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concentration in the alveolus are diluted by this xenon washout, which could cause 
the partial pressure of oxygen to decrease and could temporarily lead to hypoxia. 
To prevent diffusion hypoxia during anaesthesia emergence, xenon is substituted 
by 100 % oxygen. In a pig study comparing diffusion hypoxia after xenon and N2O 
anaesthesia, the oxygen partial pressure change was three times greater after N2O 
than xenon, probably due to the lower solubility of xenon (Calzia 1999). 
Diffusion and storage of xenon and other inhaled anaesthetic agents to air-filled 
cavities, such as into the bowel has been pointed out. For example N2O diffusion 
into the bowel during anaesthesia causes a progressive decrease in tissue perfusion. 
N2O is traditionally contraindicated for use in paralytic ileus and relatively 
contraindicated for bowel surgery (Eger 1965). When xenon was compared to N2O 
anaesthesia, the diffusion into obstructed bowel segments and increase of gas 
volume was four times higher with N2O of that observed with xenon. Xenon did 
not increase intraluminal pressure, which is probably associated with the lower 
blood/gas partition coefficient (Marx 2000). In a porcine animal model, xenon 
exposure decreased superior mesenteric artery blood flow, although intestinal 
oxygenation was maintained. In physiological conditions, xenon does not impair 
intestinal or mucosal oxygenation, as other volatile anaesthetic agents have 
demonstrated to do (Vagts 2004). 
2.3.3 The effects of Xenon in the cardiovascular system 
Xenon anaesthesia is associated with cardiovascular stability. It has virtually no 
direct influence on myocardial blood flow and global haemodynamics in healthy 
and diseased hearts (Preckel 2002). Ventricular function remains unchanged during 
xenon anaesthesia, as assessed by transoesophageal echocardiography (Luttropp 
1993, Morita 1996). Lachmann and co-workers suggested, that the haemodynamic 
stability during xenon anesthesia was a result of less stress-induced sympathetic 
stimulation, which is supported by the observation of stable or diminished plasma 
cortisol and catecholamine levels (Boomsma 1990, Lachmann 1990) Xenon’s 
effects on autonomic nervous system have been compared in previous studies to 
those with nitrous oxide or isoflurane. Xenon reduced both parasympathetic and 
sympathetic activity and appeared to have a vagotonic effect (Ishiguro 2000). On 
the contrary to other inhaled anesthetics, xenon preserved left ventricular 
contractility and decreased heart rate (Wappler 2007). In a recent meta-analysis, 
xenon anaesthesia was compared with other inhaled agents. Xenon lowered heart 
rate more (mean difference -6 beats/minute (CI -10.0 to -2.3)) than other inhaled 
agents. In comparison with propofol, the reduction of heart rate in xenon patients 
was -9 beats/ minute (mean difference, CI -17.3 to -3.3), which represents a 16.2 % 
change. Simultaneously, administration of propofol reduced MAP by a mean of 14 
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mmHg (CI -29.0 to -2.5), which was a 15.0 % change (Law 2016). A crossover 
comparison of xenon with propofol during cardiac bypass surgery patients with 
normal left ventricular function found no effect on heart rate, MAP, or LVEF and 
none of the vasodilatory effects that were observed with propofol (Dingley 2001).  
MTH influences cardiac conductance (PR-interval prolongation) and impairs 
cardiac repolarization, indicated by prolonged QT-interval, which can be 
associated with critical ventricular arrhythmias. However, in a study with healthy 
volunteers, inhaled xenon did not increase QTc interval (Neukirchen 2015). 
To summarize, xenon anaesthesia is associated with a high degree of preserved 
cardiovascular stability with no significant effects on the myocardium, 
atrioventricular conduction time, or coronary blood flow. Cardiac ion currents are 
not altered and the responsiveness of cardiac muscle to inotropic and chronotropic 
stimulation remains intact (Schroth 2002). 
2.3.4 Xenon and postoperative neurocognitive dysfunction 
Intimadately, some of the previously cognitively intact patients undergoing surgery 
and anaesthesia will develop symptoms of cognitive dysfunction after their 
operation. Commonly these involve disturbances in thinking, perception and 
attention (Needham 2017). Especially after cardiac surgery in the elderly (> 65 
years) patients, postoperative impairment of neurocognitive function has been 
recognized for years as a prevalent clinical problem (Höcker 2009). Post-operative 
cognitive dysfunction or decline (POCD) is a controversial condition inferred from 
a comparison of pre-operative to post-operative cognitive function (Skvarc 2018). 
POCD, which is distinct of post-operative delirium, can occur in 25 % to 40 % of 
elderly patients at discharge (Moller 1998). The underlying pathophysiology 
involves neuroinflammation and oxidative stress secondary to anaesthesia and 
surgery (Skvarc 2018). Predisposing factors, such as previous stroke, carotid 
stenosis, poor functional status, atrial fibrillation, renal failure, diabetes and older 
age (> 62 years) increase the risk. The incidence of POCD ranges from 28 % to 
100 % after cardiac surgery and from 7 % to 26 % after noncardiac surgery (Moller 
1998). 
Various pharmacological perioperative strategies, including xenon inhalation, 
have been studied to prevent or attenuate POCD (Bilotta 2013). The particular 
interest in xenon emerges from neuroprotective effects in cerebral ischaemia and 
neurologic dysfunction demonstrated in different animal models (Wilhelm 2002, 
Ma 2003, Schmidt 2005). However, no difference in the comparison of POCD 
incidence or early cognitive testing was demonstrated in the elderly patients 
undergoing elective surgery with desflurane or xenon anaesthesia (Coburn 2007). 
Similarly, in comparison with propofol, xenon-based anaesthesia did not decrease 
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postoperative impairment of neurocognitive function, which was observed in a 
substantial proportion in the elderly (65–83 years) patient population (Höcker 
2009). Furthermore, in a large multicentre trial on elderly (> 75 years old) mentally 
functional hip fracture patients, xenon-based anaesthesia was compared to 
sevoflurane-based general anesthesia. In the xenon group, the incidence of 
postoperative delirium was non-significantly lower, but importantly, the sequential 
organ failure (SOFA) scores and the rate of adverse effects were significantly 
lower in the xenon group than in the sevoflurane group (Coburn 2018). 
2.4 Xenon and neuro- and cardioprotection 
Growing evidence from preclinical and clinical trials has confirmed the protective 
properties of xenon administered alone or in combination with hypothermia in 
various organs (Hobbs 2008). Very low, subanaesthetic concentrations of xenon 
and mild hypothermia are, however, not protective on their own, but in 
combination they produce synergistic organoprotection, which was demonstrated 
in a rodent model (Schwiebert 2010). There are great quantity of enzymes and 
cellular structures involved in the assumed organo-protective effects of xenon post-
conditioning. These include survivor activating factor enhancement (SAFE) 
pathway and reperfusion injury salvage kinase (RISK) pathway (Smit 2014). The 
main target is the ischaemia-reperfusion injury (IRI) following an abrupt cessation 
and re-establishment of blood flow in vulnerable organs, most significantly heart, 
brain and kidney. The precise molecular targets differ between these organs.  
2.4.1 Molecular targets of xenon’s neuroprotective effect 
Xenon was identified as a competitive NMDA receptor antagonist at glycine 
coagonist site (Franks 1998, Dickinson 2007, Banks 2010) through an interaction 
with a phenylalanine residue (Armstrong 2012). This was corroborated in a study, 
which demonstrated, that xenon inhibition in NMDA receptors was mitigated, if 
the glycine concentration was higher (Dickinson 2007). Other glutamate receptor 
subtypes (AMPA, kainate) (Dinse 2005) and activation of TREK-1 two-pore 
potassium molecular and plasmalemmal ATP-sensitive potassium channel (KATP) 
inducing potassium leak currents (Gruss 2004) are involved as minor and 
secondary targets explaining xenon’s anaesthetic and neuroprotective properties.  
In the brain, xenon neuroprotection is explained by its antagonism toward 
excitatory glutamatergic synapses, most importantly on NMDA receptor, but 
additionally on “non-NMDA” receptors AMPA and kainate. It is acknowledged, 
that xenon has a blocking effect on two-pore K+ channels, on nicotinic 
acetylcholine and serotonin receptors (Dinse 2005). Importantly, ischaemic or 
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injured neurons release excessive amounts of glutamate, which results in 
depolarization and NMDA-evoked dysfunction of the plasma membrane Ca2+ 
pump. This results in intracellular influx of Ca2+, disrupting mitochondrial function 
and increasing excitability (Franks 1994). Xenon inhibits Ca2+-calmodulin 
dependent protein kinase II (CaM K II), which is in critical role in regulating 
processes such as postsynaptic plasticity following ischaemia (Petzelt 2001). 
Xenon blocks NMDA receptors, which reduce excitability and production of toxic 
cell products causing neuron necrosis (David 2003). Accumulation of toxic cell 
reaction products reduces cellular energy and promotes apoptosis. After ischaemic 
injury, cell energy stores and ATP supplies are depleted. Xenon activates opening 
of neuronal ATP-sensitive potassium channel (KATP) whilst decreasing the 
sensitivity of the channel to ATP (Bantel 2010). Xenon reduces the expression of 
pro-apoptotic factors as BAX, activates anti-apoptotic effectors, such as BclXL and 
Bcl2, resulting in a decline in neuroapoptosis (Ma 2007). Preventing the amount of 
apoptosis was demonstrated to be central mechanism in a neuron cell culture 
viability study, where xenon exposure doubled the number of viable cells assessed 
with annexin V. Necrotic cell death was not reduced with xenon exposure 
(Williamson 2004).  
Although the activation of ATP-sensitive potassium channels (KATP) or two-
pore potassium channels (TREK-1) may explain some of the neuroprotective 
effects of xenon, the pivotal protective pathway is limiting the overstimulation of 
NMDA glutamate receptors following excitotoxic stress conditions (Banks 2010, 
Liu 2010). Excitotoxic stress mediated by through NMDA receptors is generally 
associated to acute neurodegenerative conditions such as postanoxic reperfusion 
injury, stroke and traumatic brain injury (Lavaur 2016b). However, low-level, 
chronic NMDA overexcitation is involved in various neurodegenerative conditions, 
including amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s 
disease (Vaarmann 2013, Lewerenz 2015). An experimental model mimicking 
sustained, low-level NMDA excitotoxicity in cortical and basal forebrain neuronal 
cell cultures revealed, that xenon exposure in a concentration of 75 % reduced 
neuronal damage induced by a synthetic glutamate analog (L-trans-pyrrolidine-2, 
4-dicarboxylic acid PDC) (Lavaur 2016a). 
2.4.2 Xenon’s neuroprotective effects in experimental 
animal studies 
Xenon has been demonstrated to be neuroprotective in a variety of in vitro and in 
vivo models. Xenon diminishes in vitro acute neuronal injury in response to both 
exogenous administration of excitotoxins or deprivation of oxygen and glucose in 
cell cultures. In vivo, xenon mitigates the morphologic and functional 
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consequences of acute neuronal injury provoked by ischaemia (Wilhelm 2002). 
Curiously, this marked neuroprotection against hypoxemic injury has been 
demonstrated in well below anaesthetic concentrations, in some models as low as 
10–20 % MAC (Preckel 2006).  
In 2002 Nicholas Franks’ study group performed in vitro experiments with 
neonatal mice mixed neuronal and glial primary cell cultures. Neuronal damage 
was provoked with exposure to excitatory amino acids NMDA or glutamate, or by 
oxygen deprivation and quantified by the predictable release of lactate 
dehydrogenase (LDH) into the culture medium, which was indicative for cell 
injury. The putative neuroprotective intervention was assessed by the cell culture 
exposure to xenon (at different concentrations) or nitrogen (10–75 % MAC) in gas 
exposure chambers. LDH concentration was significantly reduced at all xenon 
concentrations, relating to marked mitigation of neuronal injury (Wilhelm 2002). In 
the in vivo brain injury model of the same study, rat excitatory neuronal injury was 
induced with subcutaneous N-methyl-DL-aspartate (NMDA). Xenon reduced 
histological neuronal degeneration in the arquate nucleus of the hypothalamus in a 
concentration –dependent fashion (Wilhelm 2002). The results of summarized 
preclinical studies of xenon neuroprotection are displayed in table 1. 
In a rat model of cardiopulmonary bypass-induced neurologic and 
neurocognitive dysfunction, Ma and colleagues demonstrated, that 60/30 % 
xenon/oxygen exposure attenuated the neurocognitive consequences and improved 
neurological outcome (Ma 2003).  
In a mouse model of transient cerebral ischemia, mice underwent 60 minutes of 
filament occlusion of middle cerebral artery, which is a well-established 
experimental model of focal ischemia. Xenon/oxygen 70/30 % exposure was 
compared 70/30 % N2O/oxygen and xenon/oxygen 35/30 %. The functional 
performance score was better in the animals anaesthetized with 70 % xenon 
compared with those in the N2O group. Both xenon groups demonstrated a 
significantly lower total cerebral infarct volume compared with the 70 % N2O 
group (Homi 2003). 
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Table 1.  Xenon neuroprotection in animal studies. Abbreviations: NMDA = N-methyl-D-aspartate; 
CPB = cardiopulmonary bypass; CPR = cardiopulmonary resuscitation; N2O = nitrous oxide; tPA 
= tissue plasminogen activator; HIF-1α = Hypoxia inducible factor; VF = ventricular fibrillation; 
MTH = mild therapeutic hypothermia; Xe = xenon; MRI = magnetic resonance imaging 
Authors year Model  Species Xenon Results 
Hypoxic-ischemic injury 
Wilhelm at 
al 
2002 Excitoxic neuronal 
injury by NMDA 
Neonatal 
mice cell 
culture 
Different 
concentrations in 
gas exposure 
chambers 
Xenon mitigated NMDA 
induced neuronal injury 
Ma et al 2003 Cardiopulmonary bypass 
-induced neurologic and 
neurocognitive dysfunction 
Rat 60 % in CPB Less neurological 
deficits, improved 
outcome 
Ma et al 2006 Lactate dehydrogenase 
release after oxygen 
deprivation 
Rat glial 
culture 
70 % 120 min Protective 
preconditioning 
David et al 2008 Excitotoxic neuronal 
injury (NMDA injection) 
Rat 50 % 4 hours global neuroprotection, 
reduced neurotransmitter 
release 
Derwall et 
al 
2008 8 min cardiac arrest; 
CPR 5 min 
Porcine 1 hour vs 5 hour neurologic deficit score 
improvement 
Experimental transient cerebral ischemia 
Homi et al 2003 Ligation of middle 
cerebral artery for 60 
min 
Mouse 70 % and 35 % 
compared to N2O 
70% 
Attenuated infarct size, 
improved functional 
performance score 
David et al 2003 Middle cerebral artery 
oclusion for 90 min 
Rat 50 % vs N2O 75% Reduced cortical brain 
damage 
Dingley et 
al 
2006 Unilateral carotid 
ligation for 90 min 
Rat 50 % 3 hours Neuroprotective post 
injury 
Limatola 
et al 
2010 Ligation of middle 
cerebral artery 
Mouse 70 % 2 hours 24 
hours before ligation 
Dose-dependent 
neuroprotection 
David et al 2010 Thromboembolic middle 
cerebral artery oclusion 
for 90 min 
Rat 37 % - 75 % after 
tPA-reperfusion 
Postischaemic Xe 
supresses ischaemic 
brain damage 
Sheng et al 2012 70 min temporary focal 
ischemia 
Rat Different doses for 
20 hours; 30 % for 
8, 20 or 44 hours 
Xe preconditioning via 
HIF-1α 
Experimental cardiac arrest 
Schmidt  
et al 
2005 Experimental cardiac 
arrest; preconditioning 
Porcine 75 % 15 min before 
cardiac arrest 
Brain injury surrogate 
marker reduction 
Fries et al 2008 Experimental VF; no 
flow 8 min; low flow 4 
min 
Porcine 70 % 1 hour or 5 
hours during MTH 
induction 
Histological and 
functional 
neuroprotection 
Fries et al 2012 Experimental VF; no 
flow 10 min; low flow 6 
min 
Porcine 70 % 1 hour + 
during MTH 
induction 
Neurological and cardiac 
functional outcome 
improvement 
Preventing neurotoxicity 
Ma et al 2007 Exposure to different 
gas mixtures 
Rat pup 75 % or isoflurane 
with 30% or 60 % 
Xe for 6 hours 
Reduction in isoflurane-
induced apoptosis 
Cattano  
et al 
2008 Isoflurane-induced 
neuroapoptosis 
Mouse 
pup 
70 % Neuroprotection against 
isoflurane-induced 
apoptosis 
Shu et al 2010 Neurotoxic isoflurane 
for 6 hours 
Rat pup 70 % 2 hours Xe pretreatment increased 
neuroprotection  
Cattano  
et al 
2011 Exposure to volatile 
anesthetics 
Rat pup 75 % 120 min Induced expression of 
antiapoptotic genes 
Sabir et al 2013 Isoflurane-induced 
apoptosis 
Piglet  50 % with fentanyl 
with MTH or not 
Xe does not promote 
apoptosis 
Review of the literature 
 51 
In another rat model of excitotoxic neuronal injury, significant ex-vivo and in-vivo 
postischaemic neuroprotection by xenon was demonstrated by xenon 
administration of 50 % up to 4 hours after intrastriatal NMDA injection and up to 
at least 2 hours after induction of transient brain ischaemia. Even sub-anaesthetic 
doses of xenon were associated with global neuroprotection with mitigated 
neurotransmitter release and reduced subsequent cell injury and neuronal death 
(David 2008). 
Derwall and colleagues compared differences in xenon and isoflurane 
anesthesia in a porcine model after prolonged (8 min) cardiac arrest and CPR for 5 
minutes. Xenon exposure was 1 or 5 hours. The neurologic deficit score (NDS) 
pointed a severe neurologic dysfunction in almost all untreated control animals. 
However, in the 1-hour xenon group, and to somewhat lesser extent in the 5-hour 
xenon group the NDS score was significantly reduced through postoperative 
follow-up on days 1–3. In comparison of xenon to isoflurane, there were no 
marked differencies in functional performance (Derwall 2008). 
Michael Fries and co-workers studied ensuing neurohistopathologic damage 
and functional outcome in a porcine model of ventricular fibrillation cardiac arrest, 
mimicking real-life timetable and circumstances of resuscitation. Namely, after 8 
minutes of cardiac arrest and 5 minutes of CPR, the successfully resuscitated pigs 
(32–39 kg) were randomized to receive either 70 % of xenon for 1 or 5 hours or 
controls receiving 70 % nitrogen. Neurocognitive and overall neurologic deficits 
were assessed before day 5 post-arrest, whereafter the brains were harvested for 
histological analysis. The main finding was, that xenon exposure post resuscitation 
resulted in attenuation of perivascular inflammation in the putamen and caudate 
nucleus. There was additionally a marked reduction in the injured neurons in the 
putamen. Simultaneously, the overall neurologic and neurocognitive performance 
was improved. In this study, the post-conditioning intervention was initiated no 
earlier than 1 hour after CPR, and interestingly, one-hour exposure to xenon was 
equally effective as 5 hours of treatment (Fries 2008). Another porcine study by the 
same group demonstrated, that after 10 minutes of cardiac arrest and 6 minutes of 
CPR, the combination of mild hypothermia (33 °C) for 16 hours and Xenon 70 % 
for one hour preserved cardiac output during induction of MTH significantly better 
than hypothermia as a sole intervention. Neuropathologically, in xenon + MTH –
treated animals, hippocampal astrogliosis and microgliosis and perivascular 
inflammation in the putamen was mitigated. Furthermore, neurologic deficit scores 
over a period of 5 days follow-up time were improved in xenon + MTH -treated 
animals (Fries 2012).  
A rat model of neonatal asphyxia demonstrated, that although delayed xenon 
20 % exposure as a sole intervention was associated with relative limited 
neuroprotection, the combination of xenon and hypothermia for 90 minutes, 
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initiated 4 hours after induced hypoxia-ischemia, provided synergistic histological 
and functional protection up to 30 days after injury (Ma 2005). This finding was 
corroborated in another study of induced ischaemia and hypoxia. Right common 
carotid artery occlusion was followed by 90 minutes hypoxia with 8 % oxygen in 
rat pups. Hypothermia and xenon was administrated asynchronously, with a 1 or 5 
hours interval between interventions. Significant infarct volume reduction was 
demonstrated even when hypothermia and xenon were administered with an 
intervening gap of 5 hours (Martin 2007). Similarly, other study groups have 
confirmed that combining mild hypothermia with delayed xenon inhalation had 
additional beneficial effects in neonatal rats that exceeded the individual benefit of 
either treatment alone (Hobbs 2008, Thoresen 2009). The plausible hypothesis is 
that xenon and mild hypothermia therapy converge on an anti-apoptotic pathway 
explaining why even asynchronous application of the interventions attenuates the 
injury (Kelen 2010). 
2.4.3 Xenon’s neuroprotective effects in human studies 
Until our study, xenon inhalation was investigated in humans as an anaesthetic 
agent during general anaesthesia, intensive care sedation or cardiac surgery 
(Rossaint 2003, Bedi 2003, Coburn 2005, Lockwood 2006, Rasmussen 2006, 
Wappler 2007, Höcker 2009, Cremer 2011, Hofland 2017). The focus of these 
studies was merely the safety, feasibility and properties of the anaesthesia in terms 
of perioperative hemodynamics with no data provided about any neuroprotection 
following xenon exposure. 
Xenon’s putative neuroprotection effect in cardiac arrest patients is an original 
idea by the principal investigator of this study. Furthermore, this study was the first 
report about using xenon in combination with hypothermia in any group of adult 
patients. However, combination of hypothermia with xenon for neuroprotection 
after neonatal asphyxia had been utilized previously, but it will be discussed further 
(2.4.7). 
2.4.4 Molecular targets of xenon’s cardioprotective effects 
Oxygen starvation damages cardiomyocytes through ATP depletion and acidosis 
resulting in apoptotic cardiomyocyte loss during prolonged cardiac ischaemia-
reperfusion injury (Wu 2014). In postischaemic myocardium xenon affects several 
critical intra-cellular mechanisms. These include protein kinase c-ε (PKC-ε), 
protein kinase B (Akt), glycogen synthase kinase 3β (GSK- 3β), p38 mitogen-
activated protein kinase (MAPK), MAPK-activated PK-2, heat-shock protein 27, 
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and intracellular signal-regulated kinases ½ (Weber 2005 (a), Weber 2005 (b), 
Preckel 2006, Weber 2006 (a), Weber 2006 (b), Mio 2009).  
Moreover, xenon counteracts mitochondrial permeability transition pore 
(mPTP) opening, which preserves mitochondrial function, reduces generation of 
reactive oxygen species from damaged mitochondria and restricts ischaemia-
reperfusion injury. The vascular endothelial cells are particularly vulnerable to 
hypoxia and reoxygenation during reperfusion. Nitric oxide (NO) production is 
diminished in post-ischaemic endothelial cells, which manifests as an endothelium 
dependent NO-mediated impaired relaxation of endothelial smooth muscle cells 
causing capillary malperfusion (Carden 2000). Xenon counteracts endothelial 
dysfunction by blocking calcium-dependent Ca2+ -influx into endothelial cells 
(Petzelt 1997). Xenon might significantly alter endothelial function, which 
converges to that some of the xenon’s cardioprotective properties might be 
mediated by alterations within the endothelium (Smit 2015).  
The first evidence of xenon’s protective effects in ischaemic myocardium was 
published in 2000 (Preckel 2000). Thereafter, a growing body of experimental 
evidence in different sized animal models has indicated, that xenon exerts a 
myocardium-protective effect when applied before organ ischemia as an early or 
late preconditioning stimulus. This was demonstrated as reduced infarcts, restricted 
infarct size, improved myocardial function and mitigated release of cardiac 
enzymes (Table 2) (Weber 2005, Weber 2006(a+b), Baumert 2007b, Mio 2009, Li 
2013).  
In regard of affecting an ongoing injury in OHCA patients, postischaemic 
application of xenon additionally exerts a cardioprotective effect in myocardial 
ischaemia during reperfusion as a postconditioning stimulus (Schwiebert 2010). 
Most of the available knowledge about the putative signalling in xenon 
cardioprotection is attributed to pretreatment with bioactive molecules (PKC, 
calphostin C, MAPK inhibitor, etc), which abolished xenon-related effects (Pagel 
2010). Experimental animal studies are summarized in table 2. 
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Table 2.  Cardioprotective effects by xenon in experimental animal studies. Abbreviations: 
LAD = left anterior descending coronary artery; Xe = xenon; LV = left ventricular; 
RV = right ventricular; CO = cardiac output; IR = ischaemia-reperfusion; RCA = 
right coronary artery; MAP = mean arterial pressure; HR = heart rate; MTH = mild 
therapeutic hypothermia; FiO2 = fraction of inhaled oxygen; HIF-1ɑ = hypoxia 
inducible factor; VEGF = vascular endothelial growth factor 
Experimental animal studies 
Authors Year  Model  Species Xenon Results 
Preckel et al 2002 prior LAD ligation 9 
weeks ago; LV 
dysfunction 
Rabbit  70 % Xe did not 
compromise LV 
function on cardiac 
echo 
Weber  
et al (b) 
2006 LAD occlusion for 25 
min, 120 min 
reperfusion 
Rat 70 % 3 x 5 min Increase in 
preconditioning 
mediators; reduction 
in infarct size 
Baumert et al  2007 LAD occlusion for 60 
min, 120 min 
reperfusion 
Porcine 70 % 
anaesthesia or 
3 x 10 min 
preconditioning 
Xe anaesthesia 
reduced infarct size, 
preconditioning did 
not 
Weber et al 2008 LAD occlusion for 25 
min, 120 min reperfusion 
Rat  70 % for 15 
min 
Reduction in infarct 
size 
Hein et al (a) 2008 Xe anaesthesia and 
pulmonary artery 
catheter 
Porcine 70 % Systolic ventricular 
function intact, RV 
and CO reduced 
Hein et al (b) 2008 IR injury by 90 min 
ligation of distal RCA, 
120 min reperfusion 
Porcine  70 % 1h before 
ischaemia 
Infarct size and 
severity 
(inflammation) 
reduction 
Francis et al 2008 Haemodynamic and 
hormonal effects 
during Xe anesthesia 
Beagle 
dog 
63 % + 
remifentanil 
MAP maintained, 
but reduced HR, 
stimulation of 
endogenous 
catecholamines 
Mio et al 2009 LAD occlusion for 30 
min, 120 min 
reperfusion 
Rat 70 % for 3 x 5 
min 
Infarct size 
reduction, 
preservation of 
mitochondrial 
function 
Schwiebert  
et al 
2010 LAD occlusion for 25 
min, 120 min 
reperfusion 
Rat  20 % + MTH 
34 °C 
Infarct size 
reduction 
Chakkarapani 
et al 
2012 Hypoxic-ischaemic 
insult by reduction of 
FiO2 
Piglet 50 % with or 
without MTH 
Stable haemo-
dynamics, inotrope-
sparing effect 
Goetzenich et 
al  
2014 Induced hypoxemia in 
cell culture 
Rat pup 
cardiomyo
cyte culture 
preconditioning 
24 h prior 
hypoxia 
Increase in 
preconditioning 
mediators HIF-1ɑ 
and VEGF 
Li et al  2013 1h global ischaemia, 3 
h reperfusion 
Rabbit pup 
isolated 
hearts 
75 % 
pretreatment 
Protection against 
ischaemia-
reperfusion injury 
Baumert et al 2016 LAD occlusion for 60 
min, 120 min 
reperfusion 
Porcine 70 % for 1 hour Reduction in 
diastolic 
dysfunction 
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2.4.5 Xenon’s cardioprotective effects in experimental 
animal studies 
Hettrick and colleagues investigated the cardiovascular effects of xenon in a canine 
model of dilated cardiomyopathy. The dogs were chronically instrumented to facilitate 
continuous measurement of aortic and left ventricle (LV) pressures, aortic blood flow 
and LV subendocardial segment length (Hettrick 1998). Dilated cardiomyopathy was 
induced with rapid LV pacing, which produces similar heart disease as human 
idiopathic dilated cardiomyopathy (Johnson 1982). The animals were anaesthetized 
with 1.5 MAC isoflurane combined with four different concentrations (0 %, 30 %, 50 
% and 65 %) of xenon exposure. Their conclusion was, that isoflurane and xenon in 
combination produced minimal haemodynamic effects – arterial and LV pressures, 
cardiac output and stroke volume were unchanged during administration of xenon to 
isoflurane-anaesthetized dogs. The findings were equal in the control group of non-
cardiomyopathy animals, indicating that xenon did not affect global cardiac 
performance whether the animal had a heart disease or not (Hettrick 1998) 
Preckels study group investigated the effects of xenon on a rabbit model of 
reperfusion injury after prolonged (30 minutes) coronary artery occlusion followed 
by a two-hour reperfusion period. Exposure to 70 %/30 % of xenon/oxygen during 
the first 15 minutes of reperfusion reduced myocardial infarct size in the LV area at 
risk from 51 + 3 % (controls) to 39 + 5 %. Additionally, the slope of the regression 
line relating infarct size to the LV area at risk was significantly reduced in the 
xenon-treated animals, claiming that the ratio of infact size to LV area at risk was 
smaller in xenon-treated rabbits (Preckel 2000). The same group demonstrated in 
rabbits with chronic LV dysfunction (9 weeks after coronary artery ligation), that 
xenon had minimal haemodynamic effects without affecting the maximal rate of 
increase in LV pressure (Preckel 2002). 
Volatile anaesthetics (isoflurane, sevoflurane and desflurane) generally exhibit 
a direct depressant effect on the myocardium, which is a limiting factor in their use 
in patients with compromised cardiac function. However, on the contrary, xenon 
exposure in isolated guinea pig hearts did not alter the amplitudes of Na+, L-type 
Ca2+ and inward –rectifier K+ channel currents, which are acknowledged sites 
causing cardiac side effects. Furthermore, xenon did not affect cardiac function in 
isolated hearts to any degree (Stowe 2000). In another study with isolated guinea 
pig hearts, with extracted ventricular muscle bundles, xenon exposure did not alter 
myocardial contraction force or contraction time, in contrast to isoflurane, which 
elicited an anticipated negative inotropic effect. However, the correcting positive 
inotropic stimulus effect obtained with isoprotenol, calcium and increased pacing 
frequencies was maintained also in isoflurane group (Scroth 2002). 
Grosse Hartlage and colleagues investigated in a canine model recovery from 
myocardial stunning, induced by 10 minutes of occlusion in left anterior descending 
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coronary artery. Ten dogs were chronically instrumented to provide measurement of 
heart rate; pressures in left atrium, aorta and left ventricle; coronary blood-flow 
velocity; and myocardial wall-thickening fraction. The intervention was xenon 75 % 
inhalation added to fentanyl-midazolam anesthesia compared to the anaesthesia 
alone. Global haemodynamics, blood-flow velocity and regional myocardial blood 
flow were similar in both groups. However, in the animals receiving xenon, a 
significantly better recovery of wall-thickening fraction and an attenuated plasma 
noradrenaline release during emergence from anaesthesia was demonstrated. This 
translated to that inhalational exposure to 75 % xenon improves recovery from 
postischaemic myocardial stunning (Grosse Hartlage 2004).  
In the porcine model study of Vagts and colleagues, perioperative intestinal 
oxygenation was investigated, which is commonly affected by the cardiodepressive 
effects induced by inhalational anaesthetics. The possible consequence of intestinal 
hypoperfusion could contribute to sepsis and multiorgan failure. In addition to the 
basic i.v. anaesthesia, xenon was delivered in different concentrations (0, 20, 50 
and 65 %). The authors concluded, that the mean arterial pressure (MAP) was 
stable during xenon exposure, although the heart rate and cardiac output decreased 
by 30 %. However, intestinal oxygenation was maintained, although regional 
macrohaemodynamic perfusion decreased without inducing hypoxic values in the 
intestinal mucosa (Vagts 2004). 
Much of the knowledge about xenon’s prosurvival signaling pathways is derived 
from the work of Nina C. Weber and her study group. Initially, they demonstrated in 
a rat myocardial infarct model, that three 5 min cycles of xenon/ oxygen 70 % /30 % 
inhalation intervalled with 5 minutes of NO/oxygen of 70 %/30 % before coronary 
occlusion protected myocardium against ischaemic injury (Weber 2005a). This 
preconditioning effect diminished myocardial infarct size 28 % + 10 % of the LV 
area at risk compared to 51 % + 17 % in control animals. The beneficial effects were 
mediated via induction of nonselective protein kinase C (PKC) and selective p38 
mitogen-activated protein kinase (MAPK), as the protective effects were abolished 
by pretreatment with inhibitors of these pathways. Xenon caused also 
phosphorylation, translocation and hence activation of epsilon isoform of PKC 
(PKC-ε), a previously recognized sign of enzyme activation in ischaemic and 
anaesthetic preconditioning (Weber 2005a). These results demonstrated, that 
cardioprotective xenon pretreatment implicates endogenous cardioprotective 
signaling kinases in diminishing ischaemic injury (Pagel 2010).  
Weber and colleagues further studied the downstream targets of p38 MAPK. 
Repetitive administration of xenon before coronary occlusion also additionally 
enhanced MAPK-activated protein kinase-2 (MAPKAPK-2) and small heat-shock 
protein 27 (Hsp 27) phosphorylation. These are acknowledged mediators of 
stabilization of the integrity and the actin cytoskeletal framework of the 
Review of the literature 
 57 
cardiomyocyte (Weber 2005b). Additionally, Weber’s group elucidated a crucial 
ion channel and several signaling proteins involved in xenon preconditioning. 
These include mitochondrial KATP channel (Weber 2006a), which maintain 
intracellular Ca2+ balance, inhibits Ca2+ overload and enhances oxidation-reduction 
rate. Further, xenon-induced cardioprotection is mediated also by activation of the 
reperfusion salvage kinase (RISK) pathway, which is involved during ischaemia-
reperfusion injury and protects from myocardial necrosis and apoptosis. They also 
identified extracellular signal-regulating p44/42 MAPK (ERK ½) as a mediator of 
xenon preconditioning. These kinases mediate cell division, proliferation and 
survival (Weber 2006b). Mio and colleagues investigated the role of prosurvival 
kinases that target mitochondria in rat model of LAD occlusion for 30 minutes. 
Their conclusion was, that xenon-induced cardioprotection activates prosurvival 
signaling that targets mitochondria making them less vulnerable to ischaemia-
reperfusion injury. Xenon preconditioning mitigates infarct size, activates Akt, 
glycogen synthase kinase 3β (GSK-3β) and prevents Ca2+ -induced opening of 
mPTP, which preserves mitochondrial function (Mio 2009).  
In another rat infarction study, the Weber/Preckel group investigated the induced 
postconditioning effect on ischaemia-reperfusion by combining mild hypothermia and 
xenon in a subanaesthetic concentration of 20 % (Schwiebert 2010). This had already 
proven effective in neonatal rats when administered after hypoxic-ischemic brain 
injury (Ma 2005). After 25 minutes of LAD occlusion and at the onset of 120 minutes 
of reperfusion, the intervention groups received either 1h of mild hypothermia 
(34 °C), 30 minutes of xenon 20 % inhalation or the combination of xenon and 
hypothermia. Their conclusion was, that subanaesthetic xenon and mild hypothermia 
did not establish effective postconditioning stimulus if they are administered on their 
own. However, in combination, they act synergistically protecting myocardium from 
reperfusion injury. In effect, combination of 20 % xenon and hypothermia reduced the 
infarct size statistically significantly (Schwiebert 2010). 
Roehl and colleagues investigated post-infarction myocardial remodeling 28 
days after experimental perioperative myocardial infarction in a rat model. Three 
different anaesthetic regimes, 0,6 % isoflurane, 70 % xenon and intraperitoneal 
injection of s-ketamine, were compared during 60 min of LAD occlusion and 120 
minutes of reperfusion. Quantification of cardiac dilatation, left ventricular 
function, hypertrophy, fibrosis, capillary density, apoptosis and expression of fetal 
genes was performed after 4 weeks. Initially, xenon and isoflurane reduced the 
acute effects of ischaemia-reperfusion on haemodynamics and myocardial infarct 
size at a comparable level. However, after 4 weeks, in xenon –treated animals, 
there was a lower remodeling index, better ejection fraction and reduced expression 
of β–myosin heavy chain and periostin, when compared to isoflurane- or ketamine-
treated animals. This study demonstrated, that perioperative xenon treatment 
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conferred to improved recovery of contractile function after ischaemia-reperfusion 
injury and impeded adverse cardiac remodeling (Roehl 2013). 
In the study of experimental myocardial infarction in thirty-six 30–35 kg 
weighing pigs, Baumert and colleagues studied the effects of ischaemic 
preconditioning and of xenon preconditioning and xenon anaesthesia. Myocardial 
ischaemia was produced by intermittent occlusion of left anterior coronary artery 
for one hour and followed by two hours of reperfusion. In this study, xenon 
preconditioning did not reduce myocardial infarct size, but xenon anaesthesia of 
70 % produced mitigation of the size of myocardial infarct, myeloperoxidase 
activity, and plasma tumor necrosis factor α (TNF-α) and inflammatory marker 
interleukin 6 concentrations, which can be interpreted as a postconditioning effect 
on the ischaemia-reperfusion injury. The result was statistically significant, but the 
amount of salvaged myocardium was less than with ischaemic preconditioning 
(Baumert 2007b). Hein and colleagues demonstrated also in a porcine model of 
right ventricular ischaemia, that both 70 % xenon and 0.9 % isoflurane prevented 
equally haemodynamic compromise during reperfusion, in comparison to 
barbiturate-anaesthetized animals (Hein 2010). Previously, the Baumert group had 
demonstrated in pigs, that xenon combined with isoflurane compared to isoflurane 
alone did not have significant difference in myocardial protection (Baumert 2009). 
In the same porcine myocardial infarction study by Sopka and colleagues, 
isoflurane, xenon and thiopental were compared in a right ventricular infarction 
model. In this study, both xenon and isoflurane caused a similar reduction in infarct 
size. However, xenon induced a significant increase in apoptosis compared to 
isoflurane, demonstrated in higher density of apoptotic cardiomyocytes in caspase-
3 staining. There was a high variability per animal, but the result was statistically 
significant (Sopka 2013). It has been argued before, that xenon cardioprotection 
might be attenuated in pigs, because the RISK pathway has a markedly less 
important role in this process than in smaller mammals (Pagel 2010). 
The aforementioned studies indicate, based on experiments in different sized 
animals, that intermittent exposure to xenon before, during or after ischaemic 
myocardial injury attenuates the effects of ischaemia-reperfusion response and 
protects against irreversible ischaemic injury. Xenon exposure mitigates infarct 
size and enhances functional recovery of stunned myocardium and prevents 
adverse cardiac remodeling (Pagel 2010). 
Xenon has been investigated also in human cell cultures. Hüneke and co-
workers obtained human right atrium cardiomyocytes from patients undergoing 
heart surgery. Xenon was compared to volatile anaesthetics halothane and 
isoflurane, both of which are characterized with known negative inotropic and 
proarrhytmic side effects on the heart. Ion currents were assessed with the whole 
cell patch clamp technique during superfusion of cells with solutions of these gases 
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in concentrations corresponding to their minimum MAC. As anticipated, halothane 
and isoflurane exhibited inhibitory effects on voltage-gated cardiac Ca2+ and K+ 
currents, which adjust the duration of action potentials and repolarization and are 
likely to be of pathophysiologic relevance. In contrast, xenon did not affect Ca2+ 
currents and there was only slight inhibition of transient K+ outward currents, 
which in effect translates to that 70 % xenon preserved heart contractility in 
isolated human atrial cardiomyocytes (Hüneke 2001). 
2.4.6 Xenon’s cardioprotective effects in human studies 
Clinical human studies displaying cardioprotective properties by xenon are 
summarized in table 3. 
Table 3.  Cardioprotection by xenon in human studies. Abbreviations: ICU = intensive care 
unit; Xe = xenon; HR = heart rate; MAP = mean arterial pressure; CI = contractile 
index; CAD = coronary artery disease; LV = left ventricular; TOE = 
transoesophageal echography; PET = positron emission tomography; MAC = 
minimal alveolar concentration; OPCAB = Off-pump coronary artery bypass; ECG 
= electrocardiogram; QTc = heart rate corrected ECG QT –interval; HV = healthy 
volunteer; CPB = cardiopulmonary bypass; CABG = coronary artery bypass 
grafting; TIVA = total intravenous anesthesia 
Human studies 
Authors year Setting Subjects Xenon Results  
Bedi et al 2003 Postoperative 
ICU patients 
Elective 
surgical 
patients 
28 + 9 % (9–62 
%) ICU sedation 
for 8 hours 
Compared to propofol, Xe 
provided minimal haemo-
dynamic effect and fast recovery 
Rossaint  
et al  
2003 Planned 
anaesthesia 
< 2hours 
Elective 
surgical 
patients 
60 + 5 % vs. 
isoflurane 
Effective and safe 
anaesthesia, faster recovery 
Coburn  
et al 
2005 Anaesthesia 
> 60 min 
Elective surgical 
patients 
60 % vs. propofol HR decreased, MAP 
maintained 
Wappler  
et al 
2007 No prior 
cardiac disease 
Elective surgical 
patients 
30 % vs. 
isoflurane 
Cardiovascular stability; 
isoflurane decreased CI 
Baumert  
et al  
2008 Known CAD Elective non-
cardiac surgery 
65 % vs. propofol MAP higher with Xe, better LV 
function in TOE 
Schaefer  
et al 
2011 PET study of 
myocardial 
blood flow 
Healthy 
volunteers 
1 MAC Minimal effects on coronary 
flow dynamics 
Al Tmimi  
et al 
2015 MAP > 70 
mmHg, 
noradrenaline 
dose 
Elective 
OPCAB 
surgery 
30 % & propofol 
vs. propofol only 
Improved haemodynamic 
stability, less noradrenaline 
Neukirchen 
et al 
2017 Continuous 
ECG 
monitoring, 
QTc interval 
HV + 35 abd & 
trauma patients 
60 % QTc interval unaffected with Xe 
Hofland  
et al  
2017 Troponin I 
concentration 
24 h post 
surgery 
CPB CABG 
surgery  
(n = 446) 
52–56 % vs. 
sevoflurane vs. 
propofol 
TnI release less than with 
TIVA; comparable with 
sevoflurane 
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The compelling preclinical evidence establishing xenon’s cardioprotective 
properties has been reinforced with a series of human investigations (Table 3). 
Most of them, however, were conducted in respect of safety and feasibility, in 
various surgical or intensive care patients. Bedi and co-workers investigated 
postoperative sedation in patients admitted to ICU following elective thoracic 
surgery. The duration of the sedation was 8 hours and inhaled xenon was compared 
to standard ICU regimen, propofol and alfentanil. Both sedative drugs exhibited 
similar mean Ramsay sedation scores and mean bispectral indexes, measured at 30 
min intervals. Xenon sedation was feasible, well tolerated and with minimal 
haemodynamic effects (Bedi 2003).  
In a multicenter randomized clinical trial of 224 patients, xenon 60 % was 
compared to isoflurane 0,5 % combined with N2O 60 % in elective surgical 
patients. Supplemental sufentanil was added to the anaesthesia if indicated. Xenon 
in oxygen exhibited equally effective anaesthesia when compared to isoflurane- 
N2O. The requirement for opioid injections was comparable in both groups. The 
recovery from anaesthesia was distinctly faster with xenon and it did not affect 
myocardial contractility, displayed by higher mean arterial pressure during 
anesthesia in xenon group. Data of requirements of supplemental vasoactive 
medication is not available (Rossaint 2003). 
Goto and co-workers compared xenon 60 % to N2O 60 % during fentanyl-
midazolam anesthesia in 20 elective CABG patients. The patients were assessed 
with transoesophageal echocardiography and pulmonary artery catheter. After 
reaching the predefined end-tidal concentration of both gases, the gases were 
discontinued after 15 minutes of exposure. This study illustrated, that whereas 
xenon inhalation had minimal effects on the haemodynamic parameters, N2O 
inhalation decreased mean arterial pressure, left ventricular stroke work index and 
the fractional area change of the left ventricle. The authors concluded, that inhaled 
xenon is safe also in surgical patients with heart disease (Goto 2004). 
In the randomized controlled trial by Coburn and colleagues, xenon 60 % was 
compared to propofol anaesthesia in 160 patients undergoing elective surgery. 
Anaesthesia was induced with propofol and remifentanil and maintained with 
xenon or propofol. The main differences between groups were observed during the 
first 15 minutes following induction. Namely, systolic arterial pressure initially 
decreased, but returned to baseline values in the xenon group. The propofol group 
had lower systolic and diastolic pressure. Heart rate decreased significantly in the 
xenon group, but remained at stable values. Bispectral indexes were similar. There 
were no differences in hypertension or hypotension occurrence or the time to 
emerge from anaesthesia or recovery time in the post-anaesthetic care unit. The 
conclusion was, that following anaesthesia induction, xenon maintains arterial 
pressure and a stable low heart rate (Coburn 2005). 
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Bein and co-workers compared xenon and TIVA (propofol, remifentanil and 
rocuronium) in 39 high-risk patients undergoing aortic surgery. The patients were 
assessed with transoesophageal echocardiography and myocardial cell damage was 
illustrated with troponin T and CK-MB release. In this study, no clinically relevant 
differences in global myocardial performance, myocardial contractility or 
myocardial cell damage markers were demonstrated at any time during 72 hours of 
study period. Therefore, the authors found previously reported beneficial 
cardiovascular effects of xenon speculative (Bein 2005). 
Hanss and co-workers performed an analysis on the influence of xenon 60 % 
on regulation of the autonomic nervous system in 44 patients undergoing major 
abdominal aortic surgery and at high risk of perioperative cardiac complications. 
Xenon was compared to propofol-remifentanil-based TIVA. During operation, 
heart rate, heart rate variability (HRV), arterial pressure and cardiac output were 
monitored. The postoperative analysis included 24 h Holter ECG, length of stay at 
the ICU and hospital and patient’s outcome after 6 months. In HRV analysis, 
xenon patients exhibited lower sympathetic and higher parasympathetic activity in 
comparison to TIVA patients. This resulted in reduction of heart rate in xenon 
group, but no significant differences were observed in terms of postoperative 
arrhythmias, ECG changes or in markers of myocardial damage. There were no 
differences in short- or long-term outcome (Hanss 2006). 
Rasmussen and colleagues compared xenon 50–70 % and propofol anaesthesia 
in 39 elderly patients undergoing knee replacement surgery. The mean age was 71 
and 70 years, respectively. Besides perioperative haemodynamic parameters, 
cognitive function was assessed preoperatively, at discharge and at 3 months 
postoperatively. Perioperative blood pressure, heart rate, ventilatory frequency or 
end-tidal carbon dioxide concentration did not differ between groups. Xenon was 
well tolerated in spontaneously breathing elderly patients. A high incidence of 
POCD was found in both groups at discharge. The authors found no difference in 
cognitive function, which they speculated merely to be attributed to underpowered 
sample size rather than absence of a true difference (Rasmussen 2006). 
Lockwood and colleagues addressed also POCD in 16 patients undergoing 
GABG surgery and on hypothermic cardiopulmonary bypass (CPB). This was an 
open-label dose-escalation study with xenon in concentrations of 0, 20, 35 and 
50 % xenon in oxygen and air. Brain embolic load was assessed with transcranial 
middle cerebral artery Doppler and damage to vulnerable tissues was assessed for 
the heart with troponin I, for the brain with serum S100β and for the kidney with 
serum creatinine. Delivery of xenon during cardiac surgery did not produce adverse 
clinical consequences. No evidence of organ injury or increased embolic load was 
detected. There was a tendency to lower troponin I- and S100β- concentration at 24 
hours in those patients receiving xenon (Lockwood 2006). 
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Wappler and co-workers compared xenon 60 % to isoflurane 1,2 % in 252 
patients without cardiac disease undergoing elective noncardiac surgery in a 
randomized multicenter trial. Cardiac performance and left ventricular function 
was assessed with transoesophageal echocardiography. The global haemodynamic 
as well echocardiopraphic parameters were more stable in the xenon patients, as in 
the isoflurane patients. In patients receiving isoflurane, the contractile index, left 
ventricular end-systolic wall stress and velocity of circumferential fiber shortening 
decreased significantly. Xenon did not reduce contractility and the sole and only 
alteration from baseline was a decrease in heart rate. In comparison to isoflurane, 
xenon enabled favourable cardiovascular stability in patients without cardiac 
disease (Wappler 2007). 
Autonomic cardiac control during elective noncardiac surgery was investigated 
in a randomized trial in 26 patients with increased cardiac risk. The authors 
hypothesized, that the acknowledged stable arterial pressure during xenon 
anaesthesia results from a lesser circulatory depression or a direct effect on 
vascular tone or its automatic control. They investigated beat-to-beat heart rate 
variability (HRV) by spectral decomposition to assess autonomic cardiovascular 
control. Baseline anaesthesia was achieved with etomidate and remifentanil and 
after 30 and 60 min propofol or xenon 60 % was added. Total spectral power of 
HRV was decreased with propofol, when compared to baseline etomidate 
anesthesia. Simultaneously, low frequency ratio, reflecting relative sympathetic 
contribution to HRV, was reduced with propofol. Xenon affected neither of these. 
With xenon, arterial pressure increased back close to awake levels, after an initial 
decrease from the awake state to baseline anesthesia in both groups. Blood pressure 
remained decreased with propofol. In conclusion, xenon exhibited better 
preservation of autonomic heart rate modulation when compared to propofol. This 
may partly be an explanation for higher arterial pressure and lower heart rate levels 
observed during xenon anaesthesia (Baumert 2007a).  
The same group investigated further 40 coronary artery disease patients 
undergoing non-cardiac surgery. In comparison with propofol anaesthesia, xenon 
65 % provided a higher arterial pressure level than propofol, without any signs of 
cardiovascular compromise. With xenon, transoesophageal echocardiographic 
parameters displayed better maintained left ventricle function than with propofol in 
these patients at cardiovascular risk (Baumert 2008).  
In the positron emission tomography study by Schaefer and co-workers, 
myocardial blood flow (MBF) was noninvasively quantified by H215O in six 
healthy volunteers during general anaesthesia with xenon. They found only 
minimal effects on MBF during the anaesthesia. A nonsignificant decline in MBF 
was postulated to be reflecting a decrease of myocardial oxygen consumption 
induced by the general anaesthesia on cardiac work. Coronary artery blood flow 
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was unaltered, translating to minimal or no vasodilating effects by xenon. The 
authors concluded, that xenon renders a safe option in the care of patients at risk of 
perioperative myocardial ischemia (Schaefer 2011). 
Feasibility and safety of xenon 45 – 50 % was compared with sevoflurane 1–
1.4 % anaesthesia in 30 patients undergoing CABG surgery with cardiopulmonary 
bypass (CPB) and moderate hypothermia 32–34 °C. Because of the speculative 
potential of xenon to expand intravascular gas bubbles during CPB, xenon was 
applied solely pre- and post-CPB. The peak inspiratory pressures were higher in 
the xenon group before and after weaning from CPB, reflecting density of the gas. 
The primary outcome, occurrence of adverse events, and secondary outcome, 
feasibility criteria, did not differ between groups. However, with xenon, there was 
a tendency towards less acute kidney injury, as demonstrated by a trend towards 
lower urea and creatinine values and higher creatinine clearance during 
postoperative follow-up (Stoppe 2013). 
Al Tmimi and colleagues investigated xenon 50–60 % in comparison with 
sevoflurane 1,1–1,4 % in 42 patients undergoing off-pump coronary artery bypass 
surgery (OPCAB; operation on a beating heart) in a non-inferiority randomized 
controlled trial (Al Tmimi 2012). During OPCAB, significant haemodynamic 
alterations occur, which entail a high risk for perioperative myocardial ischemia 
and haemodynamical instability. This exposes the patient to perioperative organ 
injury; myocardial infraction, stroke and kidney injury requiring dialysis (Lamy 
2012). Primary outcome in this study was the perioperative requirement of 
vasoactive medication support and secondary outcome was safety and occurrence 
of adverse events. Xenon was demonstrated to be non-inferior to sevoflurane, and 
on the contrary, xenon patients required significantly less intraoperative 
noradrenaline to achieve the predefined haemodynamic goals. There were no 
differences in safety. However, significantly more sevoflurane patients developed 
postoperative delirium. The average arterial pressure was reduced in sevoflurane 
group, but no other differences were demonstrated for other haemodynamic 
parameters. Nor did the perioperative release of inflammatory cytokines, troponin 
T, serum protein S-100β and erythropoietin differ. In conclusion, xenon 
anaesthesia offered a significant reduction in noradrenaline administration and it 
was associated with a lower risk for postoperative delirium in OPCAB patients (Al 
Tmimi 2015). 
Xenon and sevoflurane were also compared in 30 patients undergoing on-pump 
CABG. In this trial, perioperative inflammatory response was evaluated. In 
comparison with sevoflurane, xenon anaesthesia triggered pro-inflammatory 
(Interleukin-6) effects and suppressed the anti-inflammatory response (Interleukin-
10). Both groups displayed a comparable increase of oxidative stress and an 
increase of the cardioprotective mediators migration inhibitory factor (MIF) and 
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CXCL 12/SDF-1α. MIF levels decreased in the xenon group, whereas it remained 
elevated in sevoflurane group (Breuer 2015) 
In a large, international, multicenter randomized noninferiority trial, xenon, 
sevoflurane and propofol-based TIVA were compared in 492 low-risk, elective, on-
pump CABG patients. The primary outcome was cardiac troponin I release 24 
hours after surgery and secondary outcome was the feasibility and safety of xenon 
anaesthesia. The study demonstrated, that xenon was superior to propofol-based 
TIVA and noninferior to sevoflurane in respect of troponin release 24 hours after 
on-pump CABG surgery. Xenon-based anaesthesia maintenance was feasible with 
no concerns of safety or clinically relevant differences perioperatively or during 
postoperative recovery when compared to the other two regimens. This study was 
also confounded by the methodological necessity, that the two inhalatory 
anaesthetic regimens had to be interrupted with propofol-based TIVA during CPB 
period, which may have reduced the nevertheless significant differences in 
postoperative troponin I concentrations (Hofland 2017). 
In conclusion, xenon anaesthesia provides equal surgical anaesthesia when 
compared to traditional anaesthetics. However, xenon is associated with a broad 
spectrum of favorable cardiovascular properties during anaesthesia.  
In a preliminary report of our study, xenon with MTH (n = 17) was compared 
to MTH only (n = 21) in a subpopulation of patients, who had complete 
echocardiographic data (before MTH or Xe exposure, 20 hours after MTH 
commencemant, 24 hours after completing rewarming and at discharge from 
hospital or after 7 days) available. Left ventricular ejection fraction (LVEF) and 
global peak systolic longitudinal strain (GLS) were compared between groups at 
the different time points. LVEF was moderately reduced in both groups at ICU 
admission, but after 24 hours after completion of MTH and xenon therapy, both 
LVEF and GLS were significantly higher. This finding can be interpreted as an 
accelerated recovery from myocardial dysfunction after cardiac arrest in the 
patients whose post-arrest care with MTH was replenished with xenon inhalation 
(Ballo 2017).  
2.4.7 Xenon and neonatal asphyxia 
Perinatal asphyxial hypoxic-ischaemic encephalopathy is a major cause of acute 
mortality and chronic neurocognitive morbidity in infants and children worldwide 
(Vannucci 1997). It occurs approximately in 1–6/1000 live human full-term births 
at or shortly after birth with an acute mortality of 15–20 %. Severe, permanent 
handicapping conditions, such as cerebral palsy, blindness, deafness, epilepsy and 
global developmental delay are present in quarter of survivors (Vannucci 1997, 
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Perlman 1999, Volpe 2008), which establishes a major burden for the infant, the 
entire family and the community (Azzopardi 2009).  
Although the underlying mechanisms differ from hypoxic-ischaemic brain 
injury following OHCA, neonatal asphyxial brain damage shares common features 
with OHCA encephalopathy. Based on neonatal animal models of hypoxic-
ischemic injury, excessive and prolonged cytotoxic activation of NMDA glutamate 
receptors leads, at least partly, to destructive, evolving cascade of necrotic and 
apoptotic brain cell death (Nakajima 2000, Johnston 2001, Gill 2002). Studies 
involving xenon neuroprotection in experimental neonatal asphyxia models are 
summarized in table 4. 
Table 4.  Experimental animal studies of neonatal asphyxia and xenon neuroprotection. 
Rice - Vannucci model: After unilateral carotid ligation, the animals are exposed to 
hypoxemic conditions in a gas chamber with 8 % oxygen concentration. 
Abbreviations: MTH = mild therapeutic hypothermia, Xe = xenon 
Neonatal asphyxia 
Authors year Model  Species  Xenon  Results  
Ma et al 2005 Right carotid 
ligation + 90 min 
hypoxia (Vannucci 
model) 
Rat pup 20–70 % 90 
min; during, or 
2 to 24 hours 
after hypoxia 
Synergistic 
neuroprotection by 
MTH and Xe 
Martin et al 2007 Right carotid 
ligation + 90 min 
hypoxia (Vannucci 
model) 
Rat pup 20 % with 
asynchronous 
MTH 35°C 
MTH + Xe 
increased 
neuroprotection 
Hobbs et al 2008 Left carotid ligation 
+ 90 min hypoxia 
(Vannucci model) 
Rat pup 50 % 3 hour + 
MTH 
Combination better 
than Xe or MTH 
alone 
Thoresen et 
al 
2009 Left carotid ligation 
+ 90 min hypoxia 
(Vannucci model) 
Rat pup 50 % 1 hour vs 
3 hour 
immediate or 
delayed + MTH 
Combination better 
than Xe or MTH 
alone. 3h Xe best 
neuroprotection 
Chakkarapani 
et al 
2010 Hypoxemia with 
FiO2  
5–7 % 
Rat pup 50 % 18 hours 
with MTH 
Histological, global 
and regional 
neuroprotection 
with the 
combination 
Faulkner et al 2011 Transient cerebral 
ischemia 
Piglet 50 % + MTH Brain MRI 
spectroscopy injury 
mitigated 
Sabir et al 2014 Unilateral carotid 
ligation for 90 min 
Rat pup 0, 20, 50 % + 
MTH or 4 hours 
delayed 
Simultaneous 
treatment 
neuroprotective 
 
The first postinsult therapy proven effectively improve neurologic outcome after 
hypoxic-ischaemic neonatal asphyxia was mild hypothermia, as demonstrated in a 
neonatal asphyxia model in newborn piglets and rat pups (Bona 1998).  
The combination of mild therapeutic hypothermia and inhaled xenon was then 
demonstrated to be neuroprotective in several animal models. Ma and co-workers 
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illustrated in rat pup model of neonatal asphyxia, that xenon 20 % and hypothermia 
administered 4 hours after hypoxic-ischaemic injury provided synergistic 
neuroprotection assessed by morphological criteria, by hemispheric weight and by 
functional neurological assessments up to 30 days after the insult. When 
hypothermia and xenon were administered alone, no protective effect was seen (Ma 
2005). Hobbs and co-workers confirmed the same finding in rat pups: Xenon 50 % 
with hypothermia 32° C additively conferred greater protection after hypoxic-
ischaemic injury than either treatment alone. The histopathology changes were 
improved in the combination of the interventions as well as the functional 
improvement over 10 weeks follow-up into rat adulthood was sustained (Hobbs 
2008). 
Dingley and co-workers compared xenon 50 % to oxygen 30 % in a rat pup 
model of hypoxic -ischaemic insult provided with 90 min unilateral carotid 
ligation. The gases were administered for 3 hours. After one week of follow-up, the 
brains were harvested and a significant global neuroprotection was seen in the 
xenon group as demonstrated with less cortical, hippocampal and basal ganglia 
injury (Dingley 2006).  
Martin and co-workers showed in the same rat pup model (Rice-Vannucci 
model of neonatal asphyxia (Rice 1981)), that the combination of xenon and 
hypothermia increased synergistically neuroprotection, even if they were 
administered asynchronously (Martin 2007). In the study by Thoresen and co-
workers, the authors came to equal conclusion: There was an additive long-term 
neuroprotection even when hypothermia and xenon inhalation was delivered 
immediately or delayed after neonatal rat hypoxia-ischaemia (Thoresen 2009). 
These results were confirmed additionally in a piglet model of neonatal asphyxia, 
which was induced by reducing the fraction of inhaled oxygen to 5–7 % to depress 
the background amplitude integrated electroencephalography (aEEG) activity for 
45 minutes. 18-hour inhalation of xenon 50 % was compared in induced 
hypothermia (33,5 °C) or spontaneous normothermia-hyperthermia (38,5 °C). In 
particular, the authors evaluated requirements of inotropic support, and global 
haemodynamics during intervention. They concluded, that the current neonatal 
encephalopathy treatment by induced hypothermia could safely be complemented 
with inhaled xenon (Chakkarapani 2011). 
Several clinical studies in human neonatal asphyxia have been conducted in 
respect of beneficence of cooling. Gluckman and co-workers showed in a 
multicentre randomized trial (CoolCap trial), that selective head cooling for 72 
hours, within 6 hours of birth, in 218 full-term infants had a beneficial effect on 
survival in those babies, whose amplitude integrated electroencephalography 
(aEEG) had initially less severe changes (Gluckman 2005). The NICHD trial 
(National Institute of Child Health and Human Development) demonstrated, that 
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there was a significant reduction in death and disability with hypothermia treatment 
in asphyxical infants at 18 months outcome assessment (Shankaran 2005). 
Azzopardi and colleagues compared intensive care with cooling of the body to 
moderate hypothermia of 33,5 °C for 72 hours to sole intensive care in 325 infants 
suffering from perinatal asphyxial encephalopathy. Cooling did not affect mortality 
or severe disability, but resulted in improved neurologic outcome at 18 months in 
those infants who survived (Azzopardi 2009). 
Combining xenon inhalation to moderate hypothermia after birth asphyxia was 
investigated in Total Body Hypothermia plus Xenon trial (TOBY-Xe). With signs 
of moderate to severe encephalopathy 92 infants were enrolled, with inclusion 
criteria of either seizures or abnormal background activity shown in aEEG, Apgar 
score of 5 or less 10 min after birth, sustained need for resuscitation 10 min after 
birth or acidosis within 1 h after birth. The standard treatment of cooling to 33.5 °C 
for 72 hours was compared to cooling in combination of inhaled xenon 30 % for 24 
hours. The babies were assessed with magnetic resonance (MRI) spectroscopy and 
MRI fractional anisotropy within 15 days of birth. The authors concluded, that 
administration of xenon within the delayed timeframe was feasible and safe, but 
the combination of xenon with mild hypothermia did not enhance the 
neuroprotective effect of cooling after neonatal asphyxia, addressed with MRI 
alterations. The authors speculated the lack of efficacy in the combination of xenon 
and hypothermia by the suboptimal dose, and most importantly, by the significant 
delay in Xe administration (only 15 % of infants received xenon within 6 hours) 
and by the severity of asphyxic injury, which was likely to lead to minimal 
prospect of benefit of any intervention (Azzopardi 2016). 
2.4.8 Xenon organoprotection in the kidney 
The renal IRI is associated with increased reactive oxygen (ROS) species 
production and dysfunction of the antioxidant system, resulting in tubular cell 
injury and cell death (Bonventre 2011). The ensuing inflammatory process 
involves activation of proinflammatory cytokines and chemokines, complement 
activation and infiltration of neutrophils, macrophages and T cells (Bonventre 
2004). The intensity of this inflammatory response in postischaemic tissue can be 
so great that the injury affects reperfusion in distant organs (Neary 1999). 
Inflammation causes acute tubular necrosis, which accounts for 75 % of AKI 
(Khajuria 2014).  
Ma and co-workers demonstrated, that xenon preconditioning before ischemic 
renal injury or acute renal failure induced hypoxia inducible factor (HIF-1α), 
which prevented acute renal failure following IRI (Ma 2009). HIF-1α causes 
upregulation of cytoprotective factors such as erythropoietin and vascular 
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endothelial growth factor, which can interrupt apoptotic pathway and are known to 
be protective in several organ injury models (Ma 2009). Additionally, xenon might 
have a role in kidney transplantation in mitigating the kidney injury resulting from 
warm and cold ischaemia-reperfusion. In a rodent model of kidney transplantation, 
xenon exposure of graft donors or of recipients prolonged graft survival following 
IRI. Xenon -induced cell survival or graft functional recovery was abolished by 
HIF-1α and small interfering RNA (Zhao 2013).  
To summarize, the desired salubrious organoprotection effect after cardiac 
arrest in different organs are postanoxic and post-conditioning effects. However, 
the protective effect is restricted and very time-dependent, requiring initiation of 
intervention as soon as possible, preferably within 8 hours post arrest (De Deken 
2016).  
Besides xenon, noble gases without anaesthetic properties, namely helium, 
neon and argon are hypothesized to produce organoprotection. Pagel and 
colleagues demonstrated in a rabbit experimental infarct model myocardial 
protection by these gases indepently of an anaesthetic effect. The cardioprotection 
was mediated by activation of prosurvival signalling kinases and prevention of 
mPTP opening (Pagel 2007). However, in a rodent cardiac arrest model, 
replacement of air in a 50/50 % air/oxygen mixture with either helium or argon for 
24 hours did not affect clinical outcome or improve hippocampal neuronal damage 
in rats subjected to 8 min of cardiac arrest (Zuercher 2016).  
2.5 Prognostication after OHCA 
Prognosis is occasionally expressed as a risk for a good or poor outcome (Callaway 
2018). Prognostication is essential in informing the next-of-kin about the chances 
of recovery and importantly, to identify those OHCA survivors with absent 
recovery perspectives to dissuade futile extension of life-sustaining treatment 
(Horn 2014, Keijzer 2018). The best predictor of favourable outcome after OHCA 
is awakening from coma. The longer the patients remain unresponsive, indicates 
greater risk of permanent brain injury (Friberg 2013). Most patients remain 
comatose after successful resuscitation, and the duration of unresponsiveness is 
prolonged with regulation of body temperature and concurrent mechanical 
ventilation requiring sedation and neuromuscular blocking agents (Cronberg 2018). 
The main objective in OHCA prognostication is primarily to identify the patients, 
who certainly have a poor outcome, but simultaneously, limit the degree of self-
fulfilling prophecy associated with presumption of unfavourable neurologic 
prognosis (Horn 2014, Oddo 2017). Namely, an announcement of a humble 
prognosis prompts discussion of withdrawal of life-sustaining treatment (WLST), 
which independently impacts nurses’ and physician’s attitudes and eventually 
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patient care and ensures poor outcome (Püttgen 2007). Confounding issues, which 
include hypothermia-induced delayed clearance and accumulation of sedative 
drugs, hepatic or especially renal dysfunction, must be carefully excluded as the 
cause of delayed awakening (Rossetti 2016). 
The first-line approach of assessing prognosis of comatose patients has 
generally been neurologic examination. The classical findings suggesting poor 
prognosis are absent motor response to pain better than extension and lack of brain 
stem reflexes, including corneal, papillary and oculocephalic reactivity at 72 hours 
(Wijdicks 2006). However, the residual effects of sedative accumulation and 
targeted temperature management delay motor response and additionally brain 
stem responses rendering sole early clinical examination inaccurate and potentially 
inappropriate to decisive prognostication (Ben-Hamouda 2014, Oddo 2014). 
Worstly, a premature prognostication based solely on neurological examination, 
can lead to termination of life-supporting therapy in almost 20 % of patients, who 
are potentially prone to neurological recovery (Perman 2012). Moreover, preserved 
brain stem reflexes and motor response do not translate to or predict a good 
outcome (Adrie 2006). Even though, assessments by clinical examination are still 
recommended by the American Academy of Neurology (Wijdicks 2006) and lately, 
in guidelines from the European Resuscitation Council and the European Society 
of Intensive Care Medicine, as a part of multimodal prognostication approach 
(Nolan 2015). 
Two thirds of eventually deceasing patients admitted to ICU after OHCA die 
from a neurological injury. Most of the deaths are due to active WLST based on 
prognostication of a pessimistic and presumed poor neurological outcome, which is 
defined as death, persistent unresponsiveness, or the inability to undertake 
independent activities after 6 months (Wijdicks 2006). Accurate assessment of an 
uncertain neurological prognosis with correct interpretation of potential functional 
recovery ensures that treatment intensity is in line with patient’s preferences or 
advance directives (Girotra 2015). A decision of limitation or withdrawal of 
intensive care will almost inevitably portend the death of the patient and a self-
fulfilling prophecy occurs, when outcome is predicted too prematurely, e.g. during 
residual sedation originating from sedative and paralytic drug accumulation during 
hypothermia (Cronberg 2018).  
In the analysis of 939 TTM-trial patients, nearly half of the trial patients had 
regained consciousness and 15 % of OHCA survivors died, mostly for non-
neurological reasons before 72 hours after the end of TTM. At this scheduled time 
point for assessment, 33 % of patients remaining unconscious were subjected to 
neurological prognostication and three level-of-care recommendations for ICU 
treatment were advocated: 1) continue treatment, 2) do not escalate treatment and 
3) withdraw treatment. This approach resulted in that 66 % of in-hospital deaths 
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occurred after WLST. Over half of the patients died during their ICU stay. The 
median day of WLST was day 6. Of the patients involved in neurological 
prognostication, 79 % had deceased within 6 Months and only 15 % had a 
favourable neurological outcome (Dragancea 2017). If WLST is prohibited, as in 
South Korea, surviving translates to almost half of the OHCA victims having a 
poor neurocognitive outcome at 6 months (Kim 2016).  
No pre-arrest or intra-arrest parameters, including underlying morbidity, arrest 
duration or bystander CPR accurately predict outcome in individual patients 
achieving ROSC (Peberdy 2010). However, scoring systems have been developed 
to depict unfavourable outcome early, already at hospital admission. In the “OHCA 
score”, outcome prediction was validated in 130 OHCA patients and initial rhythm, 
no-flow and low-flow intervals, blood lactate and creatinine levels were identified 
independently to be associated with poor outcome (Adrie 2006). Another non-
neurological pretest probability of survival and recovery is the “CAHP (Cardiac 
Arrest Hospital Prognosis) score”, which was developed in 819 OHCA patients and 
poor outcome was defined as CPC score 3–5 at hospital discharge. Based on 
independent association with poor outcome, seven variables (age, non-shockable 
rhythm, no-flow and low-flow intervals, location of cardiac arrest, adrenaline dose 
and arterial pH) were identified and the scoring presented three patient risk groups 
(low risk, medium risk and high-risk), which establish the fundamental basis of 
early risk stratification (Maupain 2016). Both scoring systems were validated 
statistifically significantly. However, it should be borne in mind, that any scoring 
may be highly reliable in population-based estimation, but consistently in clinical 
medicine, prediction of an individual single patient’s outcome solely based on any 
scoring is hazardous, discouraged and potentially misleading, including 
inappropriate WLST (Wijdicks 2006, Püttgen 2007, Bougouin 2018). 
Therefore, assessment of neurological prognosis should be delayed for at least 
72 hours post rewarming (Morrison 2010) or even beyond 72 hours, which was 
suggested by the Swedish Resuscitation Council (Cronberg 2013). When predicting 
a poor outcome, the false positive rate should be zero. The contemporary 
prognostic tests focus almost entirely on the first few days after OHCA, although 
the awakening with eventual good outcome is occasionally delayed beyond the first 
week is some patients (Gold 2014, Oddo 2017). Especially, the 72-hour mark is not 
a magic deadline, where patients who have good outcomes are expected to awaken 
(Fugate 2015). In particular, concern has risen about the obvious existence of late 
awakeners and the risk of inadequate and arbitrary premature determinations of 
neurological outcome (Gold 2014, Cronberg 2018, Velly 2018). Potential late 
awakeners have been characterized e.g. by the circumstances surrounding their 
OHCA: initial rhythm of VF, witnessed arrest and received bystander CPR. Age 
was not identified to be predictive of belated aweakening (Gold 2014).  
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2.5.1 Biochemical markers facilitating prognostication 
The rationale of blood molecular markers of resuscitated patients is that higher 
levels of biomarkers correspond to more pronounced neuronal injury and 
consequently limited chances of recovery. Additionally, blood assessments are 
relatively easy to sample and likely to be independent from the effects of sedative 
drugs (Sandroni 2015). Elevated lactate values at hospital admission and at 12 
hours during follow-up were demontrated to associate with mortality at 30 days in 
a post-hoc analysis in 877 patients in the TTM -trial (Düring 2017).  
The most utilized molecular cerebral injury marker assays include neuron-
specific enolase (NSE), a cytoplasmic enzyme of neuron glycolysis, and the 
astroglial protein S100β, a calcium-binding soluble protein regulating neuronal 
differentiation and apoptosis (Snyder-Ramos 2003). High concentration of S100β 
is also found in some malignancies including melanoma, glioma, schwannoma and 
neuroblastoma (Martens 1998). Another potential confounder is the S100β release 
from muscle, adipocytes and chondrocytes, which may cause an initial false 
positive elevation after CPR circumstances, including chest compressions 
(Haimoto 1987, Scolletta 2012). Serum levels of S100β peak within 24 hours of 
cardiac arrest, and may therefore reflect systemic inflammation response and not 
the severity of hypoxemic cerebral injury (Tiainen 2003), although sustained 
S100β elevation has been demonstrated to accurately predict outcome (Rundgren 
2009, Mörtberg 2011).  
NSE is released from dying neurons and its concentration correlates with the 
magnitude of neuronal injury (Rossetti 2016). In post cardiac arrest patients, NSE 
values were significantly higher in patients who did not regain consciousness 
(Meynaar 2003). Formerly, it was believed, based on the data of a prospective 
randomized trial, that NSE values of more than 33 µg/l, sampled between 24 and 
72 hours post arrest, were strongly predictive of poor outcome with no false 
positives (Zandbergen 2006). Shortly, a prospective trial, however, demonstrated, 
that an increment in NSE values sampled at 24 and 48 hours post OHCA was 
specific but only moderately sensitive indicator of 6-month outcome (Oksanen 
2009). Furthermore, a retrospective data analysis illustrated, that cut-off values of 
S100β or NSE do represent many false positive estimates and are not sufficiently 
predictive of neurologic outcome (Zellner 2013). Moreover, instead of a definitive 
NSE cut-off point predicting poor outcome, serial NSE measurements with an 
increasing trend of values might be more accurate predictor of escalating neuronal 
injury (Tiainen 2003, Sandroni 2013, Nielsen 2013, Sandroni 2014).  
We could confirm this finding in a preliminary analysis of our trial, where 
increment of NSE-values from 24 and 48 to 72 hours post OHCA distinguished 
non-survivors from survivors (Arola 2013). 
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In a recent analysis of 1053 in- and out-of-hospital cardiac arrest patients, again 
a threshold value of NSE over 90 µg/l was suggested to predict poor outcome of 
CPC 4–5 with almost nonexistent false positives (Streitberger 2017). However, 
there are still cautious reports about some individual patients with eventually good 
neurologic outcome, despite peaking high NSE values (Schummer 2010). 
Confounders of NSE elevation include NSE- secreting tumors (i.e. 
parvocellular pulmonary cancer), concurrent acute brain diseases and haemolysis, 
which significantly distorts NSE values. Different assays may, moreover, differ as 
much as 40 % (Stern 2007). Presence of haemolysis should actively be considered, 
particularly by routine haemolysis quantification (Streitberger 2017). 
A novel biomarker for post cardiac arrest prognostication is neurofilament light 
chain (NFL), which is elevated in cerebrospinal fluid or blood corresponding to 
white matter axonal injury in various neurologic conditions (De Marchis 2018). In 
the substudy of TTM trial, in 717 OHCA patients, it was recently demonstrated, 
that serum NFL concentration assay analyzed at 24, 48, and 72 hours after cardiac 
arrest highly predicted a long-term poor neurologic outcome (CPC 3–5) at 6-month 
follow-up (Moseby-Knappe 2019).  
2.5.2 Neurophysiologic assessments 
2.5.2.1 Electroencephalography (EEG) 
Electroencephalography (EEG) is a non-invasive, relatively inexpensive and 
largely available assessment of cortical damage following cardiac arrest (CA). 
Interpretation of EEG, however, requires considerable experience and expertise 
(Püttgen 2007). Among expert interpretation of EEG, malignant patterns after CA 
are recognized in substantial agreement, but interpretation of e.g. reactivity is not 
as univocal (Westhall 2015). Absence of cortical activity on EEG immediately 
after restoration of circulation overestimates and does not accurately predict 
unfavourable outcome and intensivists are advised to postpone ordering of EEG at 
least 24 hours to avoid incorrectly disappointing interpretation (Jørgensen 1999). 
Intermittent two standard EEG recordings of 20–30 min (within 48 hours after 
OHCA) including stimulations of reactivity post OHCA has been demonstrated to 
be as informative as continuous EEG, with the exception of post-arrest status 
epilepticus, where continuous EEG approach is advocated (Alvarez 2013). 
Suggested time points for standard EEG assessment could be during TTM, after 
rewarming and cessation of sedation (Ben-Hamouda 2014). Three main EEG 
features need to be systematically assessed: background activity, background 
reactivity and epileptiform features (Rossetti 2016). Continuous EEG background 
activity is a robust, but strong early predictor of recovery, but residual sedation 
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may confound interpretation of quantitative EEG after CA (Callaway 2018). 
Validated and adapted criteria as well as standardized guidelines for post-cardiac 
arrest EEG interpretation were published by the American Clinical 
Neurophysiology Society (Westhall 2015). However, these definitions are still 
contradictory and under debate (Backman 2017). 
Seizures and myoclonus are common after CA and the use of continuous EEG 
to monitor EEG patterns and trends as well as to detect postanoxic status 
epilepticus has been advocated (Hovland 2006, Cloostermans 2012). However, 
during MTH, generalized, tonic-clonic, focal epileptic seizures and myoclonus are 
likely to be suppressed by routine sedative administration (Cronberg 2013). 
Notably, the added value of EEG-based coma prognostication in the clinical setting 
still needs to be demonstrated (Friberg 2013, Duez 2019).  
Clinical seizures, including myoclonus, may or may not be of epileptic origin 
as there are several types of myoclonus of which the majority are non-epileptic 
without electrographic changes. Various presentations of post-arrest motor 
manifestations can be misinterpreted as seizures (Legriel 2009, Benbadis 2010, 
Rittenberger 2012).  
Nonepileptic movements can present as the appearance of almost purposeful 
responses to discomfort, induced by common nursing activities such as 
mobilization or stimulation, by repositioning or suction, all of which are highly 
deterrent to visiting relatives (Benbadis 2010, Bouwes 2012). Generalized periodic 
epileptiform discharges (GPEDs) are often depicted as malignant EEG patterns, 
which portend poor long-term clinical prognosis, if the OHCA victim survives 
(Ribeiro 2015). Further findings prognosticating death without regaining 
consciousness are a discontinuous EEG background before the start of 
electrographic status epilepticus. However, in possibly surviving patients, a 
continuous EEG background was present prior status epilepticus, which developed 
at the median time of 46 hours post arrest (Dragancea 2015). 
Some quantitative EEG parameters have been identified to differentiate 
patients with poor or good outcomes after OHCA and TTM. These include burst-
supression ratio, wavelet subband-, response- and state entropy. The value of these 
relatively simple quantitative values need, however, to be confirmed in larger 
patient populations (Wennervirta 2009). The classification of these patterns has 
extensive variation between studies (Rundgren 2010, Cloostermans 2012).  
Myoclonus is the abrupt and involuntary twitching of a muscle group, which 
may have cortical or subcortical origin (Bouwes 2012). Generalized myoclonus 
(face, trunk and/or limbs) appearing early (< 24 hours post CA) is usually, but not 
always, a sign of severe cortical injury and an indicator of unfavorable outcome 
(Wijdicks 1994). A major development in EEG based prognostication was the 
understanding that there are different types of postarrest seizures, which are still 
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ominous conditions, but some of the victims still might have a possibility to 
recover (Elmer 2016). Status epilepticus (myoclonus and EEG seizures) should be 
distinguished from myoclonic seizures and reticular status myoclonus, which are 
myoclonus without EEG seizures. In reticular status myoclonus the cerebral cortex 
is too damaged to generate epileptiform waves. It is a sign of critical global cortical 
and subcortical injury and associated with premature death (Lucas 2012). 
A rare consequence after cardiac arrest is Lance-Adams syndrome, an action-
induced myoclonus, which is associated with good recovery, even though 
myoclonus symptoms are difficult to control (Rossetti 2009, Lee 2011). 
Survival after post arrest seizures with good neurologic recovery has been 
demonstrated to be possible in several studies. The identified particular subgroups 
of patients have late seizures, appearing after rewarming and off sedation. 
Moreover, they had retained brain stem reflexes, reactive and continuous EEG 
background and preserved somatosensory evoked potentials (SSEP) (Rossetti 
2009, Lucas 2012, Legriel 2013). 
2.5.2.2 Somatosensory evoked potentials (SSEP) 
Assessing short-latency SSEP involves electrical stimulation of peripheral nerve, 
usually the median nerve at the wrist and responses are registered over the 
contralateral sensory cerebral cortex, expected to appear within 20 ms (N20 
potential). SSEP responses are regarded as reliable even when the patient is 
sedated, in contrast to EEG (Zandbergen 2006, Fugate 2010). SSEP are commonly 
used predictors of outcome after OHCA, especially in multimodal prognostication 
approaches. The bilateral absence of N20 SSEP wave assessed after rewarming, in 
a technically well-performed test, entails death or poor vegetative state with a 
specifity of 95–100 % (Zandbergen 2006, Cronberg 2013). Further treatment will 
be regarded futile and palliative or end-of-life care should be launched 
(Zandbergen 1998). However, any other isolated SSEP findings, including 
preserved N20 potentials, does not imply a good outcome and could be misleading 
and prone to the bias of self-fulfilling prophecy and premature WLST (Sandroni 
2013, Karapetkova 2016). In multimodal assessment using several ancillary tests, 
SSEP and EEG provide complementary information and are ambiguous whenever 
used alone (Callaway 2018). 
2.6 Imaging post cardiac arrest brain injury 
Given the significant impact on survival, quantitative evaluation of post arrest 
hypoxic–ischaemic brain injury has a central part in prognostication and 
additionally when addressing the neuroprotective effect of various post arrest 
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interventions. The concept of intervening and mitigating an on-going ischaemic 
cerebral injury was introduced in 1974, when Hossmann and Zimmermann 
demonstrated in mammalian brains, that induced ischaemia in rhesus monkeys for 
up to an hour is a modifiable target and can be at least partially recovered 
(Hossmann 1974).  
Evaluation of the efficacy of any neuroprotective intervention requires 
objective quantification of the neuronal injury, usually by imaging or by 
biochemistry. Moreover, the timing and accuracy of clinical assessments is 
challenging, especially during the first week after OHCA when lingering effects of 
sedatives, neuromuscular blocking agents and hypothermia limit accurate clinical 
neurological examinations (Velly 2018). Therefore, the sensitivity and specificity 
of performed assessments, biochemical or any imaging, should be objective, 
unbiased and reproducible, include a high level of certainty and identify the very 
patients, who have no meaningful likelihood of recovery (Wijman 2009).  
2.6.1 Hypoxic-ischaemic brain injury properties 
Within minutes after cardiac arrest and cerebral hypoxia and ischaemia, energy 
depletion results in cytotoxic edema in the areas considered most vulnerable to 
injury, the vascular border zone watershed areas of the cerebral grey matter 
hemispheres supplied by the most distal branches of the main brain arteries (Busl 
2010, Okamura 2010). Hypoxia reflects reduction of oxygen supply or utilization, 
whereas ischaemia describes blood supply reduction and decreased oxygen 
delivery including limited or nonexisting removal of damaging cellular 
metabolites, such as lactate, protons and glutamate, which will then accumulate 
exacerbating brain injury (Howard 2012).). The traditionally most vulnerable and 
commonly injured area after prolonged ischaemia is the pyramidal neurons of the 
hippocampus, neocortex and cerebellum (Petito 1987, Madl 2004, Greer 2013). 
During the following days, increase of blood brain barrier permeability and 
vasogenic oedema will enhance the swelling (Järnum 2009, Okamura 2010, 
Sangalnamath 2016). If the patient starts to recover, primitive brain stem functions, 
like breathing and pupillary reflexes, reappear first, followed by the return of 
activities in deeper structures of the brain (Xiong 2011). Eventually, cortical 
activity and consciousness might recover (Jørgensen 1998). However, 30–70 % of 
these patients never regain consciousness (Tiainen 2007, Neumar 2008, Rossetti 
2016). 
Greater blood flow, synaptic activity and higher metabolic rate in grey matter 
are conventional explanations of grey matter ischaemic vulnerability. Most of the 
dendrites with postsynaptic glutamate receptors are located in the grey matter 
(GM) explaining the susceptibility to glutamate excitotoxicity (Arbalaez 1999, 
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Huang 2008, Gutierrez 2010, Kim 2013). However, there has been a marked 
discrepancy correlating GM lesion size and the ultimate functional outcome, which 
can be worse than expected by the volumetric measurement of cortical and 
subcortical infarction (De Vries 2001). Clinical experience also indicates, that 
human ischaemic brain injury is almost never restricted to GM (Goldberg 2003).  
2.6.2 Hypoxic-ischaemic white matter injury 
Previously, it was assumed, that cerebral white matter (WM) is less vulnerable to 
ischaemia than GM (Marcoux 1982, Pantoni 1996). This may be an under-
appreciation and reflection of experimental animal stroke research, which could 
have misrepresented WM injury less important, originating from that the WM 
volume in rodents is only about 14 % (Zhang 2000). However, in humans, white 
matter comprises about 50 % of forebrain volume (Zhang 2000, Matute 2012a). 
Major components of cerebral WM are myelinated or unmyelinated axons, and 
their glial cell partners including astrocytes, oligodendrocytes and blood 
vasculature supporting their correct function (Goldberg 2003, Matute 2011, Matute 
2012b). The metabolic rate of WM deduced from glucose consumption is, 
however, very comparable to GM (Harris 2012). 
The vasculature for the deeper cerebral white matter consists of widespread 
linear arterioles with sparse anastomoses, demanding that these WM neurons are 
provided with a continuous supply of energy along their entire length, although 
they are metabolically independent of their cell bodies in respect of energy 
metabolism (Matute 2012b). This makes central white matter highly vulnerable to 
focal hypoxic ischemic injury (Busl 2010, Matute 2012b, van der Eerden 2014). 
Essentially, compromised blood supply originating from various reasons, results in 
isolated WM strokes, depicted as lacunar strokes, which in humans represent 20–
25 % of all ischaemic strokes (Fisher 2011, Matute 2012b). Cerebral WM, of 
which the largest cellular volume component is axons, represents a significant 
repository of intracellular glutamate, which is released under ischaemic conditions 
(Doyle 2018). WM is highly susceptible to excessive excitotoxic neurotransmitter 
signalling, such as ischaemia-reperfusion induced excitotoxicity involving 
glutamate release, over-activation of glutamate receptor and ensuing cytotoxic Ca2+ 
activation, which result in WM demise (Fern 2019). Postischaemic excitotoxicity 
results in over-activation of oligodendrocyte functional NMDA and ultimately in 
non-NMDA glutamate (AMPA and kainate-preferring) receptors, which are 
frequently expressed in all WM cell compartments, especially in myelin 
(Karadottir 2005, Fern 2019). Ensuing WM injury, in effect by the primary or 
secondary breakdown of axons, occurs acute (Chalela 2001), subacute (Arbalaez 
1999) or delayed and progressive after global ischemia (Plum 1962).  
Review of the literature 
 77 
White matter attributes to cerebral regions abundant of myelinated axons, 
which are responsible for neural connectivity and signal transmission between 
various areas of the brain (Matute 2012a, Agematsu 2016). As a consequence, 
injury in WM leads to miscellaneous neurocognitive dysfunction, ranging from 
mild functional disability such as impairment of memory, visuospatial and 
perceptual problems to the dismal long-term disability characterized by detriment 
of awareness and insufficiency in arousal resulting in permanent unresponsiveness 
or vegetative state (Hoesch 2008, Girotra 2012, Stevens 2014, Callaway 2018, 
Keijzer 2018). Long-term cardiac arrest hypoxemia consequences may appear 
gradually and include a 10 % reduction of bilateral hippocampal volume 
accompanied with marked verbal memory deficits, also in patients who were 
discharged from hospital with a good neurological performance (Stamenova 2018). 
Imaging experimental white matter injury is technically challenging in rodents 
that display a lower WM/GM ratio than humans. This ratio is, however, 
comparable and close to humans in nonhuman primates (Gladstone 2002). In the 
experimental stroke study in marmosets, Bihel and colleagues demonstrated in 
serial magnetic resonance imaging (MRI) examinations, that diffusion tensor MRI 
revealed pathological changes and disorganization of WM, despite absent visible 
ischaemic lesions in conventional MRI images at the chronic stage. The disruption 
of WM was strongly correlated with the chronic sensorimotor deficits (Bihel 2011).  
The evaluation of brain WM injury is particularly important, when assessing 
OHCA survivors, who remain unresponsive after weaning from sedation. 
Conversely, some of these patients could have presented apparent cortical damage, 
displayed in initial diffusion weighted MRI. However, in patients remaining 
comatose, cortical changes are gradually replaced by WM changes (Greer 2011, 
Gerdes 2014). Deep white matter involvement is prominent as a late post ischaemic 
brain injury leucoencephalopathy (Howard 2012).  
2.6.3 Brain computed tomography 
Brain computed tomography (CT) detects abnormal features for the most part due 
to oedema generation, specifically sulcal effacement and widespread ischaemia 
with qualitative loss of margins of grey-white matter differentiation. Noncontrast 
CT studies do not detect pathology at the cellular level and the reliance of CT is 
based on gross features limiting its sensitivity (Hayman 2018).  
Profound anoxic brain damage following OHCA may be present in brain 
imaging already at hospital admission. However, this information may not be for 
logistic reasons immediately available, when decisions of TTM commencement are 
considered (Jeon 2017). Loss of grey-white matter differentiation corresponds to 
poor neurological outcome, and occurs commonly, in one-third of OHCA patients 
Olli Arola 
 78 
evaluated with cranial CT (Langkjær 2015). Moreover, loss of grey-white 
differentiation is rather coarse finding, and it identifies only the worse anoxic 
encephalopathies and it is subject to intra-observer variability (Hayman 2018).  
In the sub-analysis of TTM-trial, findings of generalized oedema on non-
contrast head CT was a reliable predictor of poor outcome (Moseby-Knappe 2017). 
There is also some evidence, that demonstration of a low brain grey matter to white 
matter ratio (GWR) obtained from a CT scan performed within 1 hour after ROSC, 
provides valuable information about a presumed poor outcome (Kim 2013, Scheel 
2013, Gentsch 2015). GWR is measured with CT Hounsfield units in grey and 
white matter and calculating the ratio of both (Metter 2011). The accuracy in GWR 
outcome prediction increases, when it is combined with optic nerve sheath 
diameter measurement, which correlates to increased intracranial pressure (Chae 
2016). However, the predictive performance of GWR has additionally 
demonstrated to be poor and useless (Lee 2015).  
Even though, in respect of detecting brain white matter injury, the sensitivity of 
CT is low (Hayman 2017). Most importantly, CT scans performed very early after 
OHCA are most often normal, and thus of limited value (Yanagawa 2005). Patients 
with dramatic changes at CT do not pose diagnostic dilemmas (Wu 2009). 
2.6.4 Brain magnetic resonance imaging 
Magnetic resonance imaging (MRI), through the use of diffusion-based techniques, 
can provide a non-invasive insight into the living brain (Bach 2014). It provides 
quantitative parameters related to white matter cellular swelling, water-shifts 
between extra- and intracellular compartments and minor changes in tissue water 
content (Tournier 2011). Each MRI sequence consists of thousands of voxels of 
one cubic millimeter. Measurements of the MRI signal attenuation from water 
diffusion are calculated within each voxel. Much of the knowledge about 
alterations in brain white matter microstructure obtained from diffusion MRI 
originates from studies that compared diffusion markers between populations of 
interest, e.g. with and without an intervention or more commonly, between a 
healthy control group and a diseased population (Bach 2014). 
Cellular cytotoxic oedema manifests as an increased signal on diffusion 
weighted imaging (DWI) and decreased signal on whole-brain apparent diffusion 
coefficient (ADC) imaging (Gutierrez 2010, Keijzer 2018). ADC is a scalar 
quantity very related to the mean diffusivity of water molecules in a voxel and it 
expresses the propensity of water diffusion in any direction within a voxel. Low 
whole brain ADC has been demonstrated to correlate with poor outcome (Wu 
2009). DWI identifies early cytotoxic oedema and provides adjunct prognostic 
value after OHCA (Hjort 2005). However, the clinical studies involving ADC and 
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DWI are mostly descriptive and do not draw correlations between imaging 
characteristics and functional outcome (Wu 2009) with a potential to WLST 
(Hirsch 2016). Furthermore, ADC values are likely to be affected by temperature 
(Yenari 2000). Clinically, DWI is frequently used to provide an understanding of 
the qualitative extent of hypoxic-ischaemic damage (Greer 2012). Jeon and 
colleagues demonstrated, that the combination of GWR and DWI assessed shortly 
after hospital admission improves the sensitivity of predicting neurological 
outcome (Jeon 2017). 
In the small prospective study in 12 patients DWI within 36 hours after global 
cerebral hypoxia differentiated pathological changes, which corresponded to worse 
clinical outcome after 6 months (Th 2004). Wijman and colleagues corroborated 
this in the larger prospective study, where 71 OHCA patients remaining comatose 
after weaning from sedation were scanned within 7 days post arrest, after they had 
regained normal body temperature after TTM. Functional outcome after 1, 3, and 6 
months was assessed with Glasgow Outcome Scale (GOS). The final analysis 
constituted of 51 patients. The preliminary results demonstrated, that high 
quantitative ADC signals distinguished survivors and patients with low ADC 
signals, who died or remained in vegetative state. None of the patients with over 10 
% of brain tissue with an ADC value below 650 x 10-6 mm2/s to 700 x 10-6 mm2/s 
regained consciousness during the follow-up to 3 months. This translates to that 
quantitative brain DWI may be a useful adjunct in the outcome prediction for post 
cardiac arrest patients, who prolongedly remained comatose. Additionally, it may 
provide information on the likelihood of long-term neurological impairment among 
survivors (Wijman 2009).  
However, the ideal time window of DWI and ADC for prognostication is short 
(within 3 to 5 days after OHCA), and brain region dependent (cortex, hippocampus, 
putamen and corona radiata) with low sensitivity (25–30 %) for unfavourable 
outcome, despite high specifity (95 -100 %) (Mlynash 2010, Greer 2013). 
2.6.4.1 Diffusion tensor imaging 
Diffusion Tensor imaging (DTI) is a brain MRI sequence and an extension of DWI, 
which enables the measurement of restricted diffusion of water in tissue to produce 
neural tract images by characterizing the three-dimensional diffusion of water as a 
function of spatial location (Basser 1994). It provides specific information on the 
nature of brain white matter damage, besides injury localization. It addresses white 
matter tract connectivity and axon disruption, which takes place during ischaemia 
reperfusion and inflammation. DTI allows measuring of directional preference of 
water molecules, which facilitates to make inferences about the underlying tissue 
microarchitecture (Luyt 2012). This illustrates tissue microstructure, cellular 
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density, integrity and alterations in the directionality of the neural tract (Abe 2010). 
In cardiac arrest patients, prominent feature in DTI imaging is marked decrease in 
axial diffusivity in central brain regions and in cerebral hemispheres (van der 
Eerden 2014). DTI allows assessment of WM degeneration after OHCA much 
earlier than by traditional structural MRI, which may not demonstrate the full 
extent of WM injury at the early post-arrest phase (Gerdes 2014). 
2.6.4.2 Tractography 
In tractography, collected DTI data from specified regions of interest is processed 
with a mathematic three-dimensional modelling technique to visually represent 
nerve tracts. These two- or three-dimensional images, tractograms, generate 
anatomically probabilistic estimates of white matter trajectories and display the 
continuity, asymmetry and breakdowns of neural tracts (Alexander 2007, van 
Baarsen 2016). This method uses both deterministic and probabilistic algorithms 
and has generated tract reconstructions of major projection pathways, e.g. 
corticospinal tract, corona radiata, corpus callosum, cerebellum and association 
pathways, such as arcuate, inferior longitudinal and uncinate fasciculus (Stieltjes 
2001, Mori 2002, Farquharson 2013, van Baarsen 2016). Tractography is, however, 
sensitive to thermal noise, physiologic fluctuations and image artifacts generated 
by e.g. overlapping or crossing white matter pathways. Even though, it provides 
plausible three-dimensional visualization of white matter trajectories in relation to 
brain pathology (Alexander 2007, Lerner 2014). 
    
Figure 2.  Tractography images from 2 subjects from the Xe-Hypotheca trial. Visual 
representation of white matter tract continuity and missing trajectories are displayed 
2.6.4.3 Fractional anisotropy 
The free water diffusion is termed isotropic diffusion, where molecular motion is 
equal to all directions. This may be found in the cerebrospinal fluid spaces, except 
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at the orifices of foramen Monro or the aqueduct of Sylvi (Mukherjee 2008). If the 
water diffuses in a medium with barriers, the diffusion is not uniform, which is 
termed and quantified as fractional anisotropy (FA) (Pierpaoli 1996). Anatomical 
connectivity indicates, how strongly directional local white matter tract structures 
are, which is quantified by FA measurement. Parallel organization of white matter 
fiber bundles with cell membranes, axon myelin sheaths, intracellular microtubules 
and various proteins hinder the diffusion of water and provides the basis for 
evaluation of scalar summaries of diffusion anisotropy (Alexander 2007). FA 
represents the standard deviation of the three diffusion eigenvalues, divided by 
their root-mean square (Pierpaoli 1996).  
 
Figure 3.  A) In isotropic diffusion, all of the eigenvalues (λ) or diffusion coefficients are equal. B) 
In anisotropic diffusion, the diffusion coefficient varies, when measured along different 
directions. FA is calculated from the eigenvectors (e1) and measures the fraction of the 
magnitude of the diffusion tensor that is anisotropic and its directionality, represented 
as an ellipsoid. C) Fiber tracking is initiated at region of interest and tracking is 
propagated along adjacent ellipsoids that meet certain tresholds for FA and trajectory 
curvature (Lerner 2014, reproduced with permission). 
FA is highest within white matter tracts (with a maximum theoretical value 1), 
lower in grey matter and approaches 0 in cerebrospinal fluid (Smith 2007). FA is a 
quantification of the directionality of water in the tissue, which corresponds to 
white matter organization and disorganization and it allows also quantitative 
comparison across subjects (Smith 2006). Low FA values correspond to brain 
white matter ischaemia, myelin damage, axonal degeneration and oedema, which 
all attenuate the water directional diffusivity in white matter tracts (Liu 2007). FA 
provides superior functional and anatomical information to the scalar parameters 
such as ADC (Luyt 2012).  
In the study by Velly and colleagues, 150 OHCA victims remaining 
unconscious for at least 7 days after OHCA were assessed with whole brain white 
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matter fractional anisotropy measured with DTI. The prognostic accuracy of 
neurological outcome was compared to conventional MRI sequences (fluid-
attenuated inversion recovery (FLAIR) and DWI). The neurological outcome was 
graded by Glasgow-Pittsburgh CPC at 6 months, as either favorable (CPC 1–2) or 
unfavorable (CPC 3–5). Prognostication performance was compared by assessing 
the receiver operating characteristic (ROC) curves between groups. The ROC 
curve was significantly higher in normalized white matter FA values than with the 
standard criteria for unfavorable outcome or other MRI sequences. The authors 
concluded, that normalized or unaltered white matter FA predicts accurately 
neurological outcome at 6 months. In respect of late awakeners, 12 patients were 
identified with eventually good outcome, even though they had signal 
abnormalities in the basal ganglia or cortex (Velly 2018).  
2.6.4.4 Tract based spatial statistics 
Comparison between multiple subjects from voxelwise analysis has been arbitrary 
e.g. involving the choice of spatial smoothing. In traditional morphometry, regions 
of interest (ROI) on brain scan images were delineated and then the volume 
enclosed was calculated and compared with corresponding areas in cross-subject 
analysis. This time consuming method was not able to detect smaller volume 
differences (Ashburner 2009). Voxel based morphometry (VBM) analysis, 
however, is fully automatic, relatively simple to elaborate and does not require 
prespecifying or prelocalising features or regions of interest (Smith 2006). VBM 
analysis involves the whole brain, highlights common features and differences 
across subjects in a specified population. It uses voxelwise analyses based on initial 
alignment of the diffusion data to a standard brain image template. Spatial 
smoothing and localization is then executed so that each voxel represents the 
average of itself and its neighboring voxels (Ashburner 2009). The voxelwise 
statistical analysis is then carried out to assess the in-between-group differences 
(Wang 2016). Although apparently objective, this method is sensitive to various 
artifacts, including anatomical variability, spatial smoothing, local misalignment 
and concerns of voxel comparison accuracy (Ashburner 2009, de Groot 2013). 
Tractography-based VBM approaches can overcome misalignment concerns by 
working in individual subject’s tractography results, which do not demand 
presmoothing (Smith 2006). 
In tract based spatial statistics (TBSS), alignment and smoothing problems are 
attenuated by applying an automatic whole brain analysis, which is established on 
multiple comparisons to an estimated group mean template. Namely, multiple 
subject voxelwise diffusion images are projected onto a common alignment-
invariant tract representation, the mean WM FA skeleton, which represents major 
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WM structures. This allows group comparison of standard voxel of the same part 
of the same WM tract from each and every subject. The estimation of a group mean 
FA skeleton represents the centers of all fiber bundles, which are generally 
common to all subjects involved in a study. Each subject’s FA data is then 
projected onto the mean FA skeleton in such a way that each skeleton voxel takes 
the FA value from the local centre, which is, in effect, the locally maximal FA 
value, of nearest relevant tract (Smith 2006). The thinning of the skeletonized mean 
FA image to exact thickness of one voxel of one cubic mm abandons the 
directional information captured in the diffusion data. This, however, establishes a 
possibility of inaccuracy especially in regions, where pathways of different 
structures merge, such as corpus callosum and corona radiata fiber bundles (Bach 
2014). Eventually, each brain contains hundreds of thousand voxels containing one 
FA value within each voxel (Smith 2006). Applying permutation statistics allows 
millions of comparisons across voxels, across patients and between the groups, 
which offers a remarkable statistical power (Ludbrook 1998, Nichols 2001, Ernst 
2004).  
This method estimates the localized change in FA, which represents entire 
brain WM connectivity and injury across different subjects without having to 
specify in advance regions of interest or draw by hand which specific tracts to test 
(Smith 2007). TBSS is fully automated, observer independent and it has been 
demonstrated to allow comparisons of imaging studies between groups in a 
sensitive, objective and reproducible manner (Smith 2006). To date, TBSS has 
grown to be popular and widely used in neuroimaging studies involving in-
between-group comparisons, also in determing the degree of global hypoxemic-
ischaemic injury following cardiac arrest (Abe 2010).  
Notably, the clinical role of neuroimaging studies in predicting mortality, 
morbidity and outcome after cardiac arrest has not yet been worldwide thoroughly 
defined. The implementation of group-wise data into clinical practice and to 
meaningful individual patient outcome prognostication has been, to date, 
impractical (Wijman 2009, Wu 2009, Greer 2012). Quantitave changes in MRI 
measurements should include practical and real-time information, to allow clinical 
decision-making concerning continuing or withdrawal of life-sustaining therapy. 
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3 Aims of the present study 
The aims of the present study were:  
1. To investigate the feasibility and safety of inhaled xenon in combination 
with mild therapeutic hypothermia in OHCA patients, who potentially are 
subjects to distinguished cardiac compromise 
2. To determinate the effect of inhaled xenon exposure combined with mild 
therapeutic hypothermia on the degree of severity of the postischaemic 
brain white matter injury in the study treatment group as compared with 
the control group corresponding to neuroprotective effects of inhaled 
xenon exposure. This was executed with the surrogate end-point of 
fractional anisotrophy (FA), which corresponds to brain white injury 
severity (Primary end-point) 
3. To explore the unestablished effect of xenon inhalation and mild 
therapeutic hypothermia on ongoing cardiac ischaemic reperfusion injury 
in OHCA patients, corresponding to cardioprotective effects of inhaled 
xenon exposure. This was assessed by the serial assessment of the 
myocardial injury surrogate, the cardiac TnT. Increment or decrement of 
serial TnT values reflect the amount of myocardial damage (Secondary 
end-point) 
4. To investigate whether the neuro- and cardioprotective effects by the 
combination of hypothermia with xenon exposure translates to an 
enhanced long-term outcome and survival. Further, to study if any 
assessments could be identified to prognosticate mortality at 6 months 
follow-up (Secondary end-point) 
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4 Materials and methods 
Xe-HYPOTHECA trial (ClinicalTrials.gov identifier: NCT00879892) was a 
randomized single-blind phase II clinical drug trial carried out during years 2009–
2015 at two multipurpose intensive care units in Finland. The main criteria for 
inclusion were witnessed cardiac arrest from an initial rhythm amenable to 
defibrillation (ie, ventricular fibrillation or pulseless ventricular tachycardia) and 
return of spontaneous circulation within 45 minutes. 
The ethics committee of the Hospital District of Southwest Finland and the 
institutional review boards of the Helsinki University Hospital and the Finnish 
Medicines Agency approved the study. An independent data and safety monitoring 
committee reviewed data after enrollment of every 4 patients and after each 6-
month interval. The study was conducted according to good clinical practice and 
the current revision of the Declaration of Helsinki guiding clinical drug research in 
human subjects.  
Written informed assent was obtained from the next of kin or from the legal 
representative of the patient within 4 hours after hospital admission. The patient’s 
family was informed about the right to withdraw from the study at any point but 
the data collected until possible withdrawal could be used in the analyses as 
predefined in the trial protocol. Patients were informed accordingly if they regained 
consciousness.  
4.1 Patients 
Survivors of out-of-hospital cardiac arrest remaining comatose consecutively 
admitted to the Turku and Helsinki University hospitals were screened for 
eligibility. The recruitment of a comatose patient to the study required, that the 
attending intensivist or other physician on duty had already made the decision for 
commencing mild therapeutic hypothermia (MTH) treatment for the patient. The 
patient’s eligibility to brain MRI and possible contraindications to it were carefully 
ruled out. The additional study inclusion criteria were: 
1. Ventricular fibrillation or pulseless ventricular tachycardia as initial, 
presenting cardiac rhythm 
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2. The first attempt of resuscitation by emergency medical personnel had to 
appear within 15 minutes after the collapse 
3. The cause for collapse should be considered primary as cardiogenic and 
the return of spontaneous circulation (ROSC) should have been gained 
in 45 minutes after the collapse 
4. Patient should be still unresponsive in the emergency room 
5. Age: 18–80 years 
6. Consent from the next of kin or the legal representative of the patient 
should be obtained within 4 hours after arrival to the hospital 
 
The study exclusion criteria were: 
1. Admission hypothermia (< 30 °C core temperature) 
2. Unconsciousness before cardiac arrest (reflecting to cerebral trauma, 
spontaneous cerebral haemorrhage, intoxication etc.) 
3. Response to verbal commands after the return of spontaneous circulation 
and before randomization 
4. Pregnancy 
5. Coagulopathy 
6. Terminal phase of a chronic disease 
7. Systolic arterial pressure < 80 mmHg or mean arterial pressure < 60 
mmHg for over 30 min period after ROSC 
8. Factors making participation in follow-up unlikely 
9. Enrollment in another study 
 
Before randomization, the availability of trained nurses taking care of xenon 
anaesthesia maintenance was confirmed. The clinical investigators enrolled the 
patients and after the assent was granted within inclusion criteria time frame, 
randomization was performed with sealed computer -randomized envelopes followed 
by the assigned intervention. The patients were allocated in 1:1 ratio with random 
block sizes of 4, 6, and 8 to be exposed to either mild therapeutic hypothermia 
treatment alone for 24 hours (defined as the control group) or inhaled xenon (Xe) in 
combination with hypothermia for 24 hours (defined as the xenon group). Both study 
groups consisted of 55 patients. Due to practical and safety considerations, the 
personnel involved in the patient care could not be blinded. 
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4.2 Treatment protocol 
If clinically indicated, percutaneous coronary angiography interventions (PCI) 
were performed already before ICU admission. Upon arrival at the emergency 
department, the patients underwent routine initial assessment and treatment 
including mechanical ventilation and correction of cardiovascular instability.  
Arterial and central venous catheters were inserted in all patients. The patients 
were then cooled to target core temperature of 33–34 °C. Inhaled Xe was initiated 
simultaneously immediately after randomization through a closed-circuit ventilator 
(PhysioFlex, Dräger, Lübeck, Germany). Trained study group member 
performed the priming of Xe ventilator and nitrogen washout (denitrogenization) of 
the patient still connected to conventional ICU ventilator. After switching 
ventilators, end-tidal Xe concentration was adjusted to at least 40 % ±10 %. 
Maximal allowed xenon concentration was 65 %. If the minimum Xe concentration 
of at least 20 % was for technical or other reason not achievable, Xe inhalation had 
to be terminated. The thermoconductive device on the ventilator measured Xe 
concentration continuously. The predefined concentration targets were adjusted by 
flushing the ventilation circuit with flushes of Xe, air or oxygen. Xe was delivered 
until start of rewarming. Adjustments to ventilation mode, tidal volume and 
frequency were made in accordance of standard critical care patient care. Repeated 
blood-gas analyses were performed at every hour during MTH and Xe exposure 
and later whenever clinically indicated but at least in every 4 hours. The predefined 
haemodynamic, chemical and arterial blood gas targets during intervention were: 
 
 Target 
Mean arterial pressure 60–90 mmHg 
Systolic arterial pressure > 100 mmHg 
Central venous pressure (PEEP corrected) 6–10 mmHg 
Heart rate (during MTH) > 30 beats /min 
Heart rate (after MTH)  > 40 beats/min 
Blood glucose 5,0–8,0 mmol/l 
Blood haemoglobin > 70 g/l 
Blood haematocrit 0,3–0,45 
Partial pressure of arterial oxygen 10–18 kPa 
Partial pressure of arterial carbon dioxide 4,5–5,5 kPa 
 
The study protocol allowed liberal use of vasoactive medication (adrenaline, 
noradrenaline, dopamine, dobutamine, levosimendan, vasopressin, etc.) by the 
decision of attending physician; the medication was adjusted to meet the 
predefined hemodynamic targets. The entire used medication and the amount of 
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required crystalloids or other fluids were captured in the ICU data processing 
system and eventually in the case report forms (CRF). 
Bradycardia (< 30 beats/min) was treated with boluses of atropine (0,01 mg/kg) 
and/or a raise of body target temperature (0,5 °C/h). If the safety reasons obliged 
core target temperature to be increased beyond 34 °C, xenon exposure and further 
MTH was discontinued. However, after possible study termination, the subsequent 
post cardiac arrest care continued according to the contemporary guidelines and 
treatment practices. Only the attending intensivist or physician could make 
decisions concerning entire medication (vasoactive, insulin etc.), core target 
temperature increases and study termination. 
Reasons for premature withdrawal from study treatment by the investigator or 
the attending intensivist were: 
– A failure to maintain xenon concentration > 20 % 
– A failure in ventilation and/or oxygenation of the patient with xenon 
delivery device (Physioflex) 
– If MTH was terminated prematurely; the decision could only be done by 
the attending physician 
– Adverse event/serious adverse event 
– Protocol violation 
– If for any reason the investigator or the attending physician believed that 
continued participitation in the study was not in the best interest of the 
patient 
An interim analysis was performed with 60 patients after they had undergone the 6-
months follow-up. 
4.3 Targeted temperature management 
Cooling of the patient was executed with an invasive intravascular temperature 
management device (Alcius CoolGard 3000 thermal regulation system; Zoll 
Medical Corporation, Chelmsford, MA, USA). The core target temperature of 33–
34 °C was then maintained for 24 hours. During hypothermia treatment and during 
mechanical ventilation, sedation was maintained with propofol infusion (1–
5 mg/kg/h) and additional boluses if indicated. Midazolam infusion and boluses 
could alternatively be utilized, especially in hypotensive patients. The dose of 
sedative agents during MTH was adjusted to target RASS scale of - 4 – -5, which 
facilitated potential reduction of sedative dose during concomitant Xe anaesthesia. 
Anaelgesia was assured with continuous fentanyl-infusion (50–100 µg/h) and 
additional boluses of 25–50 µg, if indicated. Target core temperature of 33 °C was 
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likely to induce shivering, which was terminated by deepening the sedation and 
anaelgesia or with neuromuscular blocking agents (e.g. cisatracurium, rocuronium) 
to additionally maintain hypothermia. These drugs could be administered as a 
continuous infusion or boluses.  
After 24 hours at target temperature, rewarming was commenced with 
maximum rate of 0.5 °C/h. Xe exposure was discontinued at the start of rewarming 
and substituted with propofol or midazolam. The invasive endovascular balloon 
membrane-cooling catheter (Microtherm, Alsius Co) was preserved to purposes 
of preventing reactive hyperthermia after rewarming. 
4.4 Assessments 
The study OHCA patients were evaluated by serial electrocardiograms (ECG) 
obtained at OHCA site, at hospital and ICU admissions, and 24, 48 and 72 hours 
after OHCA. All patients underwent a brain CT scan before ICU admission to rule 
out unexpected intracerebral causes of cardiac arrest and trauma to the head or 
neck. Routine chest x-rays were obtained according to normal ICU clinical 
practice. Whenever applicable (for logistic reasons), the study patients were 
mounted with a pulmonary artery catheter (Swan-Ganz). The ICU data processing 
system allowed meticulous capturing of given medication and organ function data; 
including fluid balance, ventilatory and haemodynamic data. All patients were 
equipped with an artery line for invasive haemodynamic monitoring and blood 
sampling. Central venous pressure was measured from a separate i.v. line. 
4.4.1 Myocardial injury markers 
Study blood samples of biochemical myocardial injury markers were obtained - 
besides whenever clinically indicated – at the ICU arrival, and 24, 48 and 72 hours 
after OHCA. The cardiac biomarker was plasma troponin-T (P-TnT). Until March 
1st, 2012, TnT was analyzed with a limit of detection of 0.03 mg/l (Electro-
chemiluminescence immunoassay, ECLIA Troponin-T Cardiac, Roche 
Diagnostics, Mannheim, Germany). Thereafter, a high-sensitivity cardiac TnT 
assay was used with a limit of detection of 5 ng/l (Electrochemiluminescence 
immunoassay, ECLIA Troponin T high-sensitive, Roche Diagnostics). The study 
latter part high-sensitivity TnT values were converted to the corresponding mg/l 
values with a specific formula.  
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4.4.2 Brain MRI 
Patients underwent brain MRI within 16 hours after completion of rewarming; the 
acceptable range was from 36 to 52 hours after OHCA, based on logistic reasons 
(study scans were performed after office hours). Magnetic resonance imaging was 
performed with a Verio 3T scanner (Siemens Medical Solutions, Munich, 
Germany) at both hospitals, with identical imaging protocols. Before each scan, the 
safety, feasibility and obvious risks were carefully considered concerning the 
patient’s stability, the scan, transport and limited resources outside ICU.  
 
 
MRI machine is generally regarded as incompatibile with most equipment required 
for monitoring the patient during intensive care (Püttgen 2007). A trained team of 
study investigator, study nurse and additionally an ICU nurse escorted the patient 
during each scan and MRI compatible infusion pumps, ventilator (Servo I, 
Maquet Getinge Group, Rastatt, Germany) and other equipment was used. The 
surviving patients underwent second MRI at 10±2 days post OHCA.  
Diffusion tensor MRI data was preprocessed using DTIprep quality control 
software. Version 5.0 of the FSL software package (FMRIB) was used for the 
tract-based spatial statistical (TBSS) analysis. Fractional anisotropy (FA) and 
diffusivity maps were calculated for each patient and these images were projected 
on a mean skeleton with a voxel size of 1 x 1 x 1 mm (i.e., 119013 voxels per 
patient), which represents the local centers of all major white matter structures. 
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These skeletonized images were then used for voxelwise statistics to identify all 
tracts with voxels revealing statistically significant differences in diffusion 
parameters. Localization and labeling of the major white matter tracts were 
confirmed according to the Johns Hopkins University white matter tractography 
atlas. Other diffusion metrics (Mean-, Axial- and Radial Diffusivity) were 
projected in the same skeleton and analyzed in similar way. 
The MRI protocol is displayed in table 5. 
Table 5.  Imaging protocol. FLAIR: Fluid Attenuated Inversion Recovery. MP-RAGE: 
Magnetization Prepared Rapid Gradient Echo. aNumber of diffusion directions: 20, 
b-value s/mm2 
 
 
MRI sequence 
In-plane 
resolution 
(mm) 
Slice 
thickness 
(mm) 
 
Echo time 
(ms) 
 
Repetition 
time (ms) 
T2-weighted 0.4 x 0.4 4.0 96 5210 
3D FLAIR 1.0 x 1.0 1.0 395 5000 
T1-weighted (3D MP-RAGE) 1.0 x 1.0 1.0 2.2 1900 
Diffusion tensor imaginga 2.0 x 2.0 3.0 100 6100 
4.4.3 EEG and neurological follow-up evaluation 
Routine EEG was not a part of the study protocol, but this assessment was 
encouraged, whenever clinically indicated. However, during the study, continuous 
EEG monitoring was progressively utilized and recommended in OHCA survivors 
in international congresses and literature (Hovland 2006, Cloostermans 2012, 
Cronberg 2013, Crepeau 2014). Therefore during this study, continuous EEG was 
increasingly ordered in the latter part study subjects to gain knowledge and 
experience of its utility and use. 
Best neurological response was assessed at 1, 24, 48, 72 and 96 hours after the 
collapse using Glascow Coma Scale (GCS). Additionally pupillary response and 
involuntary movements, such as seizures or myoclonus and extension reactions 
were reported. Recovery from coma was defined by following verbal commands. 
Best value of CPC and mRS were defined before hospital discharge. 
Neurological long-term outcome was defined according to Pittsburgh cerebral-
performance category (CPC category) and Modified Rankin Scale (mRS). The 
neurologist assessing the neurologic outcome at 3 months and 6 months after 
OHCA was unaware of the treatment assignment.  
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CPC categories: 
– CPC 1; good cerebral performance: conscious, alert, able to work, might 
have mild neurologic or psychologic deficit 
– CPC 2; moderate cerebral disability: conscious, sufficient cerebral 
function for independent activities of daily life. Able to work in 
sheltered environment  
– CPC 3; severe cerebral disability: conscious, dependent on others for 
daily support because of impaired brain function. Ranges from 
ambulatory state to severe dementia or paralysis  
– CPC 4; coma or vegetative state: any degree of coma without the 
presence of all brain death criteria. Unawarness, even if appears awake 
(vegetative state) without interaction with environment; may have 
spontaneous eye opening and sleep/awake cycles. Cerebral 
unresponsiveness 
– CPC 5; dead or certified brain death 
 
The mRS scale runs from 0–6, running from perfect health without symptoms to 
death: 
– mRS 0; no symptoms 
– mRS 1; no significant disability. Able to carry out all usual activities, 
despite some symptoms 
– mRS 2; slight disability. Able to look after own affairs without 
assistence, but unable to carry out all previous activities 
– mRS 3; moderate disability. Requires some help, but able to walk 
unassisted 
– mRS 4; moderate severe disability. Unable to attend to own bodily needs 
without assistence, and unable to walk unassisted 
– mRS 5; severe disability. Requires constant nursing care and attention, 
bedridden, incontinent 
– mRS 6; dead  
 
Additionally, the Mini-Mental State Examination (MMSE) (score range, 0-30; ≥ 24 
indicates no impairment) and the National Institutes of Health Stroke Scale 
(NIHSS) (score range, 0–42; higher scores indicate greater severity) were utilized 
to assess the 6-month neurocognitive outcome. The minimally clinically important 
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differences for CPC and NIHSS have not been established; changes in MMSE of 4 
or more points have been interpreted as clinically significant.  
4.5 Neurological prognostication consensus 
Decisions to withdraw life-sustaining treatment were based on a consensus 
agreement on a multimodal assessment of poor neurological outcome. This was 
based on following principles: 
– Neurological prognostication was accomplished if the patient remained 
unconscious 12 h after rewarming 
– All sedative medication must have been discontinued 12 h previously  
– In hypothermia-treated patients prognostication was performed after 
72 h post resuscitation. 
Neurological examination was performed by consulting neurologist; consisting: 
1. Glascow Coma Scale (eye, speech and movement responses) 
2. Brain stem reflexes 
3. Breathing 
4. Possible myoclonus 
Assessments: 
If the patient remained unconscious: 
1. Brain CT or MRI scan was performed 
2. EEG was obtained to exclude convulsive or nonconvulsive status 
epilepticus (NCSE).  
The key EEG considerations: 
– Continuity of electrical activity of the brain 
– Response to external stimuli 
– Spontaneous dynamics in brain electrical activity 
– Presence of epileptiformic waves 
– Non-convulsive status epilepticus 
3. Serum neuron specific enolase (NSE) was assessed at 24 h, 48 h and 
72 h after OHCA 
4. Sensory evoked potential (SEP) assessment was performed if CT/MRI 
or EEG provided no explanation to unconsciousness 
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Conclusions:  
Signs of poor prognosis were: 
1. CT/MRI: general cerebral edema with sulcal effacement and widespread 
ischaemia with loss of margins of brain white and grey matter 
2. EEG: generalized suppression (< 20 μV) or burst suppression, 
generalized epileptic activity or periodic epileptiformic discharges 
(PED) with background activity suppression, lack of spontaneous 
variation and lack of reactivity to external stimuli 
3. Continuous refractory to treatments myoclonic status epilepticus with 
permanent unconsciousness 
4. Serum NSE values: ascending trend 24 – 48 – 72 h 
5. Unresponsiveness to painful stimuli or extension as the best motor 
response at 72 h 
6. Absent brain stem reflexes at 72 h 
7. Bilateral absence of thalamocortical sensory evoked potentials (SEP) 
8. Generalized diminished cortical diffusion on MRI 
4.6 Statistical analysis 
The sample size of 110 patients was based on power analysis of the assumed 
fractional anisotropy (FA) values from brain magnetic resonance imaging, that is, 
the primary endpoint of the Xe-HYPOTHECA trial. However, no clinically 
relevant comparable data about the difference in the effect size was then available. 
Therefore, the arbitrary estimation was, that 55 patients per group would be needed 
to reveal an absolute median difference of 15% in FA between the groups (85% 
power and a two-sided α level of 0,05). This diffrenece eventually proved to be 
unrealistically large given that the difference in the mean FA values between those 
patients who survived and those who died was only 6.4% in this study.  
The Shapiro-Wilk W test was used to evaluate the normality of all continuous 
variables. Two-sample Student’s t-test and Mann- Whitney U test were used to 
compare continuous characteristic variables between groups. Categorical 
characteristic variables were analyzed with the κ2 test or Fisher exact test. The 
Mann-Whitney test and the Hodges-Lehmann estimate were used for the ordinal 
variables of mRS and CPC to calculate median differences between the groups. 
Between-group differences in global FA and diffusivity values (radial, axial, and 
mean) were analyzed using the 2-sample t test and analysis of covariance with 
adjustment for age, sex and study site. Permutation-based voxel-wise statistical 
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analysis of FA values was performed with tract-based spatial statistics (TBSS) in 
conjunction with family-wise error correction for multiple comparisons across 
space.  
The correlations between the increment in the level of troponin-T from hospital 
admission to 72 h and the dose of administered drugs (i.e., noradrenaline, 
adrenaline, dobutamine, dopamine, levosimendan, furosemide, propofol, 
midazolam, fentanyl, and insulin) and haemodynamic parameters (mean and 
systolic arterial pressure, central venous pressure, heart rate in 2-min [Turku] or 5-
min [Helsinki] epochs) during the first 24 h and during 72 h after ICU admission 
were calculated using Spearman correlation coefficients.  
The differences in changes in troponin-T values between groups were analyzed 
using repeated measures analysis of covariance adjusted for age, sex, study site, 
percutaneous coronary intervention (PCI), and cumulative noradrenaline use in the 
first 24 h after ICU admission. A natural logarithmic (ln) transformation was 
performed for troponin-T values before analyses due to their skewed distribution.  
Results of troponin-T values at each time point were presented as geometric 
mean (95% confidence interval [CI]). The geometric means were calculated by 
back-transforming the means of ln-transformed troponin-T values to the original 
scale. An unstructured covariance matrix was used in the repeated measures model. 
An all-available case analysis was applied to the troponin-T. The effect of 
troponin-T on survival was analyzed with Cox regression adjusted for age, sex, 
study site, and group. Results are expressed using hazard ratios (HRs) with 95% 
CIs.  
The follow-up time for survival analysis was calculated from the time of 
cardiac arrest until death or 6 months. A complete case analysis was applied to the 
primary end point available patients (due to missing MRI data for 6 patients in the 
control group and 7 patients in the Xe group). Multiple imputation was not 
performed due to lack of a good prognostic model to predict valid imputed values 
for missing data. Kaplan-Meier survival curves and a Cox proportional hazards 
model were used to compare mortality at 6 months between the groups in the 
intention to-treat population. The proportional hazards assumptions were evaluated 
with the log-cumulative hazard plot and martingale-based residuals; the 
assumptions were met. The observation was censored in the survival analysis if the 
patient was withdrawn from the study or was still alive at the end of the 6-month 
follow-up. Analyses were adjusted with the following prognostic factors: age, sex, 
time to ROSC, cooling rate, and study site.  
Additionally, the global FA and diffusivity values were used as factors 
associated with 6-month mortality after adjustment for age, sex, group, and study 
site. Secondary end points were not adjusted for multiplicity and were therefore 
described as exploratory. 
Olli Arola 
 96 
A two-sided p value < 0,05 was considered statistically significant. Statistical 
analyses were performed using SAS System for Windows, version 9.4 (SAS 
Institute, Cary, North Carolina). 
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5 Results 
 
Figure 4.  The flow of participants in the XE-Hypotheca trial. Reproduced by permission (II) 
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5.1 Patients 
Turku University Hospital recruited 66 patients between August 2009 and 
September 2014 and Helsinki University Hospital 44 patients between October 
2012 and September 2014. The first patient in Turku University Hospital was 
randomized on August the 5th 2009. The final 6-month neurological outcome 
performance assessments were completed in April 2015. A total of 224 OHCA 
patients were screened for eligibility and of these, 110 (aged 24 to 76 years) were 
enrolled and 55 randomly assigned to the xenon group and 55 to the control group 
(figure 4).  
      The main reasons for exlucion were force majeur -type situations, in which 
either study personnel was unavailable (66 patients, 58 %) or the next of kin could 
not be reached within 4 hours from the hospital admission to grant written 
informed assent to study participitation (25 patients, 22 %) (Figure 4). 
One patient in the xenon group was withdrawn from the study 6 days after 
OHCA by the next of kin. One patient already randomized to the control group 
deceased during coronary angiography before ICU admission and received no 
treatment intervention. Additional reasons for patient disclosure in the final 
analysis in the control group were: premature death due to global perfusion failure 
(4 patients); and in the xenon group: two patients mistakenly randomized (basilar 
artery thrombosis not discovered in the initial CT scan, initial presenting rhythm of 
PEA, not VF/VT) and 1 technical failure of xenon delivery.  
Both groups also consisted of patients, in whom MRI was not compatible due 
to MRI technical failure or patient condition. As a consequence, the complete case 
analysis for the primary end point consisted of 48 Xe group patients and 49 control 
group patients. The baseline characteristics in intention-to treat population are 
displayed in table 6. 
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Table 6.  Baseline characteristics in the intention-to-treat population. Abbreviations: IQR: 
interquartile range, COPD: chronic obstructive pulmonary disease, ACEi: angiotensin convertase 
enzyme inhibitor, ARB: angiotensin reseptor blocking (agent). Data are expressed as No. (%) 
unless otherwise indicated. a) Based on ECG, patient history and angiographic findings. b) 
Indicates the interval from cardiac arrest to start of any chest compression by bystander or 
emergency medical service personnel. c) Fazekas score is a MRI system of scoring white matter 
hyperintensities that are often observed in elderly persons (> 65 years) and are considered small 
vessel disease. Score 0 indicates no lesions; 1, punctate foci; 2, beginning confluence of foci; and 
3, large confluent areas.  
 
Characteristic 
Xenon  
(n = 55) 
Control  
(n = 55) 
Age, median (IQR); years 63 (55–70) 60 (54–67) 
Male sex 41 (74.5) 39 (70.9) 
Body Mass Index (BMI), median (IQR) 25.9 (23.4–27.6) 27.8 (25–31.2) 
Coronary artery disease 37 (69.1) 40 (72.7) 
Hypertension 22 (40.0) 26 (47.3) 
Congestive heart failure 6 (10.9) 4 (7.3) 
Diabetes 9 (16.4) 8 (13.0) 
Asthma/COPD 6 (10.9) 9 (16.4) 
Dyslipidemia 15 (27.3) 23 (41.8) 
Cardiomyopathy 1 (1.9) 1 (1.9) 
Chronic kidney insufficiency 1 (1.9) 3 (5.6) 
Smoker 17 (30.9) 22 (40.0) 
Previous medication   
ß-blocker 13 (24.1) 15 (27.8) 
ACEi/ARB 15 (27.8) 20 (37.0) 
Ca-channel blocker 9 (16.7) 10 (18.5) 
Diuretics 5 (9.3) 6 (11.1) 
Antiplatelet/Anticoagulant agents  15 (27.8) 19 (35.2) 
Statin 12 (22.2) 16 (29.6) 
ST-elevation myocardial infarction a 15 (27.3) 19 (34.5) 
Resuscitation circumstances   
No-flow (min); median (IQR) b 0 (0–6) 0 (0–1) 
Bystander resuscitation 38 (69.1) 40 (72.7) 
Emergency medical service delay (min); mean (SD) 8.4 (3.4) 8.7 (3.2) 
Return of spontaneous circulation (min); mean (SD) 22.6 (8.3) 21.9 (7.0) 
Cumulative adrenaline dose before ROSC; mean (SD) 1.48 (1.56) 1.57 (1.65) 
Blood glucose on admission; mean (SD) 11.9 (3.96) 12.7 (4.01) 
Cooling   
Core temperature prior start of cooling, oC; median (IQR) 34.9 (34.3–35.8) 35.4 (34.0–36.3) 
Time from OHCA to target temperature, min; median (IQR) 290 (263–338) 336 (254–395) 
Time from OHCA to initiation of xenon, min; median (IQR) 247 (209–278) - 
Previous stroke 10 (18.2) 12 (21.8) 
White matter degeneration score c   
No. of patients 48 49 
Fazekas score 0–1 39 (81.3) 38 (77.6) 
Fazekas score 2–3 9 (18.8) 11 (22.4) 
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The baseline patient characteristics did not differ between the groups. Approximately 
30 % of OHCA survivors in both groups did not receive any bystander CPR. The most 
lengthened no-flow times in the study were 13 to 14 minutes, which often, but not 
always, were associated with poor outcome and premature death. The duration of CPR 
before ROSC was associated with higher cumulative doses of adrenaline, which 
translated to higher blood glucose values on admission (data not shown). 
5.2 Anaesthesia and hypothermia 
The mean sedation depth was assessed according to the Richmond Agitation 
Sedation Scale (RASS) every 4 hours until the end of MTH treatment. RASS score 
was until the end of MTH - 4,3 + 0,6 in the control group and - 4,4 + 0,6 in the 
xenon group (p = 0,17). The cumulative doses of anaelgetic (fentanyl, oxycodone) 
or neuromuscular blocking (cisatracurium, pancuronium or rocuronium) agents 
used during MTH did not differ between the groups. 
Propofol was the principal sedative agent administered to all patients. 
Additional midazolam was given only in 4 control and 2 xenon group patients. In 
patients assigned to Xe inhalation, Xe anaesthesia was complemented with 
additional propofol, because the minimum alveolar concentration (MAC) of Xe is 
63 % (Nagata 1993); whereas the mean end-tidal Xe concentration during this 
study was 48,2 % (SD, 3,8 %; range 41,4 % to 56,9 %). The mean duration of Xe 
inhalation was 25,5 hours (range 24–28 hours). The mean Xe expenditure during 
the intervention was 56,3 litres (SD 18,2). As anticipitated, the adequate level of 
sedation (RASS of at least 4) was accomplished with significantly less propofol 
during concomitant Xe inhalation. In contrast to the preceeding studies of Xe 
anaesthesia in healthy volunteers and surgical patients, postoperative (and post–
anaesthesia) nausea and vomiting (PONV) was not witnessed. 
The propofol consumption was statistifically significantly attenuated in the Xe 
group compared to control group during first 72 hours after hospital admission, but 
the difference observed during the 24 h intervention was not sustained during the 
following days after discontinuation of xenon exposure, as the propofol dose of the 
second (24 to 48 h post OHCA) and the third (48 to 72 h post OHCA) day after 
hospital arrival did not differ between the groups (p = 0,20 and p = 0,13, 
respectively) (Table 7). The median (IQR) interval from OHCA to the inception of 
Xe treatment was 250 (209–281) minutes.  
All patients in both groups received hypothermia treatment for 24 hours. Initial 
mean core temperatures on admission to the intensive care unit were similar; 
34,9 °C in the Xe group and 35,1°C in the control group. The median (IQR) 
interval between OHCA and attainment of target temperature was 344 (257–404) 
minutes in the control group and 290 (250–338) minutes in the Xe group. The 
mean temperature during MTH was 33,1 °C in both groups. 
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5.3 Intravenous medication 
Vasoactive medication was adjusted to meet the predefined haemodynamic targets. 
Practically almost every patient was on noradrenaline infusion at least after MTH 
intervention. Only one patient in the Xe group did not require any vasoactive 
support. Dobutamine was added on top of noradrenaline in 10 patients in both 
groups. Only two patients in the control group received dopamine infusion. 
Levosimendan was used in 8 control group patients and in 9 Xe group patients, one 
of which had the medicine incepted during rewarming after discontinuation of Xe 
inhalation. Accretion of vasoactive support apparently reflected the underlying 
cardiac compromise. Moreover, the significant difference in propofol consumption 
between groups caused a trend of inotrope-sparing effect in the Xe group, in which 
cumulative doses of noradrenaline were smaller. However, this trend was not 
statistically significant. None of the other intravenous medications administered 
during the first 72 h differed significantly between the groups (Table 7). 
Table 7.  Selected intravenous medication during the first 24 and 72 hours after ICU admission. 
Median (IQR). Number of patients receiving the medication during the first 72 hours: 
Propofol: 54 control patients and 54 xenon patients; Noradrenaline: 54 control patients 
and 53 xenon patients; Dobutamine: 10 control and 10 xenon patients; Dopamine: 2 
control and 0 xenon patients; Levosimendane: 8 control and 9 xenon patients; 
Adrenaline: 7 control and 7 xenon patients; Insulin: 38 control and 40 xenon patients 
 
First 24 hours after ICU 
admission 
P-value 
First 72 hours after ICU 
admission 
P-value 
Xenon 
(N = 54) 
Control 
(N = 54) 
Xenon 
(N = 54) 
Control 
(N = 54) 
Medication       
Propofol,  
mg 
2325 
(1700–2980) 
6605 
(5071–7880) < 0.0001 
11019 
(6585–14599) 
16010 
(12060–20846) <0.0001 
Noradrenaline, 
mg 
5.0 
(1.1–14.4) 
8.3 
(3.9–12.7) 0.10 
12.1 
(5.6–34.2) 
22.3 
(10.8–41.0) 0.07 
Dobutamine, 
mg 
0.0  
(0.0–0.0) 
0.0  
(0.0–0.0) 0.87 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.71 
Dopamin,  
mg 
0.0  
(0.0–0.0) 
0.0  
(0.0–0.0) 0.33 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.16 
Levosimendan, 
mg 
0.0  
(0.0–0.0) 
0.0  
(0.0–0.0) 0.96 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.84 
Adrenaline,  
mg 
0.0  
(0.0–0.0) 
0.0  
(0.0–0.0) 0.64 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.97 
Insulin,  
IU 
9.6 
(0.0–28.1) 
8.0 
(0.0–30.4) 0.90 
14.0 
(0.0–62.9) 
25.7 
(0.0–63.1) 0.88 
Furosemide, 
mg 
20.0 
(0.0–10.0) 
2.5 
(0.0–15.0) 0.58 
30.0 
(10.0–55.0) 
30.0 
(10.0–75.0) 0.62 
Fentanyl,  
mg 
2.1  
(1.5–2.3) 
2.1  
(1.4–2.4) 0.80 
3.1  
(2.3–4.0) 
3.4  
(2.2–4.7) 0.80 
Midazolam,  
mg 
0.0  
(0.0–0.0) 
0.0  
(0.0–0.0) 0.19 
0.0  
(0.0–0.0) 
0.0  
(0.0–0.0) 0.64 
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5.4 Haemodynamic and laboratory parameters 
The median (IQR) heart rate was significantly lower in the Xe group during Xe 
inhalation than in the control group during MTH treatment. Also after rewarming 
during the first 72 h after ICU admission, the median (IQR) heart rate was 
significantly lower in the Xe group than in the control group. The other pre-defined 
haemodynamic parameters did not differ between the groups during the first 24 to 
72 h (Table 8).  
Table 8.  Abbreviations: MAP = Mean arterial pressure; SAP = Systolic arterial pressure; 
CVP = Central venous pressure. Values are median (IQR) or means (SD). The 
haemodynamic parameters were recorded in 2 minute epochs in Turku and in 5 
minute epochs in Helsinki.  
 
First 24 hours after ICU 
admission 
P- 
value 
First 72 hours after ICU 
admission 
P-
value 
Xenon 
(N = 54) 
Control 
(N = 54) 
Xenon 
(N = 54) 
Control 
(N = 54) 
Haemodynamics       
Heart rate, 
beats/min 
46.0 
(40.5–54.9) 
52.9 
(43.6–58.5) 0.02 
61.6 
(56.8–69.4) 
68.8 
(59.8–75.9) 0.03 
MAP, mmHg 79.3  (6.3) 
78.8  
(6.7) 0.68 
80.3  
(7.9) 
78.7  
(6.3) 0.27 
SAP, mmHg 110.6 (103.2–116.3) 
109.0 
(105.2–117.0) 0.91 
119.3 
(109.5–127.0) 
115.3 
(110.8–123.8) 0.29 
CVP, mmHg 10.0 (8.3–13.0) 
10.8 
(8.7–12.9) 0.67 
10.5 
(8.6–13.5) 
11.6 
(9.6–13.1) 0.20 
 
The blood pH, lactate, and glucose did not differ between the groups during ICU 
stay. There were no differences in other routine laboratory tests between the study 
groups. Assays of TnT are discussed separately. The preliminary results of NSE 
kinetics were described in chapter 2.5.1 
The impact of underlying or acquired kidney disease was assessed by RIFLE 
classification (Bellomo 2004, Chua 2012) of the study patients (table 9). 
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Table 9.  Acute kidney injury and plasma creatinine values according to RIFLE classification. 
Values are number (%) of patients or median (IQR). Baseline value was 1) the 
most recent serum creatinine value within 2 years prior to OHCA, or 2) lowest 
value during 1 week prior to hospital discharge, or 3) lowest value anytime during 
current admission. Diagnosis of acute kidney injury was based on an increase in 
serum creatinine level from a baseline value to the peak value within 6 days after 
ICU admission. RIFLE classifications: Risk = plasma creatinine increase by more 
than 1.5-fold from the baseline value to the peak value; Injury = plasma creatinine 
increase by two- to three-fold, Failure = plasma creatinine increase by more than 
three-fold.  
 Xenon group (n=54) Control group (n=54) P-value 
Plasma creatinine, µmol/l    
Baseline 67.0 (60.0 ‒ 81.0) 72.0 (61.0 ‒ 86.0) 0.32 
Peak value during the first 
6 days 92.0 (78.0 ‒ 108.0) 93 (74 ‒ 138.0) 0.67 
Acute kidney injury 18 (33.3) 19 (35.2) 1.00 
RIFLE ‒ Risk 14 (25.9) 10 (18.5) 0.49 
RIFLE ‒ Injury 2 (3.7) 6 (11.1) 0.27 
RIFLE ‒ Failure 2 (3.7) 3 (5.6) 1.00 
5.5 Myocardial infarct 
When assessing the precipitating pathology leading to cardiac arrest, ST-elevation 
myocardial infarct (STEMI) was present in 36 (32,7 %) patients, non-ST-elevation 
myocardial infarct (NSTEMI) in 64 (58,2 %) patients and an arrhythmogenic heart 
disease in 7 (6,4 %) patients. Two patients mistakenly randomized had a primary 
cerebral event (basilar artery thrombosis, subarachnoidal haemorhage) 
undiscovered at hospital admission. Primary percutaneous coronary intervention 
(PCI) was performed on admission in 14 of the 16 Xe group STEMI patients, in 16 
of the 19 control group STEMI patients and in NSTEMI patients, 1 in the Xe group 
and 2 in control group. Coronary angiography with an eventual PCI was performed 
during the entire hospital stay in 44 (81,5 %) of Xe group patients and in 47 
(87,0 %) of control group patients. Regarding occlusive coronary artery disease, 
there were no significant differences in between the study groups. Details of 
coronary heart disease are displayed in table 10. 
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Table 10.  Coronary heart disease characteristics. Values are n (%). The diagnosis of acute 
myocardial STEMI infarction was based ECG findings. * The data is based on the 
44 patients in the xenon group and for 47 patients in the control group, of which 
angiography was performed 
 Xenon 
(N = 54) 
Control 
(N = 54) 
 
P-value 
STEMI 17 (31,5) 19 (35,2) 0.68 
 Anterior 17 (31,5) 11 (20,4) 0.19 
 Inferior 0 (0,0) 5 (9,3) 0.06 
 Lateral 0 (0,0) 3 (5,6) 0.24 
 Right side 0 (0,0) 0 (0,0) 1.00 
NSTEMI 32 (59,3) 32 (59,3) 1.00 
Primary PCI on admission 15 (27,8) 18 (33,3) 0.53 
Coranary angiography during hospital stay 44 (81,5) 47 (87,0) 0.43 
Angiography findings *    
  Nonocclusive coronary artery disease 12 (27,3) 11 (23,4)  
  Left main disease 3 (6,8) 8 (17,0)  
  1-vessel disease 15 (34,1) 14 (29,8)  
  2-vessel disease 10 (22,7) 9 (19,1)  
  3-vessel disease 7 (15,9) 13 (27,7)  
 
In the deceased patients, the exact determination of the coronary artery disease was 
impossible in 7 xenon patients and in 4 of the control patients because neither 
coronary angiography nor autopsy was performed on these patients. 
 
5.6 Adverse effects 
Adverse effects were recorded as defined in the study protocol. Serious adverse 
events included complications during seven days after cardiac arrest. Some patients 
had more than one adverse event. There were no diffrences in adverse events in 
between the study groups. Serious adverse events in the intention to treat 
population are represented in the table 11. 
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Table 11.  Serious adverse events in the intention-to-treat population 
 
Serious adverse event 
Xenon 
(n = 48/55) 
Control 
(n = 50/55) 
 
P value 
Status epilepticus 15 17 0.67 
Acute kidney injury    
   Risk 14 10 0.36 
   Injury 2 6 0.27 
   Failure 2 3 1.00 
Pulmonary oedema 4 4 1.00 
Ventricular fibrillation 6 3 0.49 
Ventricular tachycardia 5 8 0.38 
Atrial fibrillation (new onset) 8 4 0.22 
Coronary stent thrombosis 1 1 1.00 
Sepsis 1 2 1.00 
Pneumonia 33 36 0.55 
Multi-organ failure 1 2 1.00 
Adult respiratory distress syndrome 1 1 1.00 
Bradycardia requiring pacemaker 1 0 1.00 
3rd degree atrioventricular block 0 1 1.00 
Subarachnoid hemorrhage 1 1 1.00 
Carotid dissection 0 1 1.00 
Carotid thrombosis 0 1 1.00 
Serious bleeding    
   Intracranial 0 1 1.00 
   Gastrointestinal 1 0 1.00 
Total 96 102 0.81 
5.7 Neuroprotection by xenon inhalation (primary 
end point) 
The effect of xe inhalation on the ongoing cerebral injury was quantified by the 
loss of directionality in the diffusion of water molecules in cerebral white matter 
tracts. Fractional anistrophy (FA) values, which quantify water directionality, is 
low, when diffusion is less organized, corresponding to more pronounced white 
matter injury. Localization and labeling of the tracts were confirmed and identified 
with Johns Hopkins University white-matter tractography atlas. 
Diffusion tensor MRI data for the TBSS analysis were obtained from 48 
patients in the Xe group and 49 patients in the control group. The interval from 
OHCA to MRI scan was 53 hours (median; IQR 47– 64 hours). For safety reasons, 
some of the MRI scans were postponed, until the patient and haemodynamic 
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condition was more stable. The reasons for missing MRI data are displayed in 
Figure 4. In brief, some patients deceased before or were too unstable before the 
scan. There were also some MRI technical failures and two xe- patients were 
excluded because of MRI contraindication (required pacemaker post arrest).  
 
Figure 5.  TBSS analysis of voxel-wise statistical analysis of FA values between the Xe and 
control group. Voxels with significantly lower FA values in the control group are 
displayed in red in statistical visualization. Voxels without significant difference 
between FA values between the groups are displayed green. The main differences 
were in cingulated gyrus, hippocampal region, forceps minor and major, superior and 
inferior longitudinal fasciculus, anterior thalamic radiation, inferior fronto-occipital 
fasiculus and corpus callosum. Reproduced by permission (II) 
Using TBSS analysis, the statistical parametric map containing 119 013 voxels was 
created to visualize the spatial distribution of areas with significantly lower FA in 
the control group (Figure 5, reproduced by permission II). 
The FA value was significantly lower in 41.7 % of the voxels in the control 
group than in the xenon group (i.e. 58,3 % of the voxels did not differ between the 
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groups). The tract-wise distribution is displayed in Figure 5. None of the voxels 
had significantly lower FA values in the xenon group. 
The mean global FA values of all voxels presented in Figure 5 were 0,433 (SD, 
0,028) in the Xe group and 0,419 (SD, 0,033) in the control group (P = 0,03; Table 
12). The age-, sex-, and study site-adjusted mean global FA value was 3,8 % higher 
(95 % CI, 1,1 % to 6,4 %) in the Xe group (adjusted mean difference, 0,016 
[95 %CI, 0,005 to 0,027], P = 0,006). The mean radial diffusivity value was 0,598 
(SD, 0,051) for the xenon group and 0,619 (SD, 0,062) for the control group. The 
adjusted radial diffusivity value was 3,9 % lower (95 % CI, 0,5 %-7,4 %) in the Xe 
group than in the control group (adjusted mean difference, -0,024 [95 % CI, -0,046 
to -0,003], P = 0,03; Table 12).  
Table 12.  Results of diffusion tensor MRI imaging in the complete case population. aData are 
adjusted for age, sex and study site. 
 
 
Global values 
Unadjusted mean 
(SD) 
Mean difference  
(95 % CI) 
 
P value 
Xenon 
group 
(n = 48) 
Control 
group 
(n = 49) 
 
 
Unadjusted 
 
 
Adjusteda 
 
 
Unadjusted 
 
 
Adjusteda 
Fractional 
anisotrophy 
0.433  
(0.028) 
0.419  
(0.033) 
0.014 
(0.002–0.026) 
0.016 
(0.005–0.027) 0.03 0.006 
Type of diffusivity, 10-3 mm2/s 
 Axial 1.190  (0.052) 
1.199  
(0.051) 
-0.009 
(-0.030–0.012) 
-0.011 
(-0.031–0.010) 0.40 0.30 
 Radial 0.598  (0.051) 
0.619  
(0.062) 
-0.021 
(-0.043–0.002) 
-0.024 
(-0.046–0.003) 0.08 0.03 
 Mean 0.795  (0.050) 
0.812  
(0.056) 
-0.017 
(-0.038–0.005) 
-0.020 
(-0.040–0.0007) 0.13 0.06 
 
Taken together, these various quantitative differences in diffusion tensor MRI 
values indicated that the loss of connectivity, demyelinisation and disruption of 
brain white matter was more pronounced in the control group. 
5.8 Cardioprotection by xenon inhalation 
(secondary end-point) 
5.8.1 Troponin-T release 
The effect of xenon inhalation and mild therapeutic hypothermia following cardiac 
arrest was assessed by quantification of myocardial injury with absolute values of 
TnT at hospital arrival, and at 24, 48, and 72 h in both groups (represented in figure 
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6). The intention-to-treat population consisted of 54 patients in both groups. Absent 
TnT assays were explained by death before ICU admission (1 control patient) and 
mistaken randomization after primary subarachnoidal haemorrhage (1 Xe patient). 
 
Figure 6.  Troponin-T levels in the xenon and control groups after OHCA at hospital admission 
(baseline) and 24, 48, 72 h post cardiac arrest. Values are presented in geometric 
means (95 % confidence intervals) on a logarithmic scale (Reproduced by permission 
III) 
The baseline values at hospital arrival did not differ between the Xe and control 
groups (geometric mean [95 % CI] 0,100 mg/l [0,070 to 0,141 mg/l] vs. 0,098 mg/l 
[0,071 to 0,135 mg/l], respectively). At 72 h after OHCA, the geometric mean 
troponin-T was 111 % higher in the control group than in the Xe group (geometric 
mean [95 % CI] 0,464 mg/l [0,300 to 0,716 mg/l] vs. 0,220 mg/l [0,128 to 0,380 
mg/l], respectively) as illustrated in the figure 6 and in table 13. Adjusted 
geometric means of troponin-T peaked at 24 h in both groups with a significant 
increase at 72 h from the baseline values (p < 0,0001). The decline of troponin-T 
from the peak to 72 h differed significantly between the groups (p = 0,0008) with a 
significant decline of 44,8 % (p < 0,0001) in the xenon group and a nonsignificant 
decline of 11,3 % (p = 0,56) in the control group. 
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Table 13.  Adjusted geometric mean values of troponin-T. *P < 0,0001 difference between 24 
and 72 hours. †P = 0,56 difference between 24 hours and 72 hours. P < 0,0008 
decline of troponin-T from 24 hours to 72 hours; difference between the groups. P 
= 0,27, difference of area under curve between the groups including baseline and 
all single time points. ǂ Data are for 52 patients due to missing values of troponin-
T of two patients at 72 hours. § Data are for 53 patients due to missing values of 
troponin-T of one patient at 72 hours. Values are adjusted for age, gender, study 
site, percutaneous coronary intervention and dose of noradrenalin during the first 
24 hours after intensive care admission. 
 Xenon group 
n = 54 
Control group 
n = 54 
 Troponin-T; Adjusted geometric mean (95 % CI) 
Baseline 0.10 (0.06–0.16) 0.09 (0.06–0.14) 
24 hours 0.39 (0.24–0.65) 0.46 (0.28–0.75) 
48 hours 0.27 (0.16–0.44) 0.32 (0.20–0.51) 
72 hours 0.22 (0.13–0.37)*ǂ 0.41 (0.24–0.69)†§ 
AUC 21.6 (13.1–35.4)ǂ 31.0 (20.3–47.1)§ 
 
In NSTEMI patients, the decline from peak to 72 h was significantly different 
between the groups (p = 0,0004): a significant decline of 48,6 % within the xenon 
group (p < 0,0001), but a nonsignificant increase of 0,9 % within the control group 
(p = 0,93). In STEMI patients, the difference of troponin-T decline between the 
groups was nonsignificant (p = 0,61); the decline from peak to 72 h was significant 
within the xenon group (p = 0,01), but nonsignificant within the control group (p = 
0,053) (table 14)  
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Table 14.  TnT Values in STEMI and NSTEMI patients. P = 0,0004 difference between the 
groups in NSTEMI. P = 0,61 difference between the groups in STEMI. *Data are 
for 31 patients due to death before 72 hours. †Data are for 31 patients due to 
death before 72 hours. ǂ Values are adjusted for age, gender, study site and dose 
of noradrenaline during the first 24 hours after ICU admission. § P = 0,01 for the 
TnT difference within group from the peak concentration at 24 hours to 72 hours. || 
P = 0,053 for the TnT difference within group from the peak concentration at 24 
hours to 72 hours. # P < 0,0001 for the TnT difference within group from the peak 
concentration at 24 hours to 72 hours. ** P = 0,94 for the TnT difference within 
group from the peak concentration at 24 hours to 72 hours. 
 Xenon Group Control Group Xenon Group Control Group 
 Absolute values (µg/L), Median (IQR) Adjustedǂ Geometric Mean (95 % CI) 
STEMI patients n = 17 n = 19 n = 17 n = 19 
Baseline (hospital 
admission) 
0.17  
(0.08–0.52) 
0.08  
(0.05–0.23) 
0.14  
(0.07–0.28) 
0.07  
(0.04–0.14) 
24 hours after 
OHCA 
1.16  
(0.58–4.07) 
1.57  
(0.50–3.69) 
1.16  
(0.55–2.43) 
0.91  
(0.44–1.89) 
48 hours after 
OHCA 
0.72  
(0.33–3.20) 
1.48  
(0.29–2.92) 
0.78  
(0.38–1.58) 
0.61  
(0.30–1.23) 
72 hours after 
OHCA 
0.64  
(0.30–2.49) 
1.51  
(0.27–2.46) 
0.74  
(0.34–1.60)§ 
0.66  
(0.31–1.40)|| 
NSTEMI patients n = 32 n = 32 n = 32 n = 32 
Baseline (hospital 
admission) 
0.07 
(0.03–0.25) 
0.10  
(0.04–0.25) 
0.09  
(0.06–0.17) 
0.09  
(0.05–0.14) 
24 hours after 
OHCA 
0.30  
(0.12–0.55) 
0.36  
(0.15–1.11) 
0.33  
(0.19–0.60) 
0.30  
(0.18–0.51) 
48 hours after 
OHCA 
0.18  
(0.07–0.39) 
0.32  
(0.10–0.63) 
0.22  
(0.13–0.40) 
0.20  
(0.12–0.34) 
72 hours after 
OHCA 
0.12 
(0.04–0.28)* 
0.34 
(0.14–0.77)† 
0.17 
(0.09–0.32)*# 
0.30 
(0.17–0.53)†** 
 
Geometric mean (95 % CI) of TnT was significantly higher in STEMI than in 
NSTEMI at each time point after baseline (table 15).  
Table 15.  Comparison of TnT values between STEMI and NSTEMI patients during 72 hours 
after OHCA. Abbreviations: STEMI = ST Elevation Myocardial Infarct; NSTEMI = 
Non ST Elevation Myocardial Infarct; OHCA = Out-of-Hospital Cardiac Arrest; CI = 
Confidence Interval; TnT = Troponin-T 
 STEMI (n = 36) NSTEMI (n = 64) P - value 
Adjusted* Geometric Mean (95% CI), µg/l 
  TnT at Baseline 0.10 (0.06–0.17) 0.09 (0.0.6–0.13) 0.668 
  TnT 24 hours 1.03 (0.597–1.7) 0.32 (0.21–0.47) 0.0003 
  TnT 48 hours 0.69 (0.410–1.16) 0.21 (0.15–0.31) 0.0002 
  TnT 72 hours 0.70 (0.40–1.22) 0.23 (0.15–0.35)† 0.001 
* Values adjusted for age, gender, study site, group and dose of noradrenaline during the first 24 
hours after ICU admission. † Missing data for two patients at 72 hours 
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The change over time of the levels of TnT differed between the Xe and the control 
groups (time by group interaction p = 0,003); after adjustment for age, sex, study 
site, PCI, and noradrenaline, the increase of troponin-T values from hospital 
admission to 72 h was significantly less in the Xe group than in the control group 
(adjusted mean difference of ln-transformed values: -0,66; 95 % CI: -1,16 to -0,16; 
ratio of adjusted geometric means: 0,52; 95 % CI: 0,31 to 0,85; p = 0,01) (table 
16).  
Table 16.  TnT increment from baseline to 72 h after OHCA. Values are median (IQR) or 
mean + SD, unless otherwise indicated. Natural logarithmic transformation for TnT 
values was used in the statistical analysis due to skewness of the data. *Data is for 
52 patients due to missing data of 2 patients at 72 hours. †Data is for 53 patients 
due to missing data of one patient at 72 hours. ǂData are adjusted for age, 
gender, study site, percutaneous coronary intervention and dose of noradrenalin 
during the first 24 hours after ICU admission. Abbreviations: TnT = Troponin-T, 
values are in µg/l, Ln = natural logarithm, Δ = Change from the baseline, CI = 
confidence interval, OHCA = out-of-hospital cardiac arrest. 
 
Xenon 
group 
(n = 54) 
Control 
group 
(n = 54) 
Mean difference  
(95 % CI) P value 
Unadjusted Adjustedǂ Unadjusted Adjustedǂ 
Absolute values, µg/l  
Baseline 
(admission) 
0.09 
(0.03–0.30) 
0.08 
(0.04–0.23) 
24 h after OHCA 0.38 
(0.15–1.27) 
0.47 
(0.12–1.74) 
48 h after OHCA 0.25 
(0.09–0.85) 
0.41 
(0.10–1.48) 
72 h after OHCA 0.22 
(0.05–0.69)* 
0.40 
(0.14–1.87)† 
Ln-transformed change from baseline 
Ln ∆TnT 24h 1.40 + 1.39 1.65 + 1.38 
-0.26 
(-0.79–0.27) 
-0.16 
(-0.62–0.30) 0.33 0.49 
Ln ∆TnT 48h 1.00 + 1.37 1.28 + 1.38 
-0.28 
(-0.80–0.25) 
-0.18 
(-0.63–0.27) 0.29 0.43 
Ln ∆TnT 72h 0.79 + 1.54* 1.56 + 1.38† 
-0.76 
(-1.33– -0.20) 
-0.66 
(-1.16– -0.16) 0.009 0.01 
 
The effect of Xe on the change in the TnT values did not differ in patients with or 
without PCI or in those with a diagnosis of STEMI (PCI or STEMI by group by 
time interaction effect; p = 0,72 and p = 0,29, respectively).  
As propofol consumption was reduced in the Xe group, consequenting in an 
inotrope-sparing effect in noradrenaline-requirement in maintaining predefined 
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haemodynamic goals, these correlations were assessed in relation to TnT 
increment. In the Xe group, the increment of TnT values from hospital admission 
to 72 h correlated significantly with noradrenaline (r = 0,51; p = 0,0001) and 
dobutamine (r = 0,27; p = 0,049) doses during the first 72 h after ICU admission. 
However, the increment of TnT from hospital admission up to 72 h did not 
correlate with administered drugs, propofol or any of the vasoactive drugs or 
hemodynamic parameters in the two groups or within the whole population (tables 
7 and 16). 
5.9 Mortality and mode of death 
The total mortality in this study was 30,9 %. Most of the deaths were due to severe 
hypoxic-ischaemic brain injury, which was assessed by the multimodal approach 
described in chapter 4.5. Neurological mode of death included permanent 
unconsciousness, which involved treatment refractory status epilepticus in 49 % of 
the deceased patients. The overall incidence of status epilepticus was 29,1 % (32 
patients). Five patients with status epilepticus eventually regained consciousness. 
All of the deceased patients had STEMI or NSTEMI, and two patients from both 
groups died after severe cardiac failure (table 17). 
Table 17.  Death, mode of death and withdrawal of life-sustaining therapy in the intention-to-
treat population. Values are mean (SD) or median (IQR) depending on the 
distribution of the data. Neurological mode of death corresponded to findings of 
severe hypoxic-ischemic brain injury. Withdrawal of life-sustaining treatments was 
executed by the principles described in the neurological prognostication 
consensus (chapter 4.5). *One patient did not receive Xe treatment due to 
technical failure of the Xe delivery device and one patient had a primary cerebral 
event but was mistakenly randomized. †One patient died in the angiolaboratory 
before ICU arrival 
 Xenon group (n = 55) Control group (n = 55) 
Deceased 15* 19† 
Mode of death   
 Neurological 13 16 
 Cardiac  2 2 
 Multi-organ 0 1 
STEMI or NSTEMI in non-survivors 15 18 
Withdrawal of life support 14 15 
 Mortality in withdrawals 14 15 
 Time from cardiac arrest to  
 withdrawal, days 
6.5  
(4.0–11) 
5.0  
(4.0–8.0) 
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Life-sustaining therapy was withdrawn after multimodal consensus agreement in 
pessimistic, hopeless situations 5–6,5 days after cardiac arrest. It is not possible to 
reliably distinguish between a cardiac and a noncardiac cause of death because all 
patients with severe ischaemic cerebral injury had also myocardial damage due to 
global, as well as occlusive, ischaemia. Of the deceased patients, 85 % did not 
regain consciousness due to a severe ischaemic encephalopathy, and the deaths 
were eventually classified as neurological mode of death. 
5.10 Outcome (secondary end-point) 
At 6 months, 75 patients (68.2 %) were alive and able to provide data for follow-
up. In the intention-to-treat population, the Kaplan-Meier mortality estimate after 
6-month follow-up was 27,3 % (15/55) in the xenon group and 34,5 % (19/55) in 
the control group (adjusted hazard ratio, 0,49 [95 % CI, 0,23-1,01], P = 0,053) 
(figure 7).  
 
Figure 7.  Probability of survival through the end of the 6-month follow-up in the intention-to-treat 
population. Values were adjusted with age, sex, time to ROSC, cooling rate and study 
site. Time point 0 indicates the time of OHCA. HR = hazard ratio, CI = confidence 
interval. Reproduced by permission (II) 
At 6 months, functional neurological outcome was not significantly different 
between the groups as assessed with the CPC (median score of 1 [IQR, 1-5] for the 
xenon group and 1 [IQR, 1-5] for the control group; median difference, 0 [95 %CI, 
0–0], P = 0,93) or the mRS (median score of 1 [IQR, 0–6] for the xenon group and 
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1 [IQR, 0-6] for the control group (table 18); median difference, 0 [95 % CI, 0–0], 
P = 0,68).  
Similarly, the rates of serious adverse events were not significantly different 
between the groups at 6 months. In addition, there was not any difference in 
neurocognitive outcome measures of MMSE (median of 29 [IQR, 27–30] for the 
xenon group and median of 29 [IQR, 28–30] for the control group) and NIHSS 
(median of 0 [IQR, 0–0] for the xenon and control groups). 
Table 18.  Neurological outcome in the complete case population. aData are expressed as 
number (%). There was no significant difference between groups in CPC score (p 
= 0,93) mRS score (p = 0,68). bOne patient was withdrawn from the study 6 days 
after index event by the next of kin. cPrior the index event, 1 patient had a CPC 
score of 3 (due to mental retardation) and a mRS score of 4. 
 Description of category 
Xenon  
groupa 
(n = 54)b 
Control  
roupa 
(n = 55) 
Cerebral Performance category score 
1 Good cerebral performance: conscious, alert, able to work, might have mild cognitive deficit 30 (55.6) 32 (58.2) 
2 Moderate cerebral disability: conscious, sufficient cerebral function for independent daily life 7 (13.0) 4 (7.3) 
3 
Severe cerebral disability: conscious, dependent on others for 
daily support; ranges from ambulatory state to severe 
dementia 
2 (3.7)c 0 
4 Coma or vegetative state 0 0 
5 Death 15 (27.8) 19 (34.5) 
Modified Rankin scale score   
0 No symptoms 23 (42.6) 22 (40.0) 
1 No significant disability: able to carry out usual activities, despite some symptoms 7 (13.0) 8 (14.5) 
2 Slight disability: able to look after own affairs without assistance, but unable to carry out all previous activities 6 (11.1) 5 (9.1) 
3 Moderate disability: requires some help, but able to walk unassisted 1 (1.9) 1 (1.8) 
4 Moderate severe disability: unable to attend to own bodily needs without assistance 2 (3.7)
c 0 
5 Severe disability: requires constant nursing care and attention 0 0 
6 Death 15 (27.8) 19 (34.5) 
 
Factors affecting mortality during the 6-month follow-up period were evaluated 
from MRI measures. In this study of all the diffusion tensor MRI variables, global 
FA exhibited the best independent predictive value for mortality (mean [SD] of 
0,433 [0,026] in the surviving patients vs 0,407 [0,035] in those who died). The 
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hazard ratio per 0,01- unit increase in FA was 0,81 (95% CI, 0,69–0,94; P = 0,006; 
adjusted by age, sex, study group and study site). The mean global FA was 6,4 % 
higher (95 % CI, 3,3–9,5 %) in the surviving patients than in those who died (table 
19). 
Table 19.  Hazard ratio (HR) was estimated for 0,01 unit increase for the fractional 
anisotrophy and for the diffusivity values. *Values were adjusted for age, gender, 
study group and study site. 
 
Surviving 
patients 
(n = 68) 
Non-surviving 
patients 
(n = 29) 
Unadjuste
d HR  
(95 % CI) 
Adjusted* 
HR  
(95 % CI) 
Unadjusted 
p value 
Adjusted
* p value 
Global values Unadjusted mean (SD)     
Fractional 
anisotrophy 
0.433 
(0.026) 
0.407  
(0.035) 
0.77 
(0.68–0.87) 
0.81 
(0.69–0.94 < 0.0001 0.006 
Axial diffusivity,  
10-3mm2/s 
1.193 
(0.037) 
1.199  
(0.076) 
1.02 
(0.93–1.12) 
0.98 
(0.89–1.08 0.68 0.70 
Radial diffusivity,  
10-3mm2/s 
0.598 
(0.044) 
0.633  
(0.076) 
1.12 
(1.04–1.20) 
1.07 
(0.98–1.17) 0.002 0.12 
Mean diffusivity,  
10-3mm2/s 
0.796 
(0.040) 
0.821  
(0.074) 
1.11 
(1.02–1.20) 
1.05 
(0.95–1.16) 0.02 0.31 
 
The predictive value of elevated TnT for both short- and long-term morbidity and 
mortality in cardiac arrest patients is renowned. Moreover, regardless of the 
underlying disease, TnT is predictive for mortality in all intensive care patients, 
which was declared in the latest consensus statement of the Joint Task Force and 
recent trials (Thygesen 2012, Babuin 2008, Gilje 2016, Thygesen 2018). In this 
study, all-cause mortality at all the time points of TnT besides the baseline within 
the groups and in the whole population had a predictive value for all-cause 
mortality at 6 months after OHCA (table 20). 
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Table 20.  TnT values in survivors and non-survivors (all-cause mortality) during 72 hours 
after OHCA. Abbreviations: TNT = Troponin-T, values are in µg/l, ln = natural 
logarithm, Δ = change from the baseline, *Data are for 74 patients due to missing 
data of one patient at 72 hours; †Data are for 31 patients due to missing data of 
two patients at 72 hours; ǂ Values are adjusted for age, gender, study site and 
group. § One surviving patient was mistakenly randomized with a primary cerebral 
event and not included in the analysis. One patient died in the angiolaboratory 
before ICU admission. Natural logarithmic transformation for TnT values was used 
in the statistical analysis due to skewness of the data.  
  
Survivors 
(n = 75§) 
non-
Survivors 
(n = 34§ ) 
 
Absolute values, 
Median (IQR) 
  
  TnT at Baseline 0.07 (0.21) 0.11 (0.22) 
  TnT 24 hours 0.34 (1.01) 1.16 (1.55) 
  TnT 48 hours 0.23 (0.82) 0.55 (1.28) 
  TnT 72 hours 0.25 (0.70)* 0.64 (2.40)† 
ln transformed 
values, Mean (SD)  
Adjustedǂ  
Hazard ratio 
(95% CI) P-value 
  ln TnT at Baseline -2.40 (1.24) -2.13 (1.20) 1.23 (0.92–1.65) 0.155 
  ln TnT 24 hours -1.09 (1.68) -0.13 (1.71) 1.34 (1.08–1.65) 0.007 
  ln TnT 48 hours -1.46 (1.67) -0.54 (1.60) 1.37 (1.09–1.72) 0.006 
  ln TnT 72 hours -1.45 (1.80)* -0.39 (1.60)† 1.31 (1.06–1.60) 0.011 
Change from the 
baseline, Mean 
(SD) 
   
  ln ΔTnT 24 hours 1.32 (1.24) 1.99 (1.59) 1.30 (1.02–1.66) 0.033 
  ln ΔTnT 48 hours 0.94 (1.25) 1.59 (1.57) 1.31 (1.02–1.69) 0.034 
  ln ΔTnT 72 hours 0.94 (1.39)* 1.75 (1.61)† 1.29 (1.01–1.64) 0.040 
 
However, the association of TnT release on survival did not differ between groups, 
as the interaction by TnT in the group for all time points was non-significant (p > 
0,10). 
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6 Discussion 
This study was to our best knowledge the first investigation, where combined 
inhaled xenon and mild therapeutic hypothermia treatment was applied to adult 
cardiac arrest survivors.  
The key findings in this prospective, randomized and controlled clinical trial 
were, that combining xenon inhalation for 24 hours to mild therapeutic 
hypothermia in comatose ventricular fibrillation-generated OHCA patients 
conferred to attenuated cerebral and myocardial injury, adressed with surrogate 
endpoints of cerebral WM injury by FA and in the heart, with altered Troponin T 
value kinetics. This represents the ongoing ischemia-reperfusion injury as a 
modifiable and viable therapeutic target for neuroprotection and cardioprotection. 
 This evidence indicates, that the extent of ongoing hypoxemic injury can be 
affected resulting that the outcome of cardiac arrest survivors might be improved. 
However, albeit these results represented a significant treatment effect in surrogate 
endpoints, no significant effect could be demonstrated in survival or neurological 
outcome, possibly originating from the underpowered sample size. 
Difficulties in translating established preclinical evidence in neuro- and 
cardioprotection to marked clinical benefit is a renowned phenomen in clinical 
medicine, particularly in experimental stroke, traumatic brain injury and 
myocardial infarction research. These difficulties are associated with the time 
frame of the therapeutic intervention, heterogeneity of the study population in 
comparison to animal models, sample size and dosing/concentration differences in 
comparison to experimental animal models and clinical situations (Hoyte 2004, 
Menon 2009, Sutherland 2012, Xu 2013, Rossello 2016, Hausenloy 2017).  
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6.1 Neuroprotective effect by xenon inhalation 
following OHCA 
6.1.1 Methodological aspects of fractional anisotrophy in 
various cerebral injuries 
Diffusion tensor MRI provides an observer-independent, fully automated and 
quantitative assessment of injury in cerebral white matter tracts, which has been 
validated in studies in various cerebral injuries. Previously, recent studies have 
indicated, that quantitative diffusion tensor MRI with low fractional anisotrophy 
values predict outcome in severe traumatic brain injury, subarachnoidal 
haemorrhage as well as after OHCA (Yeo 2012, Sener 2016, Fragata 2017, Velly 
2018, Fragata 2019). Cerebral white matter injury following these insults is 
explained by the location of WM NMDA receptors, which are expressed in WM 
myelin oligodendrocytes (Káradóttir 2005).  
Nonsurviving patients could be identified also in this study by the global low 
FA values. However, generalized outcome prediction requires comparisons and 
estimations of normal FA values in different healthy age groups, which are not 
available. For example, in elderly patients, general white matter degeneration 
involved in ageing lowers FA values.  
6.1.2 Neuroprotection by xenon in OHCA survivors 
Xenon’s neuroprotective properties in this study were demonstrated as an enhanced 
preservation of white matter tracts, which was displayed with higher fractional 
anisotrophy values. These reflect an attenuation of the ongoing disruption of white 
matter microintegrity as compared to the control group. In this study observed 
increased radial (but unchanged axial) diffusion has been correlated to mitigation 
of demyelination in previous studies (Song 2002).  
In this study the lower radial diffusivity in the Xe group reflected less 
demyelination of white matter tracts and preserved intact axons. The mean global 
FA value was significantly higher among surviving Xe-patients, when compared to 
those who died or those in the control group. In particular, of all diffusion tensor 
measures, lower FA and degree of white matter injury was the strongest predictor 
of mortality at 6 months. Each of the other diffusivity values (axial, radial and 
mean) was lower in the xenon group, but only radial diffusivity differed 
statistically significantly (table 12). Despite higher unadjusted radial and mean 
diffusivity values were independent predictors of mortality during the 6-month 
follow-up, the adjusted diffusivity values were not capable to discriminate between 
surviving or not surviving patients (table 19).  
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The statistically significant difference (p = 0.006) in adjusted global mean FA 
values between survivors and nonsurvivors seems at the first sight to be trifling; 
0.443 vs 0.407 – corresponds to only 6.4 % difference. However, this still 
represents the diffrence between life and death. These data emphasizes, that the 
equally highly significant difference (p = 0.006) in adjusted global mean FA values 
between Xe- and control group; 0.443 vs 0.419 – which is only 3.8 % difference 
(adjusted mean difference 0.016), represents a more than 50 % treatment effect of 
Xe on global FA, when associated with the values of surviving or nonsurviving 
patients (table 19). 
On average 50 % of the total brain volume consists of white matter, which is 
extremely vulnerable to even short periods of focal ischemia (Pantoni 1996). The 
observed widespread white matter injury in voxelwise TBSS visualization (figure 
4), which corresponded to lower FA values in the control group, demonstrated, that 
on average 41.7 % of white matter tracts were significantly more injured in the 
control group. The control group’s higher radial diffusivity, which corresponds to 
more pronounced demyelination, is presumably responsible for the lower FA 
values. The location (based on Johns Hopkins University white-matter tractography 
atlas) of low FA values in control group were: cingulum (cingulate gyrus) (54.6%), 
cingulum (hippocampal region) (1.4%), forceps minor (49.4%) and major (35.5%), 
superior longitudinal fasciculus (49.3%), inferior longitudinal fasciculus (34.8%), 
anterior thalamic radiation (45.1%), inferior fronto-occipital fasciculus (41.0%), 
corticospinal tract (28.7%), uncinate fasciculus (36.4%), and the body of corpus 
callosum (72.3%). These tracts are involved in multiple neurocognitive functions, 
e.g. attention, memory, language, emotions, auditory, visual and executive 
processing and motor functions of the body. 
Despite a significant demonstrated difference in white matter injury between 
the groups, there was neither significant difference in the (exploratory) analysis of 
neurological (CPC or mRS score; table 18) or cognitive outcomes (NHISS or 
MMSE score). These assays are tools for somewhat coarse analysis of mainly 
functional, motor and memory performance. However, they are important estimates 
of neurological performance allowing comparisons between studies. Generally, as 
also in this study, about 90 % OHCA victims, who were alive at the 6-month 
follow-up, had a favourable neurological outcome (CPC 1 or 2), and patients with 
severe neurological impairment were likely to die during convalescent care. 
However, these scales provide an important framework, which allows comparison 
between trials. 
Functional neurocognitive deficiency assessment requires more sensitive 
methods. The study was underpowered to detect a statistically significant 
difference in clinical outcome. 
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6.2 Cardioprotective effects by xenon inhalation 
following OHCA 
6.2.1 Methodological aspects of TnT assay on quantification 
of myocardial damage and influence in overall survival 
Troponin T (TnT) is the validated and fundamental basis of assessment of an acute 
myocardial infarct and injury by the latest definitions and recommendations 
(Thygesen 2012, Thygesen 2018). TnT is routinely used whenever a ST-segment 
elevation (STEMI) or non-ST-segment elevation myocardial infarct (NSTEMI) are 
evaluated or defined and TnT levels correspond and quantify the myocardial infarct 
size (Stone 2016). The contemporary myocardial infarction definition guidelines 
describe and differentiate even minor changes in TnT values over hours to facilitate 
confirmation or rejection of the diagnosis of acute myocardial damage, which 
eventually and most importantly guide intensity of further treatment actions 
(Thygesen 2018). This translates to, that troponin assays are considered highly 
reliable assessments in quantification of myocardial injury and simultaneously, a 
reliable indicator of any action, which may have influenced or even mitigated 
myocardial injury following an insult. 
Moreover, TnT has been identified as an independent predictive marker of all-
cause morbidity and mortality due to a cardiovascular cause or multi-organ failure 
(Gilje 2016, Morrison 2017). Increment of Tnt at hospital admission also correlates 
significantly to short- and long-term mortality in general intensive care patients, 
regardless of the underlying disease (Babuin 2008).  
6.2.2 Attenuatuation of myocardial injury by xenon 
inhalation after OHCA 
A predefined secondary objective of the trial was to assess Xenon’s 
cardioprotective effect with the extent of myocardial injury and the surrogate 
endpoint of difference in TnT increment post OHCA between groups of Xe 
inhalation and hypothermia and hypothermia only. In previous models of 
ischaemic myocardial injury in different sized animals, xenon exposure has been 
demonstrated to reduce experimental myocardial infarct size (Weber 2006b, 
Baumert 2007, Weber 2008, Mio 2009, Schwiebert 2010) and TnT release (Hein 
2008b). The main finding of this study was that among comatose survivors of VF-
generated OHCA, inhaled xenon combined with MTH attenuated TnT release 
profile corresponding to restricted myocardial injury when compared with that 
achieved by hypothermia only. This was demonstrated by the significantly lower 
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release of TnT at 72 h after OHCA in the Xe group. The TnT increment 
corresponded also to higher mortality at 6 months. 
These results indicated significantly lower TnT release in the xenon group than 
in the control group at 72 h, but not at 24 and 48 h, explaining why the area under 
the curve remained nonsignificant. The high sensitive assay of TnT peaks on 
average 12 hours after injury (Solecki 2015). Duration of CPR chest compressions 
or the amount of defibrillations required does not affect TnT release (Müllner 
1998), although it has been postulated, that the elevation of serum biomarkers post 
arrest could also be attributed to the resuscitation circumstances (Morrison 2017). 
In both study groups, the highest TnT values were at 24 h, which represents the 
initial myocardial injury leading to cardiac arrest and resuscitation.  
However, if a cardioprotective strategy is applied with a goal of ongoing 
myocardial injury restriction, the release profiles of TnT from baseline should 
decline. This was demonstrated in this study, as there was a significant difference 
in first 72 h TnT release profile with a significant decline of 44.8% in the Xe group 
and a nonsignificant decline of 11.3% in the control group from the peak at 24 h to 
72 h. The difference was even more distinct between the groups in patients with 
NSTEMI, with a significant decline in the Xe group as compared with a 
nonsignificant increment in the control group from the peak to 72 h. Although the 
decline was significant only in the xenon group, the release profile of the current 
control group was very similar to a recently published population of 699 OHCA 
patients, with a TnT decline of 10.8% (Gilje 2016).  
Occlusive coronary artery disease resulting in STEMI naturally causes higher 
TnT release than NSTEMI, consisting additionally of “TnT washout” following 
possible revascularization. The infarct mass in STEMI is likewise extended, which 
has previously been demonstrated to significantly correlate with all single-point 
measures of TnT at 24, 48, and 72 h (and also at 96 h) (Giannitsis 2008). STEMI 
patients had significantly higher TnT release than NSTEMI patients also in the 
current study. Consequently, the single-point values of TnT, rather than the area 
under the curve, were considered to be reliable estimates of the ongoing ischemia-
reperfusion injury. The demonstrated difference between the groups reflects a 
significant cardioprotective treatment effect by MTH and Xe inhalation, which was 
observed over the first 72 h. 
In the statistical analysis, the attenuation of myocardial injury in the Xe group 
was independent of age, sex, study site, dose of noradrenaline, and performed PCI. 
The effect of Xe on the TnT release was similar in patients with or without PCI or 
with a diagnosis of STEMI, as well as in both survivors and nonsurvivors. The 
severity of coronary artery disease in the study patients was evaluated by patient 
history, coronary angiography, and autopsy report (when available). The extent of 
coronary artery disease was comparable in the study groups, suggesting that the 
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effect of Xe was not likely to be modified by the severity of ischemic cardiac 
disease burden (table 10).  
6.2.3 Confounding factors of TnT release 
The accuracy of cardiac injury markers has been questionable after OHCA and 
resuscitation (Kruse 2014). There are distinct confounding factors, which could 
affect TnT release. Firstly, patients with chronic kidney disease (CKD) have a high 
prevalence of elevated troponin levels (Jacobs 2009, Unger 2016), which reduces 
the diagnostic accuracy of TnT in acute myocardial infarction in patients with CKD 
(Stacy 2014, Parikh 2015). Whether this reflects reduced TnT clearance in the 
kidneys or is a genuine representation of non-ischaemic myocardial stress or 
chronic structural heart disease, is still controversial (Diris 2004, Stacy 2014, 
Parikh 2015, Fridén 2017). In the current study, the influence of acute (or chronic) 
kidney injury was carefully ruled out by comparison of alterations in kidney 
function and RIFLE score during the first 7 days after OHCA. There were no 
statistifically significant differences, which could have inflicted the interpretation 
of TnT analysis (table 9). 
Secondly, haemodynamic parameters and requirements of vasoactive 
medication during TnT release observation over the first 72 h may influence TnT 
release. Because of the predefined haemodynamic targets, there were no 
differences in blood pressure between the study groups during intervention or 
follow-up. However, heart rate was significantly lower in Xe group than in the 
control group during MTH, with this effect lasting at least up to 72 hours after 
OHCA (table 8). Xenon’s heart rate–decreasing properties have been well 
documented previously (Dingley 2001, Coburn 2005, Wappler 2007, Al Tmimi 
2015). Coincidentaly, a recent trial demonstrated that marked sinus bradycardia 
during MTH following OHCA is an early marker of improved outcome, and it was 
suggested to represent an independent marker of favorable neurocognitive outcome 
(Thomsen 2016). Therefore, one could anticipate, that xenon’s ability to reduce 
heart rate may have some beneficial clinical value in cardiac arrest patients. 
However, this was not supported by the current results because no correlation 
could be detected between heart rate and attenuated myocardial injury, deducted 
from lower TnT release at 72 hours post OHCA. 
Thirdly, in the current trial with over 24 h of Xe inhalation, the dose of 
propofol was significantly lower during MTH and extending cumulatively to the 
follow-up over 72 h, although the propofol doses after Xe discontinuation were 
comparable. Less propofol was accompanied with a reflectory, clear, but 
nonsignificant trend of inotrope-sparing effect in Xe group. Of vasoactive 
medication, doses of noradrenaline and dobutamine showed a significant positive 
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correlation with troponin-T release only in the Xe group. Otherwise, there was not 
significant difference between the groups. Consequently, vasoactive medication 
was unlikely to have been responsible for the extended TnT release connected to 
more severe myocardial injury in the control group. 
Forthly, in preclinical animal studies and especially in cardiac surgery, 
propofol in comparison to sevoflurane has been recocnized as an anaesthetic with 
cardioprotective properties in patients with severe coronary ischemia, 
cardiovascular instability or undergoing urgent surgery. Besides antioxidant 
effects, propofol has been connected to reduction of oxidative stress and cardiac 
protection against ischaemia-reperfusion injury (Jakobsen 2007). This is illustrated 
as mitigated TnT release after CABG surgery (Javadov 2000, Xia 2006). 
Consequently, one could expect a reduction of propofol cardioprotection in the Xe 
group, as the dose of propofol was significantly lower than in the control group. 
Despite the possible cardioprotective properties of propofol, there was no 
correlation between the administered dose and the troponin-T release within the 
groups in this study. Therefore, it is unlikely that the administration or dose of 
propofol had any significant impact on the current results. 
Taken together, none of these major confounding variables included in the 
study model either differed between the groups or exhibited any correlation with 
the release of TnT. Hence, Xe combined with MTH was a significant independent 
factor attenuating the severity of the myocardial injury after OHCA addressed with 
TnT release profile. In this study, the effect on the TnT release was likely due to a 
post-conditioning effect, because xenon inhalation was initiated with a mean delay 
of 4 h after OHCA. Speculatively, earlier Xe inhalation initiation might have 
improved the cardioprotective effects by Xe, but during this study, the major factor 
delaying the treatment was waiting the written informed assent by the next of kin 
within the protocol time frame, i.e. within 4 hours from the hospital admission.  
6.3 Status epilepticus after hypoxic-ischaemic 
brain injury 
The incidence of status epilepticus did not differ between study groups. If epilepsy 
was encountered, antiepileptic drugs were started and adjusted in co-operation with 
the consulting neurologist. As propofol is an antiepileptic drug, one could argue, 
that the reduction in propofol dose during Xe inhalation could have facilitated more 
epilepsy. This was, however, not the case.  
Postanoxic status epilepticus bears a notorious reputation with high likeliness 
of severe brain injury and permanent unconsciousness. In this study, epilepsy was 
associated also with poor prognosis. However, this was not always, which has been 
demonstrated also by others (Hofmeijer 2014, Seder 2015), as 5 patients in this 
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study with post cardiac arrest epilepsy regained consciousness with eventually 
satisfactory outcome. Pessimisticly, it is very hard to to distinguish these surviving 
patients from those whose antiepileptic treatment eventually translates to be futile. 
6.4 Survival 
In this study two major variables were identified to predict all-cause mortality at 6 
months after OHCA. Firstly, low FA value (mean [SD] of 0.433 [0.026] in the 
surviving patients vs 0.407 [0.035] in those who died) distinguished the patients 
who survived or deceased after hypoxic-ischaemic brain injury (table 19). 
Secondly, TnT increment at all the time points of TnT besides the baseline within 
the groups and in the whole population had a predictive value for all-cause 
mortality at 6 months after OHCA (table 20). However, this study was not 
sufficiently powered to address Xe’s long-term effect on either cardiac or all-cause 
mortality.  
6.5 Study limitations 
Due to the small study group, this study was underpowered to identify differences 
in survival (mortality) or neurological cognitive outcome. This might also reflect, 
that these promising results in surrogate endpoints, i.e. reduced brain WM FA 
descent and cardiac TnT release mitigation, are not the sole affectors translating to 
clinical success in outcome. 
Brain grey matter injury was not investigated in this study and therefore, this 
study provides no information on the role of grey matter injury following OHCA.  
Furthermore, the effect of the beneficial intervention was demonstrated with 
the combination of xenon inhalation and targeted temperature management at 33 
°C. It is impossible to deduce, whether complementary xenon inhalation would 
have a neuroprotective effect in other normothermic or hypothermic temperatures. 
This question will be adressed in the already ongoing phase III trial. In the current 
study, however, all patients were treated with induced hypothermia in both study 
groups. In previous preclinical studies, xenon has been demonstrated to have 
neuroprotective properties with and without simultaneous hypothermia (Wilhelm 
2002, Banks 2010, Thoresen 2009, Chakkarapani 2010, Hobbs 2008 and Table 1). 
Because the standard intervention, hypothermia, was constant, differences between 
groups represent a genuine and independent treatment effect by xenon inhalation in 
OHCA survivors.  
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6.6 Clinical implications and future considerations 
of xenon use in cardiac arrest patients 
A phase III clinical trial in 1436 OHCA patients (Xenon for Neuroprotection 
During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out Of 
Hospital Cardiac Arrest (XePOHCAS – NCT3176186)) is already launched, which 
will provide further evidence, whether these observations translate to a clinical 
benefit and improved outcome in post cardiac arrest syndrome patients (Maze 
2018). 
The noble gas Xe is scarce and therefore costly, which makes its use unlikely 
in routine perioperative settings. Utilizing recirculating ventilators diminishes Xe 
consumption during anaesthesia but it is still high-priced when compared to the 
cheaper alternatives. Furthermore, closed-circuit ventilation is technically 
somewhat more challenging, which propably might cause prejudices and the 
availability of these ventilators has this far been limited. Xenon has, however, 
many attractive properties and an anaesthesia performance resembling “an ideal 
anaesthetic”, which could promote its use particularly in intensive care medicine, 
where the patients are potentially haemodynamically unstable, very exposed to 
unwanted pharmacological interactions and suspectible to secondary injurous 
cascades of cell damage.  
Hypoxic ischaemic cerebral, myocardial reperfusion injury and the multi-organ 
post cardiac arrest syndrome following successful cardiac arrest resuscitation are 
examples of these conditions, where despite all current treatment practices – 
including targeted temperature management – the modest results in outcome and 
low survival are still unresolved.  
This study provides the first evidence since mild therapeutic hypothermia 
treatment adaptation, that ischaemia reperfusion injury is modifiable and the extent 
of injury can be diminished with simultaneous combination of MTH and Xe 
inhalation in subanaesthetic doses. The putative organoprotective effect by xenon 
in e.g. kidney evokes possibilities of further post cardiac arrest syndrome burden 
attenuation, especially if the delay to xenon exposure after collapse and ischaemia-
reperfusion injury initiation is narrowed by almost immediate xenon 
administration.  
Curiously, at cardiac arrest site commenced xenon inhalation would allow 
extremely rapid evaluation of post arrest neuro- and cardioprotective treatment 
imperatives, as xenon anaesthesia involves emergence from sedation within a 
couple of minutes, which facilites immediate evaluation of consciousness. Lack of 
responsiveness after xenon discontinuation would instantly uncover the 
organoprotective goals of further treatment in unresponsive cardiac arrest 
survivors. 
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7 Summary and conclusions 
Main results and conclusions according to the aims of the study were: 
1. Combining mild therapeutic hypothermia with xenon inhalation for 24 hours 
in ventricular fibrillation-generated out-of hospital cardiac arrest victims 
remaining comatose is safe and feasible. Xenon inhalation is associated with 
stable hemodynamics, mitigation of the dose of hypnotics required during 
induced hypothermia resulting in an inotrope-sparing effect during cooling. 
Bradycardia during MTH was emphazised, which is suggested to be an 
independent marker of more favorable neurological outcome in recent 
studies. The density of Xe is higher than air, which causes a temporary 
increase in airway pressure during Xe inhalation. 
2. The combination of Xe inhalation and MTH attenuated the ischaemia 
reperfusion induced cerebral white matter injury, which was demonstrated 
with the surrogate endpoint of diffusion tensor magnetic resonance 
imaging fractional anisotrophy, which was higher, corresponding to 
enhanced preservation of white matter tracts in the Xe group in 
comparison to the MTH only control group. Similarly, DTI MRI radial 
diffusivity values were lower in the Xe group than in the control group. 
High radial diffusivity values correspond to demyelination of white matter 
axons, which was attenuated in the Xe group. These findings correspond 
to a significant neuroprotective effect by Xe + MTH compared to MTH 
only. 
3. Ischaemia-reperfusion injury in the myocardium was assessed with the 
release of cardiac intracellular protein troponin-T, which corresponds to 
cardiomyocyte disruption after ischaemic insult. In the Xe group, the profile 
of TnT release over the first 72 hours after OHCA had a significant decline 
in comparison to the control group. This finding illustrated a 
cardioprotective effect in ongoing cardiomyocyte ischaemia-reperfusion 
injury in the Xe group when compared to MTH only.  
4. Although this study was underpowered to any estimations of functional 
recovery or outcome, two factors affecting survival at 6 months were 
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identified. A low initial brain DTI MRI value of FA was associated with 
mortality during follow-up. Furthermore, high TnT values during ICU 
follow-up were associted with all-cause-mortality at 6 months.  
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Sydänpysähdys aiheuttaa nopeasti hapenpuutevaurion etenkin aivoissa 
ja sydänlihaksessa. Onnistuneen elvytyksen jälkeisestä verenkierron 
palautumisesta huolimatta aivojen ja sydämen hapenpuutevaurio jatkuu 
(reperfuusiovaurio), jota voidaan jonkin verran rajoittaa lämpötilan-
hallinnalla pitämällä potilaan lämpötila 33 – 36 ºC välillä ja estämällä 
kuumeen aiheuttama vaurion paheneminen. 
Jalokaasu ksenon on anestesiakaasu, jonka on aiemmin osoitettu eri 
eläinmalleissa vähentävän hapenpuutteen aiheuttamaa vauriota aivoissa 
ja sydänlihaksessa yksin ja jäähdytyshoitoon yhdistettynä.
Tässä tutkimuksessa verrattiin ksenonin ja jäähdytyshoidon (33 ºC) 
yhdistelmää pelkän jäähdytyshoidon vaikutukseen 110:llä kam-
miovärinästä elvytetyllä sydänpysähdyspotilaalla. Yhdistelmähoito 
vähensi sekä aivojen valkean aineen vauriota että sydänlihasvauriota 
enemmän kuin jäähdytyshoito yksin.
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